0001600620-24-000051.txt : 20240502 0001600620-24-000051.hdr.sgml : 20240502 20240502060728 ACCESSION NUMBER: 0001600620-24-000051 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 92 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981231763 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 24905056 BUSINESS ADDRESS: STREET 1: #140, 14315 - 118 AVENUE CITY: EDMONTON STATE: A0 ZIP: T5L 4S6 BUSINESS PHONE: 250-744-2487 MAIL ADDRESS: STREET 1: #140, 14315 - 118 AVENUE CITY: EDMONTON STATE: A0 ZIP: T5L 4S6 10-Q 1 auph-20240331.htm 10-Q auph-20240331
false2024Q1000160062012-3100016006202024-01-012024-03-3100016006202024-05-01xbrli:shares00016006202024-03-31iso4217:USD00016006202023-12-310001600620us-gaap:RelatedPartyMember2024-03-310001600620us-gaap:RelatedPartyMember2023-12-31iso4217:USDxbrli:shares0001600620us-gaap:ProductMember2024-01-012024-03-310001600620us-gaap:ProductMember2023-01-012023-03-310001600620auph:LicenseRoyaltyAndCollaborationRevenueMember2024-01-012024-03-310001600620auph:LicenseRoyaltyAndCollaborationRevenueMember2023-01-012023-03-3100016006202023-01-012023-03-310001600620us-gaap:CommonStockMember2023-12-310001600620us-gaap:AdditionalPaidInCapitalMember2023-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001600620us-gaap:RetainedEarningsMember2023-12-310001600620us-gaap:CommonStockMember2024-01-012024-03-310001600620us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001600620us-gaap:RetainedEarningsMember2024-01-012024-03-310001600620us-gaap:CommonStockMember2024-03-310001600620us-gaap:AdditionalPaidInCapitalMember2024-03-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001600620us-gaap:RetainedEarningsMember2024-03-310001600620us-gaap:CommonStockMember2022-12-310001600620us-gaap:AdditionalPaidInCapitalMember2022-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001600620us-gaap:RetainedEarningsMember2022-12-3100016006202022-12-310001600620us-gaap:CommonStockMember2023-01-012023-03-310001600620us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001600620us-gaap:RetainedEarningsMember2023-01-012023-03-310001600620us-gaap:CommonStockMember2023-03-310001600620us-gaap:AdditionalPaidInCapitalMember2023-03-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001600620us-gaap:RetainedEarningsMember2023-03-3100016006202023-03-31xbrli:pureauph:segment0001600620us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberauph:TwoSpecialtyPharmacyMemberus-gaap:ProductMember2024-01-012024-03-310001600620us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberauph:TwoSpecialtyPharmacyMemberus-gaap:ProductMember2023-01-012023-03-310001600620auph:LicenseRoyaltyAndCollaborationRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberauph:TwoSpecialtyPharmacyMember2024-01-012024-03-310001600620auph:LicenseRoyaltyAndCollaborationRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberauph:TwoSpecialtyPharmacyMember2023-01-012023-03-310001600620srt:MinimumMember2024-01-012024-03-310001600620srt:MaximumMember2024-01-012024-03-310001600620auph:CashCashEquivalentsAndRestrictedCashMemberus-gaap:FairValueInputsLevel1Member2024-03-310001600620auph:CashCashEquivalentsAndRestrictedCashMemberus-gaap:FairValueInputsLevel2Member2024-03-310001600620us-gaap:FairValueInputsLevel3Memberauph:CashCashEquivalentsAndRestrictedCashMember2024-03-310001600620auph:CashCashEquivalentsAndRestrictedCashMember2024-03-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMember2024-03-310001600620us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-03-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMember2024-03-310001600620us-gaap:CorporateBondSecuritiesMember2024-03-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2024-03-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2024-03-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2024-03-310001600620us-gaap:CommercialPaperMember2024-03-310001600620us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-03-310001600620us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-03-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember2024-03-310001600620us-gaap:USTreasuryBillSecuritiesMember2024-03-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBondSecuritiesMember2024-03-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBondSecuritiesMember2024-03-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBondSecuritiesMember2024-03-310001600620us-gaap:USTreasuryBondSecuritiesMember2024-03-310001600620us-gaap:FairValueInputsLevel1Member2024-03-310001600620us-gaap:FairValueInputsLevel2Member2024-03-310001600620us-gaap:FairValueInputsLevel3Member2024-03-310001600620auph:CashCashEquivalentsAndRestrictedCashMemberus-gaap:FairValueInputsLevel1Member2023-12-310001600620auph:CashCashEquivalentsAndRestrictedCashMemberus-gaap:FairValueInputsLevel2Member2023-12-310001600620us-gaap:FairValueInputsLevel3Memberauph:CashCashEquivalentsAndRestrictedCashMember2023-12-310001600620auph:CashCashEquivalentsAndRestrictedCashMember2023-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMember2023-12-310001600620us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMember2023-12-310001600620us-gaap:CorporateBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2023-12-310001600620us-gaap:CommercialPaperMember2023-12-310001600620us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001600620us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001600620us-gaap:USTreasuryBillSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel1Member2023-12-310001600620us-gaap:FairValueInputsLevel2Member2023-12-310001600620us-gaap:FairValueInputsLevel3Member2023-12-310001600620us-gaap:FairValueInputsLevel2Member2024-01-012024-03-310001600620us-gaap:FairValueInputsLevel2Member2023-01-012023-12-310001600620auph:ShortTermCorporateDebtSecuritiesMember2024-03-310001600620auph:LongTermCorporateDebtSecuritiesMember2024-03-310001600620auph:ShortTermCorporateDebtSecuritiesMember2023-12-310001600620auph:LongTermCorporateDebtSecuritiesMember2023-12-310001600620us-gaap:PatentsMember2024-03-310001600620us-gaap:IntellectualPropertyMember2024-03-310001600620us-gaap:ComputerSoftwareIntangibleAssetMember2024-03-310001600620us-gaap:PatentsMember2023-12-310001600620us-gaap:IntellectualPropertyMember2023-12-310001600620us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-310001600620us-gaap:LeaseholdImprovementsMember2024-03-310001600620us-gaap:LeaseholdImprovementsMember2023-12-310001600620us-gaap:OfficeEquipmentMember2024-03-310001600620us-gaap:OfficeEquipmentMember2023-12-310001600620us-gaap:FurnitureAndFixturesMember2024-03-310001600620us-gaap:FurnitureAndFixturesMember2023-12-310001600620us-gaap:ComputerEquipmentMember2024-03-310001600620us-gaap:ComputerEquipmentMember2023-12-310001600620auph:RockvilleMarylandMember2020-03-31utr:sqftauph:extension_option0001600620auph:RockvilleMarylandMember2020-03-012020-03-310001600620auph:RockvilleMarylandMember2024-03-310001600620auph:RockvilleMarylandMember2023-12-310001600620auph:RockvilleMarylandMember2023-01-012023-12-310001600620auph:RockvilleMarylandMember2020-03-120001600620auph:EdmontonAlbertaMember2022-10-310001600620auph:VispSwitzerlandMember2023-07-310001600620auph:VispSwitzerlandMember2024-03-310001600620auph:VispSwitzerlandMember2023-12-310001600620auph:VispSwitzerlandMember2024-01-012024-03-310001600620auph:BeinheimFranceMember2024-03-310001600620auph:OtuskaPharmaceuticalCoLtdMemberus-gaap:LicenseAgreementTermsMember2020-01-012020-12-310001600620auph:OtuskaPharmaceuticalCoLtdMemberus-gaap:LicenseAgreementTermsMember2021-01-012021-03-310001600620auph:OtuskaPharmaceuticalCoLtdMembersrt:MinimumMemberus-gaap:LicenseAgreementTermsMember2020-12-310001600620auph:OtuskaPharmaceuticalCoLtdMembersrt:MaximumMemberus-gaap:LicenseAgreementTermsMember2020-12-310001600620auph:OtuskaPharmaceuticalCoLtdMemberus-gaap:LicenseAgreementTermsMember2023-11-132023-11-130001600620auph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMemberus-gaap:LicenseAgreementTermsMember2024-01-012024-03-310001600620auph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMemberus-gaap:LicenseAgreementTermsMember2023-01-012023-03-3100016006202024-02-2900016006202024-02-292024-02-290001600620srt:MinimumMember2024-02-292024-02-290001600620srt:MaximumMember2024-02-292024-02-290001600620us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001600620us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001600620us-gaap:PerformanceSharesMember2024-01-012024-03-310001600620us-gaap:PerformanceSharesMember2023-01-012023-03-310001600620us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001600620us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001600620auph:AmendedAndRestatedEquityIncentivePlanMember2021-06-012021-06-300001600620us-gaap:EmployeeStockMember2021-06-300001600620us-gaap:EmployeeStockMember2024-01-012024-03-310001600620srt:OfficerMemberauph:PerformanceShareSandRestrictedStockUnitsRSUsMember2023-12-310001600620srt:OfficerMemberauph:PerformanceShareSandRestrictedStockUnitsRSUsMember2024-01-012024-03-310001600620srt:OfficerMemberauph:PerformanceShareSandRestrictedStockUnitsRSUsMember2024-03-310001600620us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001600620us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001600620us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001600620us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001600620us-gaap:InventoriesMember2024-01-012024-03-310001600620us-gaap:InventoriesMember2023-01-012023-03-310001600620auph:DrRobertTFosterMemberauph:EmployeeBenefitObligationsMember2024-03-310001600620auph:DrRobertTFosterMemberauph:EmployeeBenefitObligationsMember2023-12-310001600620auph:DrRobertTFosterMember2023-01-012023-03-310001600620auph:DrRobertTFosterMember2024-01-012024-03-310001600620us-gaap:EmployeeSeveranceMember2024-01-012024-03-310001600620us-gaap:ContractTerminationMember2024-01-012024-03-310001600620us-gaap:OtherRestructuringMember2024-01-012024-03-310001600620us-gaap:SubsequentEventMember2024-04-012024-04-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_____________________________________________
FORM 10-Q
_____________________________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_____________ to ________________
Commission file number: 001-36421
__________________________________________
Aurinia Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in its Charter)
__________________________________________
Alberta, Canada
(State or other jurisdiction of
incorporation or organization)
#140, 14315 - 118 Avenue
Edmonton, Alberta T5L 4S6
98-1231763
(Address of principal executive offices)(I.R.S. Employer
Identification Number)
(250) 744-2487
Registrant’s telephone number, including area code
_____________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x 
Indicate the number of shares outstanding of each of the registrant's classes of common shares, as of the latest predictable date. As of May 1, 2024, the registrant had 143,019,365 of common shares outstanding.
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common shares, no par valueAUPHThe Nasdaq Global Market LLC


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
TABLE OF CONTENTS
Page


PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)March 31, 2024December 31, 2023
ASSETS
Current assets
Cash, cash equivalents and restricted cash$64,459 $48,875 
Short-term investments255,453 301,614 
Accounts receivable, net28,909 24,089 
Inventories, net39,761 39,705 
Prepaid expenses7,646 9,486 
Other current assets1,995 1,031 
Total current assets398,223 424,800 
Non-current assets
Long-term investments199 201 
Other non-current assets1,502 1,517 
Property and equipment, net3,198 3,354 
Acquired intellectual property and other intangible assets, net4,760 4,977 
Finance right-of-use asset, net104,358 108,715 
Operating right-of-use assets, net4,394 4,498 
Total assets$516,634 $548,062 
LIABILITIES
Current liabilities
Accounts payable and accrued liabilities50,270 54,389 
Deferred revenue4,909 4,813 
Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively)
1,150 2,388 
Finance lease liability13,724 14,609 
Operating lease liabilities999 989 
Total current liabilities71,052 77,188 
Non-current liabilities
Finance lease liability67,475 75,479 
Operating lease liabilities6,339 6,530 
Deferred compensation and other non-current liabilities (of which $8.8 million in 2024 and $7.6 million in 2023 is due to a related party, respectively)
12,292 10,911 
Total liabilities157,158 170,108 
Commitments and contingencies (Note 18)
SHAREHOLDER’S EQUITY
Common shares - no par value, unlimited shares authorized, 143,690 and 143,833 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
1,207,982 1,200,218 
Additional paid-in capital105,419 120,788 
Accumulated other comprehensive loss(854)(730)
Accumulated deficit(953,071)(942,322)
Total shareholders' equity359,476 377,954 
Total liabilities and shareholders' equity$516,634 $548,062 
The accompanying notes are an integral part of these condensed consolidated financial statements.
1

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share data)
Three months ended
March 31,
20242023
(unaudited)
Revenue
Product revenue, net$48,073 $34,337 
License, collaboration and royalty revenue
2,230 72 
Total revenue, net50,303 34,409 
Operating expenses
Cost of sales7,752 421 
Selling, general and administrative47,695 50,124 
Research and development5,551 13,158 
Restructuring expenses6,683 — 
Other (income) expense, net(4,125)290 
Total cost of sales and operating expenses63,556 63,993 
Loss from operations(13,253)(29,584)
Interest expense(1,283)— 
Interest income4,526 3,814 
Net loss before income taxes(10,010)(25,770)
Income tax expense739 436 
Net loss(10,749)(26,206)
Other comprehensive (loss) gain:
Unrealized (loss) gain on available-for-sale securities, net of tax of nil
(124)73 
Comprehensive loss(10,873)(26,133)
Basic and diluted loss per share$(0.07)$(0.18)
Weighted-average common shares outstanding used in computation of basic and diluted loss per share144,013 142,641 
The accompanying notes are an integral part of these condensed consolidated financial statements.













2

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(in thousands)
(unaudited)
Common Shares
Three Months Ended March 31, 2024SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at December 31, 2023143,833 $1,200,218 $120,788 $(730)$(942,322)$377,954 
Shares issued on exercise of stock options and vesting of restricted stock units2,231 21,134 (21,106)— — 28 
Shares repurchased and cancelled, inclusive of transaction costs(2,374)(13,370)— — — (13,370)
Share-based compensation— — 5,737 — — 5,737 
Unrealized loss on available-for-sale securities, net— — — (124)— (124)
Net loss— — — — (10,749)(10,749)
Balance at March 31, 2024143,690 $1,207,982 $105,419 $(854)$(953,071)$359,476 
Common Shares
Three Months Ended March 31, 2023SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at December 31, 2022142,268 $1,185,309 $85,489 $(1,061)$(864,302)$405,435 
Shares issued on exercise of stock options and vesting of restricted stock units761 7,710 (6,071)— — 1,639 
Shared-based compensation— — 9,467 — — 9,467 
Unrealized gain on available-for-sale securities, net— — — 73 — 73 
Net loss— — — — (26,206)(26,206)
Balance at March 31, 2023143,029 $1,193,019 $88,885 $(988)$(890,508)$390,408 

The accompanying notes are an integral part of these condensed consolidated financial statements.
3

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months Ended March 31,
20242023
(in thousands)(unaudited)
Cash flows used in operating activities:
Net loss$(10,749)$(26,206)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization4,847 717 
Net amortization of premiums and discounts on short-term investments(3,206)(2,611)
Share-based compensation expense5,737 9,467 
Foreign exchange on finance lease liability(6,025)— 
Other, net1,559 217 
Net changes in operating assets and liabilities
Accounts receivable, net(4,820)(5,559)
Inventories, net(56)(6,993)
Prepaid expenses and other current assets873 3,588 
Non-current operating assets17 (17)
Accounts payable, accrued and other liabilities(6,594)(4,117)
Operating lease liabilities(181)(156)
Net cash used in operating activities (18,598)(31,670)
Cash flows used in investing activities:
Purchase of investments(121,260)(142,397)
Proceeds from investments170,505 167,766 
Purchase of property and equipment— (347)
Capitalized patent costs(12)(162)
Net cash provided by investing activities 49,233 24,860 
Cash flows from financing activities
Repurchase of common shares, net of transaction costs(12,301)— 
Finance lease payments(2,778)— 
Proceeds from exercise of stock options28 1,639 
Cash (used in) provided by financing activities (15,051)1,639 
Net increase (decrease) in cash, cash equivalents and restricted cash15,584 (5,171)
Cash, cash equivalents and restricted cash, beginning of period48,875 94,172 
Cash, cash equivalents and restricted cash, end of period$64,459 $89,001 
Supplemental cash flow information
Cash received for interest$861 $1,595 
Cash paid for income taxes$— $(1)
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash, cash equivalents$63,914 $88,327 
Restricted cash545 674 
Total cash, cash equivalents and restricted cash$64,459 $89,001 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1.Organization and Description of Business
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. Aurinia contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for development and commercialization of LUPKYNIS in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the Otsuka Territories).
On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value, including an exclusive focus on driving the commercial execution of the LUPKYNIS (voclosporin) business. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program and is exploring alternative approaches for AUR200. The corporate restructuring involved the Company reaffirming its commitment to LUPKYNIS growth, while maintaining a sharp focus on operating efficiencies and maximizing cash flows. For further discussion, refer to Note 19, Restructuring.
Aurinia's head office and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.
2.Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of March 31, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.
These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other (income) expense, net.

5

Significant Accounting Policies
The Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and specialty distributors and directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products to patients and healthcare providers. Revenues from product sales are recognized when the customer obtains control of the Company's product, which typically occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed to patients. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of March 31, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Major Customers: The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration and manufacturing services revenue in the Otsuka Territories. The percentages of total revenues, net from our main customers were as follows:
Three months ended
 March 31,
20242023
Two main specialty pharmacies
91%99%
Collaboration partnership
7%—%
In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. specialty pharmacies, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2024. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to customers or receivables.
Accounts Receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As of March 31, 2024 and December 31, 2023, accounts receivable, net are $28.9 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to
6

the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the account receivables. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of March 31, 2024 and December 31, 2023.
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.
Restructuring Expenses: Restructuring expense consists primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, Exit or Disposal Cost Obligations, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.
Common Shares: The Company’s shares have no par value or stated value and therefore, upon repurchase or issuance of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.
Recent Accounting Pronouncements
In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.
3.    Fair Value Measurements
The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale debt securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
7

•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The following table summarizes the financial assets (cash, cash equivalents, restricted cash and investments) measured at fair value on a recurring basis:
March 31, 2024
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$64,459 $— $— $64,459 
Corporate bonds— 23,745 — 23,745 
Commercial paper— 38,243 — 38,243 
Treasury bills— 134,974 — 134,974 
Treasury bonds— 58,690 — 58,690 
Total financial assets$64,459 $255,652 $— $320,111 
December 31, 2023
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$48,875 $— $— $48,875 
Corporate bonds— 33,781 — 33,781 
Commercial paper— 39,304 — 39,304 
Treasury bills— 122,806 — 122,806 
Treasury bonds— 105,924 — 105,924 
Total financial assets$48,875 $301,815 $— $350,690 
The Company's Level 1 instruments include cash, cash equivalents and restricted cash that are valued using quoted market prices. Aurinia estimates the fair values of investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of the Company's investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At March 31, 2024 and December 31, 2023, the weighted average remaining contractual maturities of Aurinia's Level 2 investments were approximately 6 months and 7 months, respectively. It is the Company's policy for these investments to have an overall rating of A-1, or higher, by Standard & Poor's, or an equivalent rating by Moody’s or Fitch.
No credit loss allowance was recorded as of March 31, 2024 and December 31, 2023, as the Company does not believe the unrealized loss is a result of a credit loss due to the nature of the investments. Aurinia also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.
Refer to Note 4, Cash, Cash Equivalents, Restricted Cash and Investments, for the carrying amount and related unrealized gains (losses) by type of investment.
8

4.    Cash, Cash Equivalents, Restricted Cash and Investments
As of March 31, 2024 and December 31, 2023, the Company had $320.1 million and $350.7 million, respectively of cash, cash equivalents, restricted cash and investments summarized below. As of March 31, 2024 and December 31, 2023, $255.7 million and $301.8 million were available-for-sale debt securities which are carried at fair market value.
March 31, 2024
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$64,459 $— $— $64,459 
Corporate bonds23,547 — (3)23,544 
Commercial paper38,273 — (30)38,243 
Treasury bills134,984 — (9)134,975 
Treasury bonds58,697 — (7)58,690 
Total cash, cash equivalents, restricted cash and short-term investments319,960 — (49)319,911 
Total long-term investment corporate bond199 1 — 200 
Total cash, cash equivalents, restricted cash and investments$320,159 $1 $(49)$320,111 
December 31, 2023
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$48,875 $— $— $48,875 
Corporate bonds33,576 4 — 33,580 
Commercial paper39,305 — (1)39,304 
Treasury bills122,757 49 — 122,806 
Treasury bonds105,903 21 — 105,924 
Total cash, cash equivalents, restricted cash and short-term investments350,416 74 (1)350,489 
Total long-term investment corporate bond
200 1 — 201 
Total cash, cash equivalents, restricted cash and investments
$350,616 $75 $(1)$350,690 

As of March 31, 2024 and December 31, 2023, accrued interest receivable from investments was $1.0 million and $0.7 million, respectively. During the three months ended March 31, 2024 and 2023, the Company had $(124) thousand and $73 thousand of unrealized losses and gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company has determined that the gross unrealized losses on investments at March 31, 2024, were temporary in nature. Realized gains or losses were immaterial during the three months ended March 31, 2024 and 2023.

The Company's short-term investments as of March 31, 2024 mature at various dates through November 2024 and the longer-term investment matures in August 2025.

5.    Inventories, net

Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of
9

costs. Capitalized costs of inventories for LUPKYNIS (voclosporin) mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. Due to the nature of the Company's supply chain process, inventory that is owned by the Company, is physically stored at third-party warehouses, logistics providers, and contract manufacturers.

The Company assesses recoverability of inventory each reporting period to determine any write-down to net realizable value resulting from excess or obsolete inventories. As of March 31, 2024 and December 31, 2023, Aurinia recorded reserves of finished goods inventories of approximately $0.5 million and $0.8 million, respectively, which were primarily related to potential inventory obsolescence.

The components of inventory, net are as follows:
(in thousands)March 31, 2024December 31, 2023
Raw materials$1,702 $1,746 
Work in process35,994 37,376 
Finished goods, net of reserve2,065 583 
Total inventories, net$39,761 $39,705 


6.Prepaid Expenses
Prepaid expenses are as follows:

(in thousands)March 31, 2024December 31, 2023
Prepaid assets$4,707 $6,892 
Prepaid deposits2,376 1,345 
Prepaid insurance563 1,249 
Total prepaid expenses$7,646 $9,486 


7.Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
March 31, 2024
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,860 $(1,307)$553 
Acquired intellectual property and reacquired rights15,126 (10,937)4,189 
Internal-use software implementation costs2,873 (2,855)18 
$19,859 $(15,099)$4,760 
December 31, 2023
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,847 $(1,297)$550 
Acquired intellectual property and reacquired rights15,126 (10,737)4,389 
Internal-use software implementation costs2,873 (2,835)38 
$19,846 $(14,869)$4,977 
10

Amortization expense for the three months ended March 31, 2024 and 2023 was approximately $0.2 million and $0.5 million, respectively.
8.    Property and Equipment, net
Property and equipment, net are as follows:
(in thousands)March 31, 2024December 31, 2023
Leasehold improvements$3,243 $3,243 
Office equipment631 631 
Furniture1,155 1,155 
Computer equipment235 235 
5,2645,264
Less accumulated depreciation(2,066)(1,910)
Property and equipment, net$3,198 $3,354 
9.    Lease Obligations
The Company has the following lease obligations:
Victoria, British Columbia
In December 2020, Aurinia entered into a lease for office space in Victoria, British Columbia. During September 2022, the fixed lease term ended on the Victoria lease and the Company exercised its right to enter into a short-term month to month lease, of which expenses are incurred in SG&A. On March 31, 2023, the Company terminated the Victoria lease. 
Rockville, Maryland
During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately seven years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of March 31, 2024, the Company had a right-of-use (ROU) asset of $4.4 million and lease liability of $7.2 million included in the condensed consolidated balance sheets. As of December 31, 2023, the Company had a right of use asset of $4.5 million and lease liability of $7.4 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability.
The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta
During October 2022, the Company entered into a long term lease in Edmonton for a total of 4,375 square feet of office space. The lease is a six year lease and has an option to renew after five years at prevailing market rates. The lease commenced on November 1, 2022 and the Company recorded the lease as an operating lease. The lease is not material to the Company's financial position.
For all leases, the Company incurs variable lease costs. These costs include operation and maintenance costs included in SG&A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.
The operating lease costs for all leases for the three months ended March 31, 2024 and March 31, 2023 were $0.2 million for both periods.
11

Monoplant
The Company, at lease inception, recorded an ROU asset of approximately $117.6 million and a corresponding lease liability of $94.1 million, which is the present value of the minimum lease payments beginning July 2023 and expiring in 2030. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease.

As of March 31, 2024, the ROU asset, net and corresponding lease liability balance were $104.4 million and $81.2 million, respectively. As of December 31, 2023, the ROU asset, net and corresponding lease liability balance were $108.7 million and $90.1 million, respectively. For the three months ended March 31, 2024, ROU amortization was $4.4 million and interest expense was $1.3 million.
The following table represents the weighted-average remaining lease terms and discount rates as of March 31, 2024:
As of March 31, 2024
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases7.45.28%
Finance lease
6.06.19%
Supplemental cash flow information related to leases are as follows:
Three months ended
March 31,
20242023
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities
Financing cash flows from finance lease
$(2,778)$— 
Operating cash flows from finance lease
$(1,370)$— 
Operating cash flows from operating leases
$(276)$(263)
Supplemental disclosure of noncash transactions
Finance right-of-use asset obtained in exchange for lease obligations (monoplant)$104,359 $— 
Finance lease liability arising from obtaining right-of-use assets (monoplant)$81,199 $— 
12

Future maturities of lease liabilities as of March 31, 2024 are as follows:
(in thousands)Finance Lease PaymentsOperating Lease Payments
Remainder of 2024$12,052 $838 
202516,070 1,141 
202616,070 1,169 
202716,070 1,198 
202816,070 1,227 
Thereafter20,087 3,303 
Total lease payments
96,419 8,876 
Less: imputed interest
(15,220)(1,538)
Total
$81,199 $7,338 

Beinheim
The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that has not yet commenced operations and is therefore, not included in the above table. As part of the agreement, the Company expects to make payments of approximately $1.0 million prior to lease commencement and the present value of minimum lease payments will total approximately $0.1 million.
10.Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)March 31, 2024December 31, 2023
Employee accruals$11,412 $22,486 
Commercial accruals20,078 16,216 
Accrued R&D projects2,665 5,503 
Trade payables5,672 4,327 
Restructuring accruals
2,070 — 
Other accrued liabilities6,965 5,190 
Income taxes payable1,408 667 
Total accounts payable and accrued liabilities$50,270 $54,389 
As of March 31, 2024, liabilities related to restructuring costs of $2.1 million are included within accounts payable and accrued liabilities on the condensed consolidated balance sheets. Restructuring accruals primarily include employee severance and contract termination expenses.


11.Deferred Compensation and Other Non-current Liabilities

The Company recorded other non-current liabilities of $12.3 million and $10.9 million as of March 31, 2024 and December 31, 2023, respectively. The balance as of March 31, 2024 and December 31, 2023 primarily included deferred compensation arrangements whereby certain former executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. One of the former officers, Dr. Robert T. Foster, is considered a related party following his appointment to the Board of Directors on September 21, 2023. For further discussion, refer to Note 17, Related Party Transactions.
13

12.License and Collaboration Agreements
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories. For full description of the agreements the Company has entered into with Otsuka, please refer to the Annual Report on Form 10-K for the year ended December 31, 2023.

As part of the agreement, the Company received an upfront cash payment of $50.0 million in 2020 for the license agreement and has received $40.0 million in regulatory and pricing approval related milestones. The Company provides semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, sharing capacity of the monoplant and receives tiered royalties ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.
On November 13, 2023, Otsuka filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labour, and Welfare for the manufacture and sale in Japan of voclosporin. The Company is eligible to receive a payment of $10 million upon approval in Japan, which is anticipated in the second half of 2024, along with low double-digit royalties on net sales once launched.
For the three months ended March 31, 2024 and March 31, 2023, the Company recognized $2.2 million and $0.1 million, respectively of license, collaboration and royalty revenue from services provided under the Otsuka agreement.

Riptide License
On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. Effective February 14, 2024 the Company is ceasing future development of AUR300.
13.    Shareholder's Equity

On February 15, 2024, Aurinia announced that its Board of Directors had approved a share repurchase program of up to $150 million of common shares of the Company, affirming its confidence in the Company's growth prospects.

On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program. This program may be implemented through open market or privately negotiated purchases, including under a plan intended to comply with the affirmative defense under Rule 10b5-1, Rule 10b-18 or an automatic securities purchase plan, an accelerated share repurchase program, or other mechanisms. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. The purchase price of any Common Shares will be determined in accordance with applicable U.S. securities laws and subject to receiving the Exemptive Relief, the value of the consideration offered per Common Share will not exceed the market price of the Common Shares calculated pursuant to applicable Canadian securities regulation.
As of March 31, 2024, the Company had repurchased approximately 2.4 million of Aurinia's common shares for $13.4 million (including transaction costs which consist of commissions and excise tax). The cost of repurchased shares are reported as a reduction in common stock and under Alberta law, the shares were cancelled and not reissued.
14.Net Loss per Common Share
Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
14

Three months ended
 March 31,
(in thousands, except per share data)20242023
Net loss$(10,749)$(26,206)
Weighted average common shares outstanding144,013 142,641 
Net loss per common share (expressed in $ per share)$(0.07)$(0.18)
The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:
Three months ended
March 31,
(in thousands)20242023
Stock options11,081 12,678 
Unvested performance awards1,503 921 
Unvested restricted stock units7,326 6,983 
19,910 20,582 

15.Share-based Compensation
The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards (PAs), and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. As of March 31, 2024, 0.7 million shares were purchased under the ESPP.
In addition to stock options, PAs and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan.
Stock Options

The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the business day immediately prior to the date of grant. The Board of Directors approves the vesting criteria and periods at its discretion. The options issued under the Plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The assumptions used for the annual volatility and expected life of the options are reviewed and updated annually. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent
15

remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior.
The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March 31, 2024 and March 31, 2023:
20242023
Annualized volatility77 %71 %
Risk-free interest rate4.04 %4.08 %
Expected life of options in years5.0 years5.0 years
Estimated forfeiture rate13.1 %12.7 %
Dividend rate0.0 %0.0%
Fair value per common share option$4.62 $5.44 
The following table summarizes the option award activity for the three months ended March 31, 2024:

March 31, 2024
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2023
11,556 $10.63 
Granted63 7.12 
Exercised(6)4.85 
Forfeited or cancelled
(532)11.62 
Outstanding - March 31, 2024
11,081 $10.57 
Restricted Stock Units and Performance Awards
The Company has granted RSUs and PAs under the Plan, as well as inducements for certain new hires as discussed above. The RSUs and PAs are fair valued based on the previous business days' market price of common shares on the date of the grant.
The following table summarizes the RSU and PA activity for the three months ended March 31, 2024:
March 31, 2024
Number of shares (in thousands)Weighted average fair value price $
Unvested balance, December 31, 2023
7,807 $9.29 
Granted4,491 6.94 
Vested(2,225)9.48 
Forfeited(1,244)9.12 
Unvested balance, March 31, 2024
8,829 $8.07 
16

Share-based Compensation Expense
The Company recognized share-based compensation expense for the three months ended March 31, 2024 and March 31, 2023 as follows:
Three months ended
March 31,
(in thousands)20242023
Research and development$(2,166)$1,590 
Selling, general and administrative7,537 7,589 
Capitalized under inventories366 288 
Share-based compensation expense$5,737 $9,467 
As of March 31, 2024, there was $40.4 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.6 years.

16.Income Taxes

The effective tax rates for the three months ended March 31, 2024 and March 31, 2023 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances.

The Company recognized an income tax expense of approximately $739 thousand and $436 thousand for the three months ended March 31, 2024 and March 31, 2023, respectively. The expense recognized for these periods is a result of income in certain jurisdictions. This tax expense was not offset by a tax benefit as the Company had losses that are fully offset by a valuation allowance in its significant jurisdictions.
17.Related Party Transactions
On September 21, 2023, the Company appointed Dr. Robert T. Foster to the Board of Directors. Dr. Foster is considered a related party since he is one of the former executive officers of the Company who, as of March 8, 2012 was provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations are contingent on the occurrence of uncertain future events. Dr. Foster was not a related party of the Company between his resignation from the Company in 2014, and his appointment to the Board of Directors on September 21, 2023. As of March 31, 2024, the Company had $0.8 million and $8.8 million of current and non-current liabilities related to Dr. Foster, respectively. As of December 31, 2023, the Company had $0.8 million and $7.6 million of current and non-current liabilities related to Dr. Foster, respectively. As of March 31, 2024 and December 31, 2023 the Company had made payments of $0.1 million to him for each period as a related party for the deferred compensation.
18.Commitments and Contingencies
The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Other Funding Commitments
In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.
17

19.Restructuring
On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value, including an exclusive focus on driving the commercial execution of the LUPKYNIS (voclosporin) business. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program and is exploring alternative approaches for AUR200. The corporate restructuring involved the Company reaffirming its commitment to LUPKYNIS growth ensuring product quality and patient safety, while maintaining a sharp focus on operating efficiencies and maximizing cash flows. The Company also announced it plans to reduce employee headcount by at least 25% by the end of the first quarter of 2024.
As of March 31, 2024, the restructuring expenses recorded by the Company were as follows:
(in thousands)
Three months ended March 31, 2024
Employee severance and one time benefits
$5,207 
Contract terminations
919 
Other costs
557 
Total
$6,683 
During the first quarter of 2024, restructuring expenses of approximately $6.7 million were recorded in connection with this program and are included within operating expenses on the condensed consolidated statements of operations and comprehensive loss.
20.Subsequent Events
From April 1, 2024 through April 30, 2024 the Company has repurchased approximately 1.0 million of additional Aurinia common shares for $5.2 million (including transaction costs). The cost of repurchased shares will be reported as a reduction in common stock and subsequently canceled.
18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q. The information in this discussion contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, (the Exchange Act), which are subject to the “safe harbor” created by those sections, as well as “forward-looking information” as defined in applicable Canadian securities laws. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans; objectives of management; the key potential benefits of LUPKYNIS; our estimate, based on our patient-specific estimated glomerular filtration rate (eGFR) dosing regimens, the average utilization in our clinical trials, and accounting for factors including mandatory rebates, channel discounts, and anticipated patient adherence, that we expect our average annualized net realizable revenue per patient to be approximately $70,000 to $75,000; our belief that we have sufficient financial resources to fund our current plans for at least the next few years; our potential to receive certain payments and royalties under our agreement with Otsuka Pharmaceuticals Co. Ltd., or Otsuka. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “propose,” “intend,” “continue,” “potential,” “possible,” “foreseeable,” “likely,” “unforeseen” and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: the accuracy of reported data from third-party studies and reports; that our IP rights are valid and do not infringe the IP rights of third parties; our assumptions relating to the capital required to fund operations for the next few years; the assumption that our current good relationships with our suppliers, service providers and other third parties will be maintained; assumptions relating to the burn rate of our cash for operations; assumptions relating to the capital required to fund operations for the next few years; assumptions relating to the progress of our pre-clinical activities that our third party service providers will comply with their contractual obligations. Even though management believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. We discuss many of these risks, uncertainties and other factors in greater detail under the heading “Risk Factors” in Part I, Item 1A of our 2023 Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission on February 15, 2024 and with applicable Canadian securities regulatory authorities. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this discussion completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Overview
Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, we introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active LN. We continue to conduct clinical and regulatory activities to support the LUPKYNIS development program. We contracted with Otsuka as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories.
On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value, including an exclusive focus on driving the commercial execution of the LUPKYNIS business. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program and is exploring alternative approaches for AUR200. The corporate restructuring involved the Company reaffirming its commitment to LUPKYNIS growth, while maintaining a sharp focus on operating efficiencies and maximizing cash flows. For further discussion, refer to Note 19, Restructuring.
LUPKYNIS is an orally administered CNI immunosuppressant that has been demonstrated to improve near and long-term outcomes in LN when used in combination with MMF (although MMF is not currently approved as such) and steroids. By inhibiting calcineurin, LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. LUPKYNIS also potentially stabilizes podocytes, which can protect against proteinuria.
19

Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The mechanism of action of LUPKYNIS has been validated with certain earlier generation CNIs for the prevention of rejection in patients undergoing solid organ transplants and in several autoimmune indications, including uveitis, keratoconjunctivitis sicca, psoriasis, rheumatoid arthritis, and for LN in Japan. We believe that LUPKYNIS possesses pharmacologic properties with the potential to demonstrate best-in-class differentiation
Recent Developments
Conclusion of Strategic Review Process
Effective February 14, 2024, the Board of Directors elected to conclude its strategic review process.
Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program and is exploring alternative approaches for AUR200. As previously reported, the Company expects to recognize $50 million to $55 million in annual cost savings, with 75% of those savings recognized in 2024, excluding a one-time restructuring charge of approximately $7 million incurred in the first quarter. The Board of Directors also approved a share repurchase program of up to $150 million worth of our common shares, affirming its confidence in the Company's growth prospects. For further discussion, refer to Note 13, Shareholder's Equity and Note 19, Restructuring.
The price of LUPKYNIS is based on one unit of 60 capsules we refer to as a “wallet”. As of January 1, 2024, the wholesale acquisition cost (WAC) of a LUPKYNIS wallet is $4,898. Based on our patient-specific eGFR dosing regimens, the average utilization in our clinical trials, and accounting for factors including mandatory rebates, channel discounts, and anticipated patient adherence, duration of therapy and compliance, we are adjusting our expected average annualized net realizable revenue per patient for us to be approximately $70,000 - $75,000. When determining the price of LUPKYNIS, we considered the burden of LN disease in the context of value that LUPKYNIS offers to patients and the U.S. healthcare system.
Policies and Significant Judgments and Estimates
There have been no material changes to our critical accounting policies and significant judgments and estimates as described in our Annual Report on Form 10-K for the year ended December 31, 2023.
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and specialty distributors and directly to our ex-U.S. partner Otsuka. These customers subsequently distribute our products to patients and health care providers. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer).
Our estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix to accrue for variable consideration related to inventory sold to our customers that has not yet been dispensed to patients. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies, that has not yet been dispensed. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. As of March 31, 2024, we did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December 31, 2023.
20

Results of Operations
Three Months ended March 31, 2024 compared to Three Months ended March 31, 2023
The following table sets forth our results of operations for the three months ended March 31, 2024 and March 31, 2023.
Three months ended March 31,
(in thousands)20242023Change
Revenue
Product revenue, net$48,073 $34,337 $13,736 
License, collaboration and royalty revenue
2,230 72 2,158 
Total revenue, net50,303 34,409 15,894 
Operating expenses
Cost of sales7,752 421 7,331 
Selling, general and administrative47,695 50,124 (2,429)
Research and development5,551 13,158 (7,607)
Restructuring expenses6,683 — 6,683 
Other (income) expense, net(4,125)290 (4,415)
Total cost of sales and operating expenses63,556 63,993 (437)
Loss from operations(13,253)(29,584)16,331 
Interest expense(1,283)— (1,283)
Interest income4,526 3,814 712 
Net loss before income taxes(10,010)(25,770)15,760 
Income tax expense739 436 303 
Net loss$(10,749)$(26,206)$15,457 
Total Revenue, Net
Total net revenue was $50.3 million and $34.4 million for the three months ended March 31, 2024 and March 31, 2023, respectively.
We currently sell to two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and license, collaboration and royalty revenue in the Otsuka Territories.
The percentage of total revenues, net from our main customers were as follows:
Three months ended March 31,
20242023
Two main specialty pharmacies
91%99%
Collaboration partnership
7%—%
Product Revenue, Net
Net product revenue was $48.1 million and $34.3 million for the three months ended March 31, 2024 and March 31, 2023, respectively. The increase is primarily due to an increase of sales of LUPKYNIS to our two main specialty pharmacies, driven predominantly by further penetration of the LN market.
This penetration can be demonstrated by a total of approximately 2,178 patients on therapy as of March 31, 2024, compared to approximately 1,731 patients on therapy as of March 31, 2023. The increase in patients was driven by 448 additional patient start forms and 148 new patients who were either restarting LUPKYNIS or receiving it through a hospital pharmacy during the three months ended March 31, 2024, compared to 466 PSFs received during the three months ended March 31, 2023.
21

Additionally, our 12-month persistency rate has increased to 56% at March 31, 2024 from approximately 51% at March 31, 2023.
License, Collaboration and Royalty Revenue
License, collaboration and royalty revenue was $2.2 million and $0.1 million for the three months ended March 31, 2024 and March 31, 2023, respectively. The increase is due to manufacturing services revenue from Otsuka related to shared capacity services that commenced in the third quarter of 2023.
Cost of Sales
Cost of sales was $7.8 million and $0.4 million for the three months ended March 31, 2024 and March 31, 2023, respectively. The increase is primarily due to increased sales of LUPKYNIS (voclosporin), coupled with the amortization of the monoplant finance right of use asset, which was placed into service in late June 2023.
Gross Margin
Gross margin for the three months ended March 31, 2024 and March 31, 2023 was approximately 85% and 99%, respectively. The decrease in gross margin is due to the increase in cost of sales.
Selling, General and Administrative Expenses
SG&A expenses decreased to $47.7 million for the three months ended March 31, 2024 compared to $50.1 million for the three months ended March 31, 2023. SG&A expenses consisted of the following:
Three Months Ended
March 31,
(in thousands)20242023
Salaries, incentive pay and employee benefits$21,661 $22,298 
Professional fees and services12,954 13,258 
Share-based compensation expense7,537 7,589 
Other public company costs, facility costs, insurance, information technology, amortization of property and equipment2,842 3,822 
Travel, trade shows and sponsorships2,701 3,157 
$47,695 $50,124 
The primary drivers for the decrease were lower employee costs due to the reduction in general and administrative headcount, which occurred late in the first quarter of 2024, lower corporate costs related to insurance and information technology and lower spend for travel and business meetings.
Research and Development Expenses
R&D expenses were $5.6 million and $13.2 million for the three months ended March 31, 2024 and March 31, 2023, respectively. R&D expenses consisted of the following:
Three Months Ended
March 31,
(in thousands)20242023
Contract research organizations (CRO) and developmental expenses$3,116 $4,230 
Clinical supply and distribution915 3,273 
Salaries, incentive pay and employee benefits3,492 3,825 
Share-based compensation expense(2,166)1,590 
Other costs194 240 
$5,551 $13,158 
22


The primary drivers for the decrease were due to a reduction in share-based compensation related to the reduction in headcount, which occurred late in the first quarter of 2024 and a decrease of clinical supply and distribution costs related to ceasing development of our AUR200 and AUR300 programs.
Restructuring Expenses
During the first quarter of 2024, restructuring expenses were approximately $6.7 million which includes employee severance, one-time benefit payments and contract termination expenses. The company recognized the majority of the planned restructuring costs in the first quarter.
Other (Income) Expense, net

Other (income) expense, net was $(4.1) million and $0.3 million for the three months ended March 31, 2024 and March 31, 2023, respectively. The increase was primarily due to the foreign exchange remeasurement of the monoplant lease liability, which commenced in June 2023 and is denominated in CHF.

Interest Expense
Interest expense was $1.3 million and nil for the three months ended March 31, 2024 and March 31, 2023, respectively. The interest expense is due to the monoplant finance lease, which commenced in June 2023 and is denominated in CHF.

Interest Income

Interest income was $4.5 million and $3.8 million for the three months ended March 31, 2024 and March 31, 2023, respectively. The increase is due to higher yields on our investments as a result of increased interest rates.
Liquidity and Capital Resources
As of March 31, 2024, we had cash, cash equivalents and restricted cash of approximately $64.5 million and investments of $255.7 million compared to cash, cash equivalents and restricted cash of $48.9 million and investments of $301.8 million at December 31, 2023. The decrease is primarily related to the continued investment in commercialization activities and post approval commitments of our approved drug, LUPKYNIS, monoplant payments, share repurchases and restructuring related payments partially offset by an increase in cash receipts from sales of LUPKYNIS and payments from Otsuka. Cash, cash equivalents and restricted cash and investments are primarily held in U.S. dollars. As of March 31, 2024 and December 31, 2023, we had working capital of $327.2 million and $347.6 million, respectively.
We are devoting the majority of our operational efforts and financial resources towards the commercialization and post- approval commitments of our approved drug, LUPKYNIS. Taking into consideration the cash and cash equivalents and investments as of March 31, 2024, we believe that our cash position is sufficient to fund our current plans which include funding commercial activities, such as our FDA related post approval commitments, manufacturing and packaging commercial drug supply, funding our supporting commercial infrastructure, funding our working capital obligations and share repurchases for at least the next few years.

23

Cash Flow Summary
The following table summarizes our cash flows for the three months ended March 31, 2024 and March 31, 2023:
Three Months Ended March 31,
(in thousands)20242023
Net cash (used in) provided by:
Operating activities$(18,598)$(31,670)
Investing activities49,233 24,860 
Financing activities(15,051)1,639 
Net increase (decrease) in cash and cash equivalents
$15,584 $(5,171)

Net cash used in operating activities was $18.6 million for the three months ended March 31, 2024 compared to $31.7 million for the three months ended March 31, 2023. The decrease is primarily due to an increase in cash receipts from sales of LUPKYNIS and cash receipts from Otsuka. See "Total Revenue" above for further discussion regarding our increased sales of LUPKYNIS.
Cash provided by investing activities was $49.2 million during the three months ended March 31, 2024 compared to $24.9 million during the three months ended March 31, 2023. The increase was primarily related to the timing of proceeds of investments.
Cash used in financing activities was $15.1 million during the three months ended March 31, 2024 compared to cash provided by financing activities of $1.6 million during the three months ended March 31, 2023. The decrease was primarily due to share repurchases which began in February 2024 and quarterly lease payments for our monoplant finance lease, which commenced during the third quarter of 2023.
Share Repurchase Program
In February 2024, our Board of Directors approved a share repurchase program of up to $150 million of our common shares. On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program.
As of March 31, 2024, we had repurchased approximately 2.4 million of our common shares for $13.4 million (including transaction costs which consist of commissions and excise tax). The cost of repurchased shares is reported as a reduction in common stock and the repurchased shares were subsequently canceled.
Off‑Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any off‑balance sheet arrangements as such term is defined in Item 303(a)(4)(ii) of Regulation S-K under the Securities Act.
Contractual Obligations
There have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023.
Item 3. Quantitative and Qualitative Disclosures About Market Risks
Our activities can expose us to market risks which include interest rate risk, foreign currency risk, inflation risk and credit risk. Risk management is carried out by management under policies approved by our Board of Directors, with oversight provided by
24

the Audit Committee of our Board of Directors. Our overall risk management program seeks to minimize adverse effects on our financial performance.
Interest Rate Risk
Financial assets and financial liabilities with variable interest rates expose us to cash flow interest rate risk. We manage our interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct
operations on a day-to-day basis. As of March 31, 2024, our investment portfolio includes cash, cash equivalents, restricted cash and investments of $320.1 million that earn interest at various rates. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. Our investments held during the year were comprised of highly rated instruments such as certificates of deposits, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities. As of March 31, 2024, these instruments primarily have a maturity of less than a year.

As of March 31, 2024, a hypothetical decrease of 100 basis points on the interest rates of our investments would result annually in $2.6 million less interest in our portfolio. We do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio, due to the short-term nature of the investments and our current ability to hold these investments to maturity.

Accounts receivable, accounts payable and accrued liabilities bear no interest. We do not believe that our results of operations or cash flows would be affected to a significant degree by a sudden change in market interest rates relative to our investment portfolio.

Foreign Currency Risk

We are exposed to financial risk related to the fluctuation of foreign currency exchange rates. Foreign currency risk for the Company is the risk variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Swiss Franc, Canadian dollar and Great British Pound, which could affect our operating and financial results.

As of March 31, 2024, we had an $81.2 million finance lease liability on our balance sheet related to the monoplant. An assumed 10% fluctuation in the Swiss Franc would have an approximate $8.1 million fluctuation in the valuation of the lease liability.

There were no other foreign currency fluctuations that would have had a material impact on our financial condition or results of operations as of March 31, 2024.

Inflation Risk

Inflation has been increasing in recent periods and is expected to continue to be volatile in the future. Inflation generally affects us by increasing our cost of labor, commercial support, manufacturing and clinical trial expenditures. In addition, inflation also impacts our government and payer rebates as it pertains to the consumer price index (CPI) penalty. Our investment portfolio may experience the risk of realized losses on our investments if we were to sell before maturity due to the market volatility caused by increased interest rates.

Credit Risk

Our exposure to credit risk generally consists of cash and cash equivalents, investments and accounts receivable. We place our cash and cash equivalents with highly rated financial institutions and invest the excess cash in highly rated investments. It is the
Company's intent for these investments to have an overall rating of A-1, or higher, by Standard & Poor’s, or an equivalent rating by Moody’s or Fitch. Our investment policy limits investments to certain types of debt and money market instruments issued by institutions primarily with investment grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.

We are subject to credit risk in connection with our accounts receivable due from our two main specialty pharmacies for U.S. commercial sales and collaboration partnership with Otsuka which accounted for the majority of our accounts receivable, net balances as of March 31, 2024. We monitor economic conditions, including the creditworthiness of our customers and collaboration partner. We regularly communicate with our customers regarding the status of receivable balances and have not experienced and issues with collectability. The timing between the recognition of revenue for product sales and the receipt of
25

payment is not significant. Our standard credit terms range from 30 to 45 days. During the quarter ended March 31, 2024, we did not recognize any allowance for credit losses related to credit risk for our customers or write any amounts off.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of March 31, 2024, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended March 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
26

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. For further discussion, refer to Note 18, Commitments and Contingencies.
There are no material developments to report in respect of the litigation described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Item 1A. Risk Factors.
Under Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023 we identified important factors that could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report. There has been no material change in our risk factors subsequent to the filing of our prior reports referenced above except as mentioned below. However, the risks described in our reports are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Issuer Purchases of Equity Securities
The following table summarizes our common share activity of our repurchased shares under our share repurchase program announced on February 15, 2024. Refer to Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources" for further details of the share repurchase program.
Period
Total number of shares purchased
Average price paid per share in $
Total number of shares purchased as part of publicly announced program
Approximate dollar value of shares that may yet be purchased under program
(in thousands)(1)(2)
2/21/2024-3/21/2024
1,732,787$5.771,732,787$140,000
3/22/2024-3/28/2024
640,587$4.98640,587$136,809
Total
2,373,3742,373,374
(1)The approximate value of shares that may yet be purchased under the program does not include commissions that may be paid to brokers in connection with such purchases.
(2)As of March 28, 2024, if calculated under the exemptive relief, value of shares that may yet be repurchased would be approximately $96.8 million. The calculation is based on 15% of our common shares outstanding before the repurchase program began less shares repurchased multiplied by the close price as of March 28, 2024.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
None.
27

Item 6. Exhibits.
The following exhibits are filed as part of this report:
Exhibit
Number		Description
3.1
3.2
3.4#
31.1*
31.2*
32.1**
32.2**
101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Filed herewith.
#
Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because they are not material and are the type that Aurinia treats as private or confidential.
**Furnished herewith. Exhibits 32.1 and 32.2 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.

28

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AURINIA PHARMACEUTICALS INC.
May 1, 2024By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer, Director
(Principal Executive Officer)
May 1, 2024By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)
29
 EX-3.4 2 vknappertzseveranceagreeme.htm EX-3.4 Document
Exhibit 3.4
image_0a.jpg

March 4, 2024

CONFIDENTIAL – NOT FOR DISCLOSURE VIA ELECTRONIC MAIL
Volker Knappertz, M.D.
[redacted]

Re: Severance Agreement, Release, and Covenant Not To Sue

Dear Volker:
As we have discussed, your employment with Aurinia Pharma U.S., Inc. (“Corporation”) will terminate today, March 4, 2024 (“Termination Date”).
Effective as of the Termination Date, you are to cease all efforts on behalf of the Corporation – you are not to hold yourself out as an employee, agent, or authorized representative of the Corporation, negotiate or enter into any agreements on behalf of the Corporation, or otherwise bind the Corporation in any way.

Following the Termination Date, regardless of whether you sign this letter agreement, you will receive your final paycheck, which will include wages, the 2024 merit increase retroactive to January 1, 2024 through the Termination Date and all accrued but unused vacation through the Termination Date. Also, regardless of whether you sign this letter agreement, you also will receive under separate cover information regarding your right, at your own cost, to continuation health care coverage under the Consolidated Omnibus Budget Reconciliation Act. You will receive information regarding any conversion, distribution, or other rights relating to these benefits under separate cover from the applicable plan provider.

To ensure an amicable and smooth transition, the Corporation offers you the following severance package pursuant to the terms of this letter agreement, as stated below:
1.    Severance Payments. In exchange for your agreement to the release and covenant not to sue set forth below, provided you do not timely revoke your signature, and consistent with the Employment Agreement you signed dated July 11, 2022, the Corporation will provide you with:
(a)    A    payment    of    $542,062.50    (FIVE    HUNDRED    FORTY-TWO THOUSAND SIXTY-TWO DOLLARS AND FIFTY CENTS) less all
required withholdings, representing twelve months of your base salary. The severance payment will be paid in a lump sum on the second payroll date following the Effective Date of the letter agreement;


Certain identified information has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed.




(b)    A payment of $327,819.00 (THREE HUNDRED TWENTY-SEVEN THOUSAND EIGHT HUNDRED NINETEEN DOLLARS AND ZERO
CENTS), less all required withholdings, representing the 2023 Discretionary Bonus Payment pursuant to Section 5 of the Employment Agreement dated July 11, 2022, paid in a lump sum, no later than the second payroll date following the Effective Date of this letter agreement;

(c)    If you properly elect to continue coverage in the Corporation’s medical, dental, and vision plan(s) pursuant to the Consolidated Omnibus Budget Reconciliation Act (“COBRA”) and the applicable terms of the plan, the Corporation will pay all COBRA premiums (at the same level of coverage or less for you in effect immediately prior to the Termination Date) for the first twelve (12) months of such coverage unless your COBRA coverage period ends earlier or you obtain no less favorable health insurance coverage through new employment using commercially reasonably efforts to obtain such coverage (the “COBRA Payment Period”). Any further coverage beyond this COBRA Payment Period will be at your expense.

Should the COBRA policy lapse due to your non-payment of any employee premiums and/or your failure to submit required COBRA forms, it shall be your responsibility to cure such defects, and the Corporation will not be held liable for any lapses in coverage and will not be required to make any payments for continued healthcare coverage for you during any lapse in COBRA coverage.

Should you, during the COBRA Payment Period, become eligible to receive health insurance benefits from another employer, you must notify the Corporation within ten (10) business days of such event. Upon such notification, the COBRA Payment Period will immediately terminate if such coverage is no less favorable, and the Corporation will have no further obligation to pay the COBRA premiums for you.

If the Corporation, in its sole discretion, determines the payments of any COBRA premiums would violate the nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient Protection and Affordable Care Act of 2010, together with the Health Care and Education Reconciliation Act of 2010 (collectively, the “Act”) or Section 105(h) of the Internal Revenue Code, the premium payments will be imputed as income and treated as taxable to you to the extent necessary to eliminate any discriminatory treatment or taxation under the Act or Section 105(h) of the Code.

(d)    Outplacement services in the amount of $52,000 for twelve (12) months through LHH Programs paid by the Corporation to LHH on your behalf. This must be initiated by you within 90 days of the Effective Date.







In connection with the above severance payments, the Corporation will issue you a Form W-2. You acknowledge and agree that the Corporation has made no representations to you regarding the tax consequences of any financial consideration provided to you under this letter agreement, and that you are solely and entirely responsible for the payment and discharge of any additional federal, state, and local taxes, if any, that may, at any time, be found to be due on, or as a result of, any amount that is provided to you under this letter agreement. In that regard, you agree to indemnify, defend, and hold the Corporation, or any of its parent corporations, subsidiaries, or related entities, harmless from any claim or liability for any such taxes and related penalties and/or interest owed by you, in the event such taxes, penalties, and/or interest are assessed by the United States Internal Revenue Service or any other taxing authority.

You acknowledge and agree that, absent this letter agreement, you have no legal, contractual, or other entitlement to the payments set forth in this paragraph 1, and such payments and other benefits constitute valid and sufficient consideration for your release of claims and other obligations set forth below and that the payments constitute at least the full amount to which you are entitled under the Employment Agreement dated July 11, 2022 and you acknowledge that you are not entitled to any further payments under the Corporation’s Severance Pay Policy.

You agree that the Employment Agreement is terminated, is of no further force and effect, and that, other than as spelled out below, you are not entitled to any further payments or benefits under the Employment Agreement, including any further severance payments or incentive compensation. Notwithstanding the prior sentence, you and the Corporation agree that the restrictions in, and requirements of, Paragraphs 19, 20, 21, 24, 25, 26, 27, 28, 29, 30, 31, 34, 36, 38, Schedule B and Schedule D of the Employment Agreement shall remain in full force and effect and be enforceable and shall survive the ending of your employment.

You acknowledge and agree that, should you breach any of your commitments in this letter agreement, the Corporation may, in addition to pursuing all legal and equitable rights and remedies that might be available to it, without limitation, terminate any payment or any other obligations otherwise due and owing to you under this letter agreement.
2.    No Other Compensation Or Benefits. Except as provided above, you shall not be entitled to any other or further compensation, remuneration, benefits, reimbursement, or payments from the Corporation.

3.    No Admission Of Liability. This letter agreement is a result of a compromise and shall never be construed as, and is not, an admission by the Corporation (or its parent corporations, subsidiaries, and/or affiliates) of any liability, wrongdoing, or responsibility on their part.

4.    Release & Covenant Not To Sue. In exchange for the consideration outlined in paragraph 1 above, you hereby waive and release any and all claims you have or might have against the Corporation and any of its predecessors, subsidiaries, affiliates, and related entities or any of their past and present officers, directors, shareholders, agents, attorneys, employees, successors, and all other related or affiliated persons, firms, or entities (“Released Parties”), arising from or related to your employment with and/or the termination of your employment from


the Corporation. These claims include, but are not limited to, all claims arising under federal, state, and local statutory or common law; those covered by the Americans With Disabilities Act, the Age Discrimination In Employment Act (“ADEA”), Title VII of the Civil Rights Act, and the Family and Medical Leave Act (“FMLA”); and all other claims for breach of contract, tort, wrongful termination, unpaid wages, and relating to any other law prohibiting employment discrimination or relating to employment. This is a general release. You expressly acknowledge that this general release includes, but is not limited to, any and all claims arising out of or related to your employment with and separation from the Corporation.

By signing this letter agreement, you expressly acknowledge and represent that (a) you have suffered no injuries or occupational diseases arising out of or in connection with your employment with the Corporation; (b) you have received all wages to which you were entitled as an employee of the Corporation; (c) you received all leave to which you were entitled under the FMLA; and (d) you are not aware of any facts or circumstances constituting a violation of the FMLA, the Fair Labor Standards Act, or any applicable state leave or wage payment law.

You expressly state, understand, intend, and agree that this letter agreement forever precludes you from bringing, instituting, maintaining, further pursuing, or participating in any lawsuit against the Released Parties for any causes or claims released in this paragraph 4, other than to enforce its terms and/or compliance with the Older Workers Benefit Protection Act (“OWBPA”). You specifically waive any right to become, and promise not to become, a representative or member of any class, collective or multi-party action or proceeding in which a claim against the Released Parties is made in which the Corporation or any Released Parties identified in this letter agreement is a party.

You represent that you have not filed or otherwise initiated any lawsuit, charge, claim, or demand against any of the Released Parties. Nothing in this letter agreement is intended to impair your rights under whistleblower laws or cause you to disclose your participation in any governmental whistleblower program or any whistleblowing statute(s) or regulation(s) allowing for anonymity.

Additionally, nothing in this letter agreement prohibits, prevents, or otherwise limits you from filing a charge or complaint with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before any federal, state, or local government agency (e.g., EEOC, NLRB, SEC) or in any legislative or judicial proceeding nor does anything in this letter agreement preclude, prohibit or otherwise limit, in any way, your rights and abilities to contact, communicate with or report unlawful conduct, or provide documents, to federal, state, or local officials for investigation or participate in any whistleblower program administered by any such agencies. However, to the maximum extent permitted by law, you agree that if such an administrative claim is made with the EEOC, NLRB or any state or local government agency equivalent, you shall not be entitled to recover any individual monetary relief or other individual remedies. In addition, nothing in this letter agreement, including but not limited to the release of claims nor the confidentiality, non-disparagement, affirmations, liquidated damages, cooperation, and/or return of property clauses, prohibits you from: (1) reporting possible violations of federal or other law or regulations, including any possible securities laws violations, to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S. Securities and





Exchange Commission, the Commodity Futures Trading Commission, the U.S. Congress, or any agency Inspector General; (2) making any other disclosures that are protected under the whistleblower provisions of federal or other law or regulations; or (3) filing a charge or complaint or otherwise fully participating in any governmental whistleblower programs, including but not limited to any such programs managed or administered by the U.S. Securities and Exchange Commission, the Commodity Futures Trading Commission and/or the Occupational Safety and Health Administration. You are not required to notify or obtain permission from the Corporation when filing a governmental whistleblower charge or complaint or engaging or participating in protected whistleblower activity. Moreover, nothing in this letter agreement prohibits or prevents you from receiving individual monetary awards or other individual relief by virtue of participating in such governmental whistleblower programs.
Additionally, nothing in this letter agreement will waive, relinquish, diminish, or in any way affect (i) any vested rights you may have under any Corporation retirement plan; (ii) any rights or claims that, as a matter of law, cannot be released or waived; or (iii) your right to challenge the validity and enforceability of this letter agreement’s release of claims under the ADEA.

5.    Confidentiality Of Letter Agreement And Business Information. You represent and warrant that you will keep the terms of this letter agreement strictly confidential, and that you will not disclose them to anyone, unless such disclosure is (a) lawfully required by any governmental agency, including government taxing authorities; (b) subpoenaed; (c) otherwise required to be disclosed by law (including legally required financial reporting); or (d) necessary in any legal proceeding in order to enforce any provision of this letter agreement. You agree to provide the Corporation five days’ written notice prior to any such required or necessary disclosure. You and the Corporation acknowledge and agree that the provisions of this paragraph 5 create no liability for disclosures made: (a) prior to your execution of this letter agreement; (b) by persons from public information released prior to your execution of this letter agreement; (c) pursuant to paragraph 8 to enforce the terms of this letter agreement; or (d) as otherwise compelled by operation of law.

The foregoing notwithstanding, you and the Corporation acknowledge that you may discuss the contents of this letter agreement with your spouse, attorney, and/or tax advisor, and you shall be liable for the actions of your spouse, attorney, and/or tax advisor with respect to their compliance with the confidentiality obligation of this paragraph.

You acknowledge and affirm your continuing obligation to keep confidential any and all confidential or proprietary information that you acquired during your employment with the Corporation. You agree not to disclose any such information to any person or entity outside of the Corporation at any time in the future or to use any such information for the benefit of anyone other than the Corporation. You agree to continue to be bound by any other preexisting agreement relating to the Corporation’s proprietary information and your obligation to maintain the confidentiality of such information. Even if you do not execute this letter agreement, these confidentiality obligations continue to apply to you.

You understand and agree that this letter agreement shall not be admissible as evidence in any court or administrative proceeding; provided, however, that either party may submit this letter agreement to an appropriate legal forum in the event of an alleged breach of any of its terms.



6.    No Disparagement. You agree not to make any disparaging, or defamatory statements or communications about the Corporation or any of the other Released Parties.

7.    Return of Corporation Property. As of the Termination Date, you shall return to the Corporation all of the Corporation’s property in your possession including, but not limited to: computers; cellular phones; credit cards; files, notes, books, binders, manuals, and other printed material; computer disks and software; client files; and all other tangible and intangible property belonging to the Corporation and obtained by you in connection with your employment with the Corporation, including all copies of such property, in any form, electronic or otherwise. You agree to provide the Corporation with any password(s) you installed and/or used on any Corporation computer or other Corporation property.

8.    Remedy. Failure to abide by the terms of this letter agreement, including those of paragraphs 5, 6, 7, and/or 9, shall constitute a breach of this letter agreement and shall entitle the Corporation and the Released Parties, where appropriate, to immediate injunctive relief to enjoin further breaches of the aforementioned paragraphs, consequential damages, and reimbursement of all fees and costs actually incurred in bringing such legal action.

9.    Future Cooperation.

(a)    At any time following the Termination Date, you agree to cooperate fully and completely with the Corporation, its advisors, and its legal counsel and respond to questions candidly and truthfully with respect to any internal inquiry or investigation, any federal, state, or local agency investigation, or any legal proceeding involving the Corporation or any parent, predecessor, subsidiary, affiliate, or related entity (collectively for this paragraph 9 only, “the Corporation Entities”). Such cooperation shall include being available at reasonable times and places for interviews, reviewing documents, testifying in depositions or legal or administrative proceedings, and otherwise meeting with the Corporation in connection with the preparation of defenses to any pending or potential future claims against any of the Corporation Entities. The Corporation agrees to reimburse you for all reasonable out-of-pocket expenses incurred in connection with rendering such services. If you are legally required to appear or participate in any non-criminal proceeding that involves or is brought against any of the Corporation Entities, you agree to disclose to the Corporation no later than ten business days prior to the date that such disclosure is to be made, what you plan to produce, and otherwise to cooperate fully with the Corporation as set forth herein.

(b)    In the event of receipt by you of a subpoena issued at the request of any private sector person or entity at any time following the Termination Date regarding any matter related to or involving any of the Corporation Entities, you agree to notify the Corporation promptly before complying with the subpoena, so that the Corporation may take appropriate action to protect its interests, including moving to quash the subpoena, as long as provision of such notice does not violate any applicable law, rule, or court order. If the Corporation seeks to prevent disclosure in accordance with applicable legal procedures and provides you with notice before the deadline for compliance with a subpoena, you shall not make any such disclosure until either such objections are withdrawn or the objections are finally adjudicated by the tribunal.





10.    OWBPA. Pursuant to the OWBPA, you acknowledge and understand that:

(a)    You are waiving claims for age discrimination under the ADEA in exchange for the payments described above;
(b)    You have received consideration beyond that to which you would be entitled without signing this letter agreement;
(c)    You have been advised in writing of the right to consult with an attorney before signing this letter agreement;
(d)    You have a period of at least forty-five (45) days from the Termination Date within which to review and consider this letter agreement before signing it;
(e)    You may revoke this letter agreement by providing written notice to the Corporation within seven days following its execution, and that the letter agreement shall not become effective and enforceable until such seven-day period has expired.

Any notice of revocation of this letter agreement shall not be effective unless given in writing and received by the Corporation within the seven-day revocation period via email, personal delivery, or overnight courier, postage prepaid, addressed as follows:

Lucy Alexis Shieh, SPHR, SHRM-SCP
Vice President, HR Operations
77 Upper Rock Circle, Suite 700
Rockville, MD 20870
[redacted]

The Effective Date of this letter agreement is the eighth day after which you have signed this letter agreement provided you have not timely revoked your signature.

11.    Eligibility Requirements/ Applicable Data.    All U.S. employees in the Corporation (“Decisional Unit”) were eligible to be selected for separation as part of the reduction program. Eligible employees were selected for separation based on various considerations including but not limited to work/job elimination, tenure, job performance, skill sets and/or roles/responsibilities. Attached as Exhibit “A” are the job titles and ages of all eligible U.S. employees selected for the separation as part of the program, along with the job titles and ages of all eligible employees in the Decisional Unit who were not selected for separation as part of the program.

12.    Voluntary & Entire Agreement; Choice Of Law. Your signature below will indicate that you are entering into this letter agreement freely and with a full understanding of its terms and not in reliance upon any representations other than those explicitly set forth in this letter agreement. No changes to this letter agreement will be valid unless in writing and signed by both you and me. This letter agreement constitutes the entire understanding and agreement of the parties related to the matters discussed herein and supersedes any prior agreement regarding the subject





matter hereof. Notwithstanding the above, any other any invention, confidentiality, non- competition, and/or non-solicitation agreements/provisions between you and Aurinia are hereby incorporated in this letter agreement and remain enforceable notwithstanding this letter agreement, including 19, 20, 21, 24, 25, 26, 27, 28, 29, 30, 31, 34, 36, 38, Schedule B and Schedule D of the Employment Agreement, which shall remain in full force and effect and be enforceable and shall survive the ending of your employment. This letter agreement shall be interpreted and enforced in accordance with the laws of the State of Maryland.


*    *    *

If you are voluntarily willing to enter into this letter agreement, please signify your acceptance in the space indicated below and return to me within 45 days. Bear in mind that you are not able to sign this letter agreement until March 4, 2024 and you shall not be entitled to commencement of the severance payments until you have executed this letter agreement.

Sincerely,



/s/ Max Donley
Executive Vice President, Operations and Strategy


I, VOLKER KNAPPERTZ, HAVE READ AND UNDERSTAND THIS LETTER AGREEMENT, AND I ACCEPT AND AGREE TO ALL OF ITS TERMS AND CONDITIONS. I ENTER INTO THIS LETTER AGREEMENT VOLUNTARILY, WITH FULL KNOWLEDGE OF ITS EFFECT.




04-Mar-2024
image_9a.jpg/s/ Volker Knappertz, M.D.
Signature    Date


 EX-31.1 3 auph-2024q1exx311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Peter Greenleaf, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:May 1, 2024By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 4 auph-2024q1exx312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a),
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Joseph Miller, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc..;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:May 1, 2024By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-32.1 5 auph-2024q1exx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Greenleaf, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:May 1, 2024By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)

 EX-32.2 6 auph-2024q1exx322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Miller, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:May 1, 2024By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-101.SCH 7 auph-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Inventories, net link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Prepaid Expenses link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Lease Obligations link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Deferred Compensation and Other Non-current Liabilities link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - License and Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Shareholder's Equity link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Inventories, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Prepaid Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Summary of Significant Accounting Policies- Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Total Revenues, Net From Main Customers (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Inventories, net (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Prepaid Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Lease Obligations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Accounts Payable and Accrued Liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - License and Collaboration Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Shareholder's Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Share-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Share-based Compensation - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Share-based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Share-based Compensation - Performance Awards and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Share-based Compensation - Allocated Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Restructuring - Restructuring and Related Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 auph-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 auph-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 auph-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Restructuring Expenses Restructuring Costs [Policy Text Block] Restructuring Costs Net changes in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type [Domain] Award Type [Domain] Tiered royalty percentages on future sales Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent Outstanding - Beginning of Period (in shares) Outstanding - End of Period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Remaining lease term Lessee, Operating Lease, Remaining Lease Term Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Unvested performance awards Performance Shares [Member] Computer equipment Computer Equipment [Member] Total cash, cash equivalents, restricted cash and investments, unrealized losses Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Losses Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Losses Commitments and contingencies (Note 18) Commitments and Contingencies Operating Lease Payments Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Total cash, cash equivalents, restricted cash and investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments Shareholder's Equity Equity [Text Block] Non-current operating assets Increase (Decrease) in Other Noncurrent Assets Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] Commercial accruals Commercial Related Accruals, Current Commercial Related Accruals, Current Customer [Axis] Customer [Axis] Current liabilities Liabilities, Current [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted average exercise price $ Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Forfeited or cancelled (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Diluted loss per share (in usd per share) Diluted Net loss per common share (expressed in usd per share) Earnings Per Share, Diluted Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Payments of deferred compensation Deferred Compensation Arrangement with Individual, Compensation Expense Level 3 Fair Value, Inputs, Level 3 [Member] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Non-current assets Assets, Noncurrent [Abstract] Shares issued on exercise of stock options and vesting of restricted stock units Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair value per common share option (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Unrealized gain (loss) on available-for-sale securities, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] 2026 Finance Lease, Liability, to be Paid, Year Two Lease Obligations Lessee, Operating Leases [Text Block] Corporate bonds Corporate Bond Securities [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Employee Stock Employee Stock [Member] Stock repurchased during period, value Stock repurchased during period, value Stock Repurchased During Period, Value Cash, Cash Equivalents, Restricted Cash and Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Shares issued on exercise of stock options and vesting of restricted stock units (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Accounts receivable, net Increase (Decrease) in Receivables Schedule of Loss Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Patents Patents [Member] Dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Property and Equipment, net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Finance right-of-use asset obtained in exchange for lease obligations (monoplant) Finance Right-of-Use Asset Obtained in Exchange for Lease Obligations Finance Right-of-Use Asset Obtained in Exchange for Lease Obligations Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Small Business Entity Small Business Annualized volatility (as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Restructuring and Related Cost, Incurred Cost Restructuring and Related Cost, Incurred Cost Local Phone Number Local Phone Number Beinheim Beinheim, France [Member] Beinheim, France Operating lease liabilities Operating Lease, Liability, Noncurrent Unvested restricted stock units Restricted Stock Units (RSUs) [Member] Depreciation and amortization Depreciation Summary of Cash, Cash Equivalents, Restricted Cash and Investments Marketable Securities [Table Text Block] Monoplant Visp, Switzerland [Member] Visp, Switzerland Income Statement Location [Axis] Income Statement Location [Axis] Short-term investments Debt Securities, Current Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Payables and Accruals [Abstract] Expected payments prior to commencement of lease Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service [Domain] Product and Service [Domain] Lease, Cost Lease, Cost [Table Text Block] Inventories, net Increase (Decrease) in Inventories Unrealized (loss) gain on available-for-sale securities, net of tax of nil Unrealized loss on available-for-sale securities, net Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Research and development Research and Development Expense [Member] Restructuring reserve, accrual adjustment Restructuring Reserve Award Type [Axis] Award Type [Axis] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Contract Termination Contract Termination [Member] Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Selling, general and administrative General and Administrative Expense [Member] Number of shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Property, plant and equipment, gross Property, Plant and Equipment, Gross Related Party Transactions Related Party Transactions Disclosure [Text Block] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Number of shares purchased (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award Entity File Number Entity File Number Total long-term investment corporate bond Long-Term Corporate Debt Securities [Member] Long-Term Corporate Debt Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Cash received for interest Proceeds from Interest Received Operating lease liabilities Operating Lease, Liability, Current Prepaid expenses Total prepaid expenses Prepaid Expense, Current Interest expense Finance Lease, Interest Expense Internal-use software implementation costs Computer Software, Intangible Asset [Member] Shares repurchased and cancelled, inclusive of transaction costs (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Number of customers Concentration Risk, Number of Customers Concentration Risk, Number of Customers Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Acquired intellectual property and other intangible assets, net Net Carrying Amount Finite-Lived Intangible Assets, Net Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Counterparty Name [Domain] Counterparty Name [Domain] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Dr. Robert T. Foster Dr. Robert T. Foster [Member] Dr. Robert T. Foster Operating lease costs Operating Lease, Cost Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets Additional Cash Flow Elements, Summations [Abstract] Common stock, issued (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Deferred revenue Contract with Customer, Liability, Current Unrealized Losses Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss Schedule of Share-based Payment Award Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Total financial assets Assets, Fair Value Disclosure Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Deferred Compensation and Other Non-current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block] Stock options Employee Stock Option [Member] Unrecognized share-based compensation expense weighted average recognition period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total cost of sales and operating expenses Costs and Expenses Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Restructuring accruals Restructuring Accruals, Current Restructuring Accruals, Current Document Type Document Type Entity Address, Address Line One Entity Address, Address Line One 2027 Finance Lease, Liability, to be Paid, Year Three Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Unrealized Gains Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain Subsequent Event [Table] Subsequent Event [Table] Share-based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other, net Other Noncash Income (Expense) 2025 Finance Lease, Liability, to be Paid, Year One Weighted average exercise price $ Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Income taxes payable Taxes Payable, Current Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Subsequent Event Subsequent Event [Member] Capitalized under inventories Inventories [Member] Customer Concentration Risk Customer Concentration Risk [Member] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively) Other Liabilities, Current Accounts payable, accrued and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Prepaid deposits Deposits Assets, Current Raw materials Inventory, Raw Materials, Net of Reserves Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Related Party [Domain] Related Party, Type [Domain] Common Shares Stockholders' Equity, Policy [Policy Text Block] Outstanding, Weighted average exercise price - Beginning of Period (in usd per share) Outstanding, Weighted average exercise price - End of Period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Other current assets Other Assets, Current Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Total cash, cash equivalents, restricted cash and investments, Amortized Cost Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Amortized Cost Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Amortized Cost Inventories, net Total inventories, net Inventory, Net Purchase of investments Payments to Acquire Marketable Securities Statistical Measurement [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Interest receivable Interest Receivable Otuska Otuska Pharmaceutical Co., Ltd. [Member] Otuska Pharmaceutical Co., Ltd. Repurchase of common shares, net of transaction costs Payments for Repurchase of Common Stock Product revenue, net Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Restructuring costs and asset impairment charges Restructuring Costs and Asset Impairment Charges Thereafter Finance Lease, Liability, to be Paid, Due after Year Four Finance Lease, Liability, to be Paid, Due after Year Four Inventory Disclosure [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Product Revenues Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets Assets, Current [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] Number of extension options Lessee, Operating Lease, Number of Extension Options Lessee, Operating Lease, Number of Extension Options Total lease payments Finance Lease, Liability, to be Paid Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Operating cash flows from operating leases Operating Lease, Payments Allocation of Share-Based Payments Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Cash, cash equivalents, restricted cash and investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments Common stock, outstanding (in shares) Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding Major Customers Concentration Risk, Credit Risk, Policy [Policy Text Block] Edmonton, Alberta Edmonton, Alberta [Member] Edmonton, Alberta Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Lease termination option term Lessee, Operating Lease, Lease Termination Term Lessee, Operating Lease, Lease Termination Term Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Treasury bills US Treasury Bill Securities [Member] Customer [Domain] Customer [Domain] Schedule of Inventories, Net Schedule of Inventory, Current [Table Text Block] Number of shares (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Total Operating Lease, Liability Remainder of 2024 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Total liabilities Liabilities Service Revenue Service [Member] Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Amended and Restated Equity Incentive Plan Amended and Restated Equity Incentive Plan [Member] Amended and Restated Equity Incentive Plan Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] License, collaboration and royalty revenue License, Royalty and Collaboration Revenue [Member] License, Royalty and Collaboration Revenue Non-current liabilities Liabilities, Noncurrent [Abstract] Title of Individual [Axis] Title of Individual [Axis] Plan Name [Axis] Plan Name [Axis] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Related Party Transaction [Domain] Related Party Transaction [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Earnings Per Share [Abstract] Long-term investments Debt Securities, Noncurrent Subsequent Event [Line Items] Subsequent Event [Line Items] Number of shares (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Selling, general and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Total current assets Assets, Current Finance lease payments Financing cash flows from finance lease Finance Lease, Principal Payments Revenue from Contract with Customer [Abstract] Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Prepaid assets Prepaid Assets, Current Prepaid Assets, Current Foreign exchange on finance lease liability Foreign Translation on Finance Lease Liability Foreign Translation on Finance Lease Liability Entity Filer Category Entity Filer Category Restructuring Type [Axis] Restructuring Type [Axis] Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Stock repurchased during period, (in shares) Stock repurchased during period, (in shares) Stock Repurchased During Period, Shares Trade payables Accounts Payable, Trade, Current Estimated Fair Value Debt Securities, Held-to-Maturity, Fair Value Concentration risk (as percent) Concentration Risk, Percentage Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Weighted average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Prepaid insurance Prepaid Insurance 2028 Finance Lease, Liability, to be Paid, Year Four Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Accounts Receivable, Net Accounts Receivable [Policy Text Block] Marketable Securities [Line Items] Marketable Securities [Line Items] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Other accrued liabilities Other Accrued Liabilities, Current Accounts receivable, net Accounts and Other Receivables, Net, Current Other (income) expense, net Other Operating Income (Expense), Net Furniture Furniture and Fixtures [Member] Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Amortized Cost Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss Statement of Financial Position [Abstract] Total shareholders' equity Balance Balance Equity, Attributable to Parent Commercial paper Commercial Paper [Member] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Total cash, cash equivalents, restricted cash and investments, unrealized gains Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Gains Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Gains Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finance Lease Payments Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Restricted cash Restricted Cash and Cash Equivalents Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Employee Benefit Obligations Employee Benefit Obligations [Member] Employee Benefit Obligations Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected life of options in years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Events [Abstract] Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Treasury bonds US Treasury Bond Securities [Member] Prepaid Expenses Prepaid Expenses [Text Block] Prepaid Expenses Capitalized patent costs Payments to Acquire Intangible Assets Restructuring Restructuring and Related Activities Disclosure [Text Block] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Finished goods inventories Inventory, Finished Goods, Gross Accrued R&D projects Accrued Research, Current Accrued Research, Current Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Beginning balance (in usd per share) Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Reduce employee headcount percentage Restructuring and Related Cost, Reduce Employee Headcount Percentage Restructuring and Related Cost, Reduce Employee Headcount Percentage Purchase of property and equipment Payments to Acquire Other Productive Assets Common Shares Common Stock [Member] Stock repurchase program, period Stock Repurchase Program, Period in Force City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Loss per Common Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Marketable Securities [Table] Marketable Securities [Table] Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Lease term Lessee, Operating Lease, Term of Contract Minimum Minimum [Member] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Schedule of Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Area of property (in sqft) Area of Real Estate Property Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Stock repurchase program, percentage Stock Repurchase Program, Percentage Stock Repurchase Program, Percentage Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] LIABILITIES Liabilities [Abstract] Cash paid for income taxes Income Taxes Paid, Net Cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Net amortization of premiums and discounts on short-term investments Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and shareholders' equity Liabilities and Equity Other non-current assets Other Assets, Noncurrent Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Risk-free interest rate (as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Basic loss per share (in usd per share) Basic Net loss per common share (expressed in usd per share)) Earnings Per Share, Basic Operating right-of-use assets, net Operating Lease, Right-of-Use Asset Unrecognized share-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Shares repurchased and cancelled, inclusive of transaction costs Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Number of positions eliminated, percent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Officer Officer [Member] Restructuring expenses Restructuring Costs Remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Entity Address, City or Town Entity Address, City or Town Related Party Related Party [Member] Principles of consolidation Consolidation, Policy [Policy Text Block] Cash flows used in investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Document Transition Report Document Transition Report Proceeds from investments Proceeds from Sale and Maturity of Marketable Securities Available-for-sale debt securities Debt Securities, Available-for-Sale Cash, cash equivalents and restricted cash Cash, Cash Equivalents And Restricted Cash [Member] Cash, Cash Equivalents And Restricted Cash Member Schedule of Total Revenues, Net From Main Customers Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Eligible to receive a payment Research And Development Arrangement, New Drug Application, Eligibility Payment Receivable Upon Approval Research And Development Arrangement, New Drug Application, Eligibility Payment Receivable Upon Approval Property, Plant and Equipment [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Common shares - no par value, unlimited shares authorized, 143,690 and 143,833 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Outstanding Title of Individual [Domain] Title of Individual [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Other comprehensive (loss) gain: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Weighted average exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Proceeds from tenant improvements Payments for (Proceeds from) Tenant Allowance Proceeds from exercise of stock options Proceeds from Stock Options Exercised Corporate bonds Short-Term Corporate Debt Securities [Member] Short-Term Corporate Debt Securities Finance lease, liability Total Finance Lease, Liability Derivative, average remaining maturity Derivative, Average Remaining Maturity Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Related Party [Axis] Related Party, Type [Axis] Acquired intellectual property and reacquired rights Intellectual Property [Member] Entity Registrant Name Entity Registrant Name Employee Severance Employee Severance [Member] Rockville, Maryland Rockville, Maryland [Member] Rockville, Maryland Document Period End Date Document Period End Date Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Finance lease, weighted average discount rate Finance Lease, Weighted Average Discount Rate, Percent Finance lease liability Finance Lease, Liability, Noncurrent Regulatory and pricing approval milestone revenue Research and Development Arrangement, Contract to Perform for Others, Compensation Received Research and Development Arrangement, Contract to Perform for Others, Compensation Received Entity Central Index Key Entity Central Index Key Share-based compensation expense Share-Based Payment Arrangement, Expense Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Gross Carrying Value Finite-Lived Intangible Assets, Gross Income tax expense Income tax (benefit) expense Income Tax Expense (Benefit) Estimated forfeiture rate (as percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Finished goods, net of reserve Inventory, Finished Goods, Net of Reserves Finance right-of-use asset, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Employee accruals Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] License Agreement Terms License Agreement Terms [Member] Number of operating segments Number of Operating Segments Other Restructuring Other Restructuring [Member] Revenue Benchmark Revenue Benchmark [Member] Cash paid for amounts included in the measurement of lease liabilities Cash Flow, Lessee [Abstract] Cash Flow, Lessee Equity [Abstract] Inventories, net Inventory Disclosure [Text Block] Operating lease, weighted average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Total revenue, net Revenues Revenue from Contract with Customer, Excluding Assessed Tax Amendment Flag Amendment Flag Intangible Assets Intangible Assets Disclosure [Text Block] Upfront payments received Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Schedule of Performance Shares Activity Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Cash, cash equivalents Cash and Cash Equivalents, at Carrying Value Operating lease, weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Financial assets: Assets, Fair Value Disclosure [Abstract] Finance lease, operating lease, weighted average remaining lease term (years) Finance Lease, Weighted Average Remaining Lease Term Leasehold improvements Leasehold Improvements [Member] Weighted-average common shares outstanding used in computation of diluted loss per share (in shares) Weighted average common shares outstanding diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Finance lease liability arising from obtaining right-of-use assets (monoplant) Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Interest income Interest Income (Expense), Nonoperating, Net Number of additional shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Operating expenses Operating Expenses [Abstract] Less: imputed interest Finance Lease, Liability, Undiscounted Excess Amount License and Collaboration Agreements Revenue from Contract with Customer [Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Unrealized gain (loss) on available-for-sale securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Additional paid in capital Additional Paid-in Capital [Member] Total assets Assets Cover [Abstract] Subsequent Events Subsequent Events [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Restructuring and Related Activities [Abstract] Operating cash flows from finance lease Finance Lease, Interest Payment on Liability Deferred compensation and other non-current liabilities (of which $8.8 million in 2024 and $7.6 million in 2023 is due to a related party, respectively) Other non-current liabilities Other Liabilities, Noncurrent Weighted average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited or cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Total lease payments Lessee, Operating Lease, Liability, to be Paid Finance lease, right-of-use asset, amortization Finance Lease, Right-of-Use Asset, Amortization Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Two Specialty Pharmacy Two Specialty Pharmacy [Member] Two Specialty Pharmacy Lease extension term Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Finance lease liability Finance Lease, Liability, Current Work in process Inventory, Work in Process, Net of Reserves Weighted-average common shares outstanding used in computation of basic loss per share (in shares) Weighted average common shares outstanding basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Loss from operations Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Office equipment Office Equipment [Member] Revenue Revenues [Abstract] Cost of sales Cost of Revenue Future value of minimum lease payments of leases not yet commenced Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid Performance Share sand Restricted Stock Units (RSUs) Performance Share sand Restricted Stock Units (RSUs) [Member] Performance Share sand Restricted Stock Units (RSUs) Related Party Transaction [Axis] Related Party Transaction [Axis] Cash flows used in operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Statement [Line Items] Receivable standard credit terms (in days) Accounts Receivable, Credit Term Accounts Receivable, Credit Term Type of Restructuring [Domain] Type of Restructuring [Domain] SHAREHOLDER’S EQUITY Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] EX-101.PRE 11 auph-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 image_0a.jpg begin 644 image_0a.jpg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end GRAPHIC 13 image_9a.jpg begin 644 image_9a.jpg MB5!.1PT*&@H -24A$4@ ^P $" 8 4)K7Z "7!(67, $SE M !,Y0%USO"5 -$E$051XG.W.H0T S#L/[_]'; V$B)+84G24:2)$F2 H)-4[VD.2)$F2) D >%CZL,B:AR+N0 !)14Y$KD)@@@$! end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COVER - shares
 3 Months Ended
Mar. 31, 2024
May 01, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-36421  
Entity Registrant Name Aurinia Pharmaceuticals Inc.  
Entity Incorporation, State or Country Code Z4  
Entity Address, Address Line One #140, 14315 - 118 Avenue  
Entity Address, City or Town Edmonton  
Entity Address, State or Province AB  
Entity Address, Postal Zip Code T5L 4S6  
Entity Tax Identification Number 98-1231763  
City Area Code (250)  
Local Phone Number 744-2487  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   143,019,365
Title of 12(b) Security Common shares, no par value  
Trading Symbol AUPH  
Security Exchange Name NASDAQ  
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001600620  
Current Fiscal Year End Date --12-31  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets    
Cash, cash equivalents and restricted cash $ 64,459 $ 48,875
Short-term investments 255,453 301,614
Accounts receivable, net 28,909 24,089
Inventories, net 39,761 39,705
Prepaid expenses 7,646 9,486
Other current assets 1,995 1,031
Total current assets 398,223 424,800
Non-current assets    
Long-term investments 199 201
Other non-current assets 1,502 1,517
Property and equipment, net 3,198 3,354
Acquired intellectual property and other intangible assets, net 4,760 4,977
Finance right-of-use asset, net 104,358 108,715
Operating right-of-use assets, net 4,394 4,498
Total assets 516,634 548,062
Current liabilities    
Accounts payable and accrued liabilities 50,270 54,389
Deferred revenue 4,909 4,813
Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively) 1,150 2,388
Finance lease liability 13,724 14,609
Operating lease liabilities 999 989
Total current liabilities 71,052 77,188
Non-current liabilities    
Finance lease liability 67,475 75,479
Operating lease liabilities 6,339 6,530
Deferred compensation and other non-current liabilities (of which $8.8 million in 2024 and $7.6 million in 2023 is due to a related party, respectively) 12,292 10,911
Total liabilities 157,158 170,108
Commitments and contingencies (Note 18)
SHAREHOLDER’S EQUITY    
Common shares - no par value, unlimited shares authorized, 143,690 and 143,833 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 1,207,982 1,200,218
Additional paid-in capital 105,419 120,788
Accumulated other comprehensive loss (854) (730)
Accumulated deficit (953,071) (942,322)
Total shareholders' equity 359,476 377,954
Total liabilities and shareholders' equity $ 516,634 $ 548,062
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
shares in Thousands, $ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively) $ 1,150 $ 2,388
Deferred compensation and other non-current liabilities (of which $8.8 million in 2024 and $7.6 million in 2023 is due to a related party, respectively) $ 12,292 $ 10,911
Common stock, par value (in usd per share) $ 0 $ 0
Common stock, issued (in shares) 143,690 143,833
Common stock, outstanding (in shares) 143,690 143,833
Related Party    
Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively) $ 800 $ 800
Deferred compensation and other non-current liabilities (of which $8.8 million in 2024 and $7.6 million in 2023 is due to a related party, respectively) $ 8,800 $ 7,600
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue    
Total revenue, net $ 50,303 $ 34,409
Operating expenses    
Cost of sales 7,752 421
Selling, general and administrative 47,695 50,124
Research and development 5,551 13,158
Restructuring expenses 6,683 0
Other (income) expense, net (4,125) 290
Total cost of sales and operating expenses 63,556 63,993
Loss from operations (13,253) (29,584)
Interest expense (1,283) 0
Interest income 4,526 3,814
Net loss before income taxes (10,010) (25,770)
Income tax expense 739 436
Net loss (10,749) (26,206)
Other comprehensive (loss) gain:    
Unrealized (loss) gain on available-for-sale securities, net of tax of nil (124) 73
Comprehensive loss $ (10,873) $ (26,133)
Basic loss per share (in usd per share) $ (0.07) $ (0.18)
Diluted loss per share (in usd per share) $ (0.07) $ (0.18)
Weighted-average common shares outstanding used in computation of basic loss per share (in shares) 144,013 142,641
Weighted-average common shares outstanding used in computation of diluted loss per share (in shares) 144,013 142,641
Product revenue, net    
Revenue    
Total revenue, net $ 48,073 $ 34,337
License, collaboration and royalty revenue    
Revenue    
Total revenue, net $ 2,230 $ 72
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Unrealized gain (loss) on available-for-sale securities, net of tax $ 0 $ 0
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Shares
Additional paid in capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Balance (in shares) at Dec. 31, 2022   142,268      
Balance at Dec. 31, 2022 $ 405,435 $ 1,185,309 $ 85,489 $ (1,061) $ (864,302)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of restricted stock units (in shares)   761      
Shares issued on exercise of stock options and vesting of restricted stock units 1,639 $ 7,710 (6,071)    
Share-based compensation 9,467   9,467    
Unrealized loss on available-for-sale securities, net 73     73  
Net loss (26,206)       (26,206)
Balance (in shares) at Mar. 31, 2023   143,029      
Balance at Mar. 31, 2023 $ 390,408 $ 1,193,019 88,885 (988) (890,508)
Balance (in shares) at Dec. 31, 2023 143,833 143,833      
Balance at Dec. 31, 2023 $ 377,954 $ 1,200,218 120,788 (730) (942,322)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of restricted stock units (in shares) 6 2,231      
Shares issued on exercise of stock options and vesting of restricted stock units $ 28 $ 21,134 (21,106)    
Shares repurchased and cancelled, inclusive of transaction costs (in shares)   (2,374)      
Shares repurchased and cancelled, inclusive of transaction costs (13,370) $ (13,370)      
Share-based compensation 5,737   5,737    
Unrealized loss on available-for-sale securities, net (124)     (124)  
Net loss $ (10,749)       (10,749)
Balance (in shares) at Mar. 31, 2024 143,690 143,690      
Balance at Mar. 31, 2024 $ 359,476 $ 1,207,982 $ 105,419 $ (854) $ (953,071)
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows used in operating activities:    
Net loss $ (10,749) $ (26,206)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization 4,847 717
Net amortization of premiums and discounts on short-term investments (3,206) (2,611)
Share-based compensation expense 5,737 9,467
Foreign exchange on finance lease liability (6,025) 0
Other, net 1,559 217
Net changes in operating assets and liabilities    
Accounts receivable, net (4,820) (5,559)
Inventories, net (56) (6,993)
Prepaid expenses and other current assets 873 3,588
Non-current operating assets 17 (17)
Accounts payable, accrued and other liabilities (6,594) (4,117)
Operating lease liabilities (181) (156)
Net cash used in operating activities (18,598) (31,670)
Cash flows used in investing activities:    
Purchase of investments (121,260) (142,397)
Proceeds from investments 170,505 167,766
Purchase of property and equipment 0 (347)
Capitalized patent costs (12) (162)
Net cash provided by investing activities 49,233 24,860
Cash flows from financing activities    
Repurchase of common shares, net of transaction costs (12,301) 0
Finance lease payments (2,778) 0
Proceeds from exercise of stock options 28 1,639
Cash (used in) provided by financing activities (15,051) 1,639
Net increase (decrease) in cash, cash equivalents and restricted cash 15,584 (5,171)
Cash, cash equivalents and restricted cash, beginning of period 48,875 94,172
Cash, cash equivalents and restricted cash, end of period 64,459 89,001
Supplemental cash flow information    
Cash received for interest 861 1,595
Cash paid for income taxes 0 (1)
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets    
Cash, cash equivalents 63,914 88,327
Restricted cash 545 674
Total cash, cash equivalents and restricted cash $ 64,459 $ 89,001
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization and Description of Business
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business Organization and Description of Business
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. Aurinia contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for development and commercialization of LUPKYNIS in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the Otsuka Territories).
On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value, including an exclusive focus on driving the commercial execution of the LUPKYNIS (voclosporin) business. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program and is exploring alternative approaches for AUR200. The corporate restructuring involved the Company reaffirming its commitment to LUPKYNIS growth, while maintaining a sharp focus on operating efficiencies and maximizing cash flows. For further discussion, refer to Note 19, Restructuring.
Aurinia's head office and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of March 31, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.
These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other (income) expense, net.
Significant Accounting Policies
The Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and specialty distributors and directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products to patients and healthcare providers. Revenues from product sales are recognized when the customer obtains control of the Company's product, which typically occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed to patients. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of March 31, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Major Customers: The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration and manufacturing services revenue in the Otsuka Territories. The percentages of total revenues, net from our main customers were as follows:
Three months ended
 March 31,
20242023
Two main specialty pharmacies
91%99%
Collaboration partnership
7%—%
In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. specialty pharmacies, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2024. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to customers or receivables.
Accounts Receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As of March 31, 2024 and December 31, 2023, accounts receivable, net are $28.9 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to
the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the account receivables. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of March 31, 2024 and December 31, 2023.
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.
Restructuring Expenses: Restructuring expense consists primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, Exit or Disposal Cost Obligations, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.
Common Shares: The Company’s shares have no par value or stated value and therefore, upon repurchase or issuance of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.
Recent Accounting Pronouncements
In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale debt securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The following table summarizes the financial assets (cash, cash equivalents, restricted cash and investments) measured at fair value on a recurring basis:
March 31, 2024
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$64,459 $— $— $64,459 
Corporate bonds— 23,745 — 23,745 
Commercial paper— 38,243 — 38,243 
Treasury bills— 134,974 — 134,974 
Treasury bonds— 58,690 — 58,690 
Total financial assets$64,459 $255,652 $— $320,111 
December 31, 2023
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$48,875 $— $— $48,875 
Corporate bonds— 33,781 — 33,781 
Commercial paper— 39,304 — 39,304 
Treasury bills— 122,806 — 122,806 
Treasury bonds— 105,924 — 105,924 
Total financial assets$48,875 $301,815 $— $350,690 
The Company's Level 1 instruments include cash, cash equivalents and restricted cash that are valued using quoted market prices. Aurinia estimates the fair values of investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of the Company's investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At March 31, 2024 and December 31, 2023, the weighted average remaining contractual maturities of Aurinia's Level 2 investments were approximately 6 months and 7 months, respectively. It is the Company's policy for these investments to have an overall rating of A-1, or higher, by Standard & Poor's, or an equivalent rating by Moody’s or Fitch.
No credit loss allowance was recorded as of March 31, 2024 and December 31, 2023, as the Company does not believe the unrealized loss is a result of a credit loss due to the nature of the investments. Aurinia also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.
Refer to Note 4, Cash, Cash Equivalents, Restricted Cash and Investments, for the carrying amount and related unrealized gains (losses) by type of investment.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cash, Cash Equivalents, Restricted Cash and Investments
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Cash, Cash Equivalents, Restricted Cash and Investments Cash, Cash Equivalents, Restricted Cash and Investments
As of March 31, 2024 and December 31, 2023, the Company had $320.1 million and $350.7 million, respectively of cash, cash equivalents, restricted cash and investments summarized below. As of March 31, 2024 and December 31, 2023, $255.7 million and $301.8 million were available-for-sale debt securities which are carried at fair market value.
March 31, 2024
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$64,459 $— $— $64,459 
Corporate bonds23,547 — (3)23,544 
Commercial paper38,273 — (30)38,243 
Treasury bills134,984 — (9)134,975 
Treasury bonds58,697 — (7)58,690 
Total cash, cash equivalents, restricted cash and short-term investments319,960 — (49)319,911 
Total long-term investment corporate bond199 1 — 200 
Total cash, cash equivalents, restricted cash and investments$320,159 $1 $(49)$320,111 
December 31, 2023
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$48,875 $— $— $48,875 
Corporate bonds33,576 4 — 33,580 
Commercial paper39,305 — (1)39,304 
Treasury bills122,757 49 — 122,806 
Treasury bonds105,903 21 — 105,924 
Total cash, cash equivalents, restricted cash and short-term investments350,416 74 (1)350,489 
Total long-term investment corporate bond
200 1 — 201 
Total cash, cash equivalents, restricted cash and investments
$350,616 $75 $(1)$350,690 

As of March 31, 2024 and December 31, 2023, accrued interest receivable from investments was $1.0 million and $0.7 million, respectively. During the three months ended March 31, 2024 and 2023, the Company had $(124) thousand and $73 thousand of unrealized losses and gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company has determined that the gross unrealized losses on investments at March 31, 2024, were temporary in nature. Realized gains or losses were immaterial during the three months ended March 31, 2024 and 2023.
The Company's short-term investments as of March 31, 2024 mature at various dates through November 2024 and the longer-term investment matures in August 2025.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories, net
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Inventories, net Inventories, net
Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of
costs. Capitalized costs of inventories for LUPKYNIS (voclosporin) mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. Due to the nature of the Company's supply chain process, inventory that is owned by the Company, is physically stored at third-party warehouses, logistics providers, and contract manufacturers.

The Company assesses recoverability of inventory each reporting period to determine any write-down to net realizable value resulting from excess or obsolete inventories. As of March 31, 2024 and December 31, 2023, Aurinia recorded reserves of finished goods inventories of approximately $0.5 million and $0.8 million, respectively, which were primarily related to potential inventory obsolescence.

The components of inventory, net are as follows:
(in thousands)March 31, 2024December 31, 2023
Raw materials$1,702 $1,746 
Work in process35,994 37,376 
Finished goods, net of reserve2,065 583 
Total inventories, net$39,761 $39,705 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid Expenses
 3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses Prepaid Expenses
Prepaid expenses are as follows:

(in thousands)March 31, 2024December 31, 2023
Prepaid assets$4,707 $6,892 
Prepaid deposits2,376 1,345 
Prepaid insurance563 1,249 
Total prepaid expenses$7,646 $9,486 
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
March 31, 2024
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,860 $(1,307)$553 
Acquired intellectual property and reacquired rights15,126 (10,937)4,189 
Internal-use software implementation costs2,873 (2,855)18 
$19,859 $(15,099)$4,760 
December 31, 2023
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,847 $(1,297)$550 
Acquired intellectual property and reacquired rights15,126 (10,737)4,389 
Internal-use software implementation costs2,873 (2,835)38 
$19,846 $(14,869)$4,977 
Amortization expense for the three months ended March 31, 2024 and 2023 was approximately $0.2 million and $0.5 million, respectively.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, net
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment, net Property and Equipment, net
Property and equipment, net are as follows:
(in thousands)March 31, 2024December 31, 2023
Leasehold improvements$3,243 $3,243 
Office equipment631 631 
Furniture1,155 1,155 
Computer equipment235 235 
5,2645,264
Less accumulated depreciation(2,066)(1,910)
Property and equipment, net$3,198 $3,354 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease Obligations
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Lease Obligations Lease Obligations
The Company has the following lease obligations:
Victoria, British Columbia
In December 2020, Aurinia entered into a lease for office space in Victoria, British Columbia. During September 2022, the fixed lease term ended on the Victoria lease and the Company exercised its right to enter into a short-term month to month lease, of which expenses are incurred in SG&A. On March 31, 2023, the Company terminated the Victoria lease. 
Rockville, Maryland
During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately seven years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of March 31, 2024, the Company had a right-of-use (ROU) asset of $4.4 million and lease liability of $7.2 million included in the condensed consolidated balance sheets. As of December 31, 2023, the Company had a right of use asset of $4.5 million and lease liability of $7.4 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability.
The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta
During October 2022, the Company entered into a long term lease in Edmonton for a total of 4,375 square feet of office space. The lease is a six year lease and has an option to renew after five years at prevailing market rates. The lease commenced on November 1, 2022 and the Company recorded the lease as an operating lease. The lease is not material to the Company's financial position.
For all leases, the Company incurs variable lease costs. These costs include operation and maintenance costs included in SG&A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.
The operating lease costs for all leases for the three months ended March 31, 2024 and March 31, 2023 were $0.2 million for both periods.
Monoplant
The Company, at lease inception, recorded an ROU asset of approximately $117.6 million and a corresponding lease liability of $94.1 million, which is the present value of the minimum lease payments beginning July 2023 and expiring in 2030. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease.

As of March 31, 2024, the ROU asset, net and corresponding lease liability balance were $104.4 million and $81.2 million, respectively. As of December 31, 2023, the ROU asset, net and corresponding lease liability balance were $108.7 million and $90.1 million, respectively. For the three months ended March 31, 2024, ROU amortization was $4.4 million and interest expense was $1.3 million.
The following table represents the weighted-average remaining lease terms and discount rates as of March 31, 2024:
As of March 31, 2024
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases7.45.28%
Finance lease
6.06.19%
Supplemental cash flow information related to leases are as follows:
Three months ended
March 31,
20242023
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities
Financing cash flows from finance lease
$(2,778)$— 
Operating cash flows from finance lease
$(1,370)$— 
Operating cash flows from operating leases
$(276)$(263)
Supplemental disclosure of noncash transactions
Finance right-of-use asset obtained in exchange for lease obligations (monoplant)$104,359 $— 
Finance lease liability arising from obtaining right-of-use assets (monoplant)$81,199 $— 
Future maturities of lease liabilities as of March 31, 2024 are as follows:
(in thousands)Finance Lease PaymentsOperating Lease Payments
Remainder of 2024$12,052 $838 
202516,070 1,141 
202616,070 1,169 
202716,070 1,198 
202816,070 1,227 
Thereafter20,087 3,303 
Total lease payments
96,419 8,876 
Less: imputed interest
(15,220)(1,538)
Total
$81,199 $7,338 

Beinheim
The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that has not yet commenced operations and is therefore, not included in the above table. As part of the agreement, the Company expects to make payments of approximately $1.0 million prior to lease commencement and the present value of minimum lease payments will total approximately $0.1 million.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Payable and Accrued Liabilities
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)March 31, 2024December 31, 2023
Employee accruals$11,412 $22,486 
Commercial accruals20,078 16,216 
Accrued R&D projects2,665 5,503 
Trade payables5,672 4,327 
Restructuring accruals
2,070 — 
Other accrued liabilities6,965 5,190 
Income taxes payable1,408 667 
Total accounts payable and accrued liabilities$50,270 $54,389 
As of March 31, 2024, liabilities related to restructuring costs of $2.1 million are included within accounts payable and accrued liabilities on the condensed consolidated balance sheets. Restructuring accruals primarily include employee severance and contract termination expenses.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Deferred Compensation and Other Non-current Liabilities
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Deferred Compensation and Other Non-current Liabilities Deferred Compensation and Other Non-current Liabilities
The Company recorded other non-current liabilities of $12.3 million and $10.9 million as of March 31, 2024 and December 31, 2023, respectively. The balance as of March 31, 2024 and December 31, 2023 primarily included deferred compensation arrangements whereby certain former executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. One of the former officers, Dr. Robert T. Foster, is considered a related party following his appointment to the Board of Directors on September 21, 2023. For further discussion, refer to Note 17, Related Party Transactions.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License and Collaboration Agreements
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
License and Collaboration Agreements License and Collaboration Agreements
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories. For full description of the agreements the Company has entered into with Otsuka, please refer to the Annual Report on Form 10-K for the year ended December 31, 2023.

As part of the agreement, the Company received an upfront cash payment of $50.0 million in 2020 for the license agreement and has received $40.0 million in regulatory and pricing approval related milestones. The Company provides semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, sharing capacity of the monoplant and receives tiered royalties ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.
On November 13, 2023, Otsuka filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labour, and Welfare for the manufacture and sale in Japan of voclosporin. The Company is eligible to receive a payment of $10 million upon approval in Japan, which is anticipated in the second half of 2024, along with low double-digit royalties on net sales once launched.
For the three months ended March 31, 2024 and March 31, 2023, the Company recognized $2.2 million and $0.1 million, respectively of license, collaboration and royalty revenue from services provided under the Otsuka agreement.

Riptide License
On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. Effective February 14, 2024 the Company is ceasing future development of AUR300.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholder's Equity
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Shareholder's Equity Shareholder's Equity
On February 15, 2024, Aurinia announced that its Board of Directors had approved a share repurchase program of up to $150 million of common shares of the Company, affirming its confidence in the Company's growth prospects.

On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program. This program may be implemented through open market or privately negotiated purchases, including under a plan intended to comply with the affirmative defense under Rule 10b5-1, Rule 10b-18 or an automatic securities purchase plan, an accelerated share repurchase program, or other mechanisms. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. The purchase price of any Common Shares will be determined in accordance with applicable U.S. securities laws and subject to receiving the Exemptive Relief, the value of the consideration offered per Common Share will not exceed the market price of the Common Shares calculated pursuant to applicable Canadian securities regulation.
As of March 31, 2024, the Company had repurchased approximately 2.4 million of Aurinia's common shares for $13.4 million (including transaction costs which consist of commissions and excise tax). The cost of repurchased shares are reported as a reduction in common stock and under Alberta law, the shares were cancelled and not reissued.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss per Common Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Net Loss per Common Share Net Loss per Common Share
Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three months ended
 March 31,
(in thousands, except per share data)20242023
Net loss$(10,749)$(26,206)
Weighted average common shares outstanding144,013 142,641 
Net loss per common share (expressed in $ per share)$(0.07)$(0.18)
The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:
Three months ended
March 31,
(in thousands)20242023
Stock options11,081 12,678 
Unvested performance awards1,503 921 
Unvested restricted stock units7,326 6,983 
19,910 20,582 
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based Compensation
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-based Compensation Share-based Compensation
The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards (PAs), and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. As of March 31, 2024, 0.7 million shares were purchased under the ESPP.
In addition to stock options, PAs and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan.
Stock Options

The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the business day immediately prior to the date of grant. The Board of Directors approves the vesting criteria and periods at its discretion. The options issued under the Plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The assumptions used for the annual volatility and expected life of the options are reviewed and updated annually. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent
remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior.
The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March 31, 2024 and March 31, 2023:
20242023
Annualized volatility77 %71 %
Risk-free interest rate4.04 %4.08 %
Expected life of options in years5.0 years5.0 years
Estimated forfeiture rate13.1 %12.7 %
Dividend rate0.0 %0.0%
Fair value per common share option$4.62 $5.44 
The following table summarizes the option award activity for the three months ended March 31, 2024:

March 31, 2024
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2023
11,556 $10.63 
Granted63 7.12 
Exercised(6)4.85 
Forfeited or cancelled
(532)11.62 
Outstanding - March 31, 2024
11,081 $10.57 
Restricted Stock Units and Performance Awards
The Company has granted RSUs and PAs under the Plan, as well as inducements for certain new hires as discussed above. The RSUs and PAs are fair valued based on the previous business days' market price of common shares on the date of the grant.
The following table summarizes the RSU and PA activity for the three months ended March 31, 2024:
March 31, 2024
Number of shares (in thousands)Weighted average fair value price $
Unvested balance, December 31, 2023
7,807 $9.29 
Granted4,491 6.94 
Vested(2,225)9.48 
Forfeited(1,244)9.12 
Unvested balance, March 31, 2024
8,829 $8.07 
Share-based Compensation Expense
The Company recognized share-based compensation expense for the three months ended March 31, 2024 and March 31, 2023 as follows:
Three months ended
March 31,
(in thousands)20242023
Research and development$(2,166)$1,590 
Selling, general and administrative7,537 7,589 
Capitalized under inventories366 288 
Share-based compensation expense$5,737 $9,467 
As of March 31, 2024, there was $40.4 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.6 years.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The effective tax rates for the three months ended March 31, 2024 and March 31, 2023 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances.

The Company recognized an income tax expense of approximately $739 thousand and $436 thousand for the three months ended March 31, 2024 and March 31, 2023, respectively. The expense recognized for these periods is a result of income in certain jurisdictions. This tax expense was not offset by a tax benefit as the Company had losses that are fully offset by a valuation allowance in its significant jurisdictions.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions
 3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
On September 21, 2023, the Company appointed Dr. Robert T. Foster to the Board of Directors. Dr. Foster is considered a related party since he is one of the former executive officers of the Company who, as of March 8, 2012 was provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations are contingent on the occurrence of uncertain future events. Dr. Foster was not a related party of the Company between his resignation from the Company in 2014, and his appointment to the Board of Directors on September 21, 2023. As of March 31, 2024, the Company had $0.8 million and $8.8 million of current and non-current liabilities related to Dr. Foster, respectively. As of December 31, 2023, the Company had $0.8 million and $7.6 million of current and non-current liabilities related to Dr. Foster, respectively. As of March 31, 2024 and December 31, 2023 the Company had made payments of $0.1 million to him for each period as a related party for the deferred compensation.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Other Funding Commitments
In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value, including an exclusive focus on driving the commercial execution of the LUPKYNIS (voclosporin) business. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program and is exploring alternative approaches for AUR200. The corporate restructuring involved the Company reaffirming its commitment to LUPKYNIS growth ensuring product quality and patient safety, while maintaining a sharp focus on operating efficiencies and maximizing cash flows. The Company also announced it plans to reduce employee headcount by at least 25% by the end of the first quarter of 2024.
As of March 31, 2024, the restructuring expenses recorded by the Company were as follows:
(in thousands)
Three months ended March 31, 2024
Employee severance and one time benefits
$5,207 
Contract terminations
919 
Other costs
557 
Total
$6,683 
During the first quarter of 2024, restructuring expenses of approximately $6.7 million were recorded in connection with this program and are included within operating expenses on the condensed consolidated statements of operations and comprehensive loss.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events
 3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
From April 1, 2024 through April 30, 2024 the Company has repurchased approximately 1.0 million of additional Aurinia common shares for $5.2 million (including transaction costs). The cost of repurchased shares will be reported as a reduction in common stock and subsequently canceled.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of March 31, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.
Principles of consolidation
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.
These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other (income) expense, net.
Product Revenues
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and specialty distributors and directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products to patients and healthcare providers. Revenues from product sales are recognized when the customer obtains control of the Company's product, which typically occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed to patients. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of March 31, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Major Customers Major Customers: The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration and manufacturing services revenue in the Otsuka Territories.
Accounts Receivable, Net
Accounts Receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As of March 31, 2024 and December 31, 2023, accounts receivable, net are $28.9 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to
the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the account receivables. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of March 31, 2024 and December 31, 2023.
Share-Based Compensation
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.
Restructuring Expenses
Restructuring Expenses: Restructuring expense consists primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, Exit or Disposal Cost Obligations, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.
Common Shares
Common Shares: The Company’s shares have no par value or stated value and therefore, upon repurchase or issuance of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.
Recently Adopted Accounting Pronouncements
Recent Accounting Pronouncements
In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Schedule of Total Revenues, Net From Main Customers The percentages of total revenues, net from our main customers were as follows:
Three months ended
 March 31,
20242023
Two main specialty pharmacies
91%99%
Collaboration partnership
7%—%
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following table summarizes the financial assets (cash, cash equivalents, restricted cash and investments) measured at fair value on a recurring basis:
March 31, 2024
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$64,459 $— $— $64,459 
Corporate bonds— 23,745 — 23,745 
Commercial paper— 38,243 — 38,243 
Treasury bills— 134,974 — 134,974 
Treasury bonds— 58,690 — 58,690 
Total financial assets$64,459 $255,652 $— $320,111 
December 31, 2023
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$48,875 $— $— $48,875 
Corporate bonds— 33,781 — 33,781 
Commercial paper— 39,304 — 39,304 
Treasury bills— 122,806 — 122,806 
Treasury bonds— 105,924 — 105,924 
Total financial assets$48,875 $301,815 $— $350,690 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cash, Cash Equivalents, Restricted Cash and Investments (Tables)
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Summary of Cash, Cash Equivalents, Restricted Cash and Investments
March 31, 2024
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$64,459 $— $— $64,459 
Corporate bonds23,547 — (3)23,544 
Commercial paper38,273 — (30)38,243 
Treasury bills134,984 — (9)134,975 
Treasury bonds58,697 — (7)58,690 
Total cash, cash equivalents, restricted cash and short-term investments319,960 — (49)319,911 
Total long-term investment corporate bond199 1 — 200 
Total cash, cash equivalents, restricted cash and investments$320,159 $1 $(49)$320,111 
December 31, 2023
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$48,875 $— $— $48,875 
Corporate bonds33,576 4 — 33,580 
Commercial paper39,305 — (1)39,304 
Treasury bills122,757 49 — 122,806 
Treasury bonds105,903 21 — 105,924 
Total cash, cash equivalents, restricted cash and short-term investments350,416 74 (1)350,489 
Total long-term investment corporate bond
200 1 — 201 
Total cash, cash equivalents, restricted cash and investments
$350,616 $75 $(1)$350,690 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories, net (Tables)
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories, Net
The components of inventory, net are as follows:
(in thousands)March 31, 2024December 31, 2023
Raw materials$1,702 $1,746 
Work in process35,994 37,376 
Finished goods, net of reserve2,065 583 
Total inventories, net$39,761 $39,705 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid Expenses (Tables)
 3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses are as follows:

(in thousands)March 31, 2024December 31, 2023
Prepaid assets$4,707 $6,892 
Prepaid deposits2,376 1,345 
Prepaid insurance563 1,249 
Total prepaid expenses$7,646 $9,486 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets (Tables)
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
March 31, 2024
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,860 $(1,307)$553 
Acquired intellectual property and reacquired rights15,126 (10,937)4,189 
Internal-use software implementation costs2,873 (2,855)18 
$19,859 $(15,099)$4,760 
December 31, 2023
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,847 $(1,297)$550 
Acquired intellectual property and reacquired rights15,126 (10,737)4,389 
Internal-use software implementation costs2,873 (2,835)38 
$19,846 $(14,869)$4,977 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, net (Tables)
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment, net
Property and equipment, net are as follows:
(in thousands)March 31, 2024December 31, 2023
Leasehold improvements$3,243 $3,243 
Office equipment631 631 
Furniture1,155 1,155 
Computer equipment235 235 
5,2645,264
Less accumulated depreciation(2,066)(1,910)
Property and equipment, net$3,198 $3,354 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease Obligations (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Lease, Cost
The following table represents the weighted-average remaining lease terms and discount rates as of March 31, 2024:
As of March 31, 2024
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases7.45.28%
Finance lease
6.06.19%
Supplemental cash flow information related to leases are as follows:
Three months ended
March 31,
20242023
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities
Financing cash flows from finance lease
$(2,778)$— 
Operating cash flows from finance lease
$(1,370)$— 
Operating cash flows from operating leases
$(276)$(263)
Supplemental disclosure of noncash transactions
Finance right-of-use asset obtained in exchange for lease obligations (monoplant)$104,359 $— 
Finance lease liability arising from obtaining right-of-use assets (monoplant)$81,199 $— 
Lessee, Operating Lease, Liability, Maturity
Future maturities of lease liabilities as of March 31, 2024 are as follows:
(in thousands)Finance Lease PaymentsOperating Lease Payments
Remainder of 2024$12,052 $838 
202516,070 1,141 
202616,070 1,169 
202716,070 1,198 
202816,070 1,227 
Thereafter20,087 3,303 
Total lease payments
96,419 8,876 
Less: imputed interest
(15,220)(1,538)
Total
$81,199 $7,338 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Payable and Accrued Liabilities (Tables)
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)March 31, 2024December 31, 2023
Employee accruals$11,412 $22,486 
Commercial accruals20,078 16,216 
Accrued R&D projects2,665 5,503 
Trade payables5,672 4,327 
Restructuring accruals
2,070 — 
Other accrued liabilities6,965 5,190 
Income taxes payable1,408 667 
Total accounts payable and accrued liabilities$50,270 $54,389 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss per Common Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Loss Per Share, Basic and Diluted The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three months ended
 March 31,
(in thousands, except per share data)20242023
Net loss$(10,749)$(26,206)
Weighted average common shares outstanding144,013 142,641 
Net loss per common share (expressed in $ per share)$(0.07)$(0.18)
Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share
The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:
Three months ended
March 31,
(in thousands)20242023
Stock options11,081 12,678 
Unvested performance awards1,503 921 
Unvested restricted stock units7,326 6,983 
19,910 20,582 
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based Compensation (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Payment Award Valuation Assumptions
The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March 31, 2024 and March 31, 2023:
20242023
Annualized volatility77 %71 %
Risk-free interest rate4.04 %4.08 %
Expected life of options in years5.0 years5.0 years
Estimated forfeiture rate13.1 %12.7 %
Dividend rate0.0 %0.0%
Fair value per common share option$4.62 $5.44 
Schedule of Option Activity
The following table summarizes the option award activity for the three months ended March 31, 2024:

March 31, 2024
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2023
11,556 $10.63 
Granted63 7.12 
Exercised(6)4.85 
Forfeited or cancelled
(532)11.62 
Outstanding - March 31, 2024
11,081 $10.57 
Schedule of Performance Shares Activity
The following table summarizes the RSU and PA activity for the three months ended March 31, 2024:
March 31, 2024
Number of shares (in thousands)Weighted average fair value price $
Unvested balance, December 31, 2023
7,807 $9.29 
Granted4,491 6.94 
Vested(2,225)9.48 
Forfeited(1,244)9.12 
Unvested balance, March 31, 2024
8,829 $8.07 
Allocation of Share-Based Payments
The Company recognized share-based compensation expense for the three months ended March 31, 2024 and March 31, 2023 as follows:
Three months ended
March 31,
(in thousands)20242023
Research and development$(2,166)$1,590 
Selling, general and administrative7,537 7,589 
Capitalized under inventories366 288 
Share-based compensation expense$5,737 $9,467 
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring (Tables)
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
As of March 31, 2024, the restructuring expenses recorded by the Company were as follows:
(in thousands)
Three months ended March 31, 2024
Employee severance and one time benefits
$5,207 
Contract terminations
919 
Other costs
557 
Total
$6,683 
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization and Description of Business (Details)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of positions eliminated, percent 25.00%
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies- Narrative (Details)
 3 Months Ended
Mar. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Property, Plant and Equipment [Line Items]    
Number of operating segments | segment 1  
Number of customers | segment 2  
Accounts receivable, net | $ $ 28,909,000 $ 24,089,000
Allowance for doubtful accounts | $ $ 0 $ 0
Minimum    
Property, Plant and Equipment [Line Items]    
Receivable standard credit terms (in days) 30 days  
Maximum    
Property, Plant and Equipment [Line Items]    
Receivable standard credit terms (in days) 45 days  
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Schedule of Total Revenues, Net From Main Customers (Details) - Two Specialty Pharmacy - Revenue Benchmark - Customer Concentration Risk
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Product revenue, net    
Property, Plant and Equipment [Line Items]    
Concentration risk (as percent) 91.00% 99.00%
License, collaboration and royalty revenue    
Property, Plant and Equipment [Line Items]    
Concentration risk (as percent) 7.00% 0.00%
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Financial assets:    
Total financial assets $ 320,111 $ 350,690
Cash, cash equivalents and restricted cash    
Financial assets:    
Total financial assets 64,459 48,875
Corporate bonds    
Financial assets:    
Total financial assets 23,745 33,781
Commercial paper    
Financial assets:    
Total financial assets 38,243 39,304
Treasury bills    
Financial assets:    
Total financial assets 134,974 122,806
Treasury bonds    
Financial assets:    
Total financial assets 58,690 105,924
Level 1    
Financial assets:    
Total financial assets 64,459 48,875
Level 1 | Cash, cash equivalents and restricted cash    
Financial assets:    
Total financial assets 64,459 48,875
Level 1 | Corporate bonds    
Financial assets:    
Total financial assets 0 0
Level 1 | Commercial paper    
Financial assets:    
Total financial assets 0 0
Level 1 | Treasury bills    
Financial assets:    
Total financial assets 0 0
Level 1 | Treasury bonds    
Financial assets:    
Total financial assets 0 0
Level 2    
Financial assets:    
Total financial assets $ 255,652 $ 301,815
Derivative, average remaining maturity 6 months 7 months
Level 2 | Cash, cash equivalents and restricted cash    
Financial assets:    
Total financial assets $ 0 $ 0
Level 2 | Corporate bonds    
Financial assets:    
Total financial assets 23,745 33,781
Level 2 | Commercial paper    
Financial assets:    
Total financial assets 38,243 39,304
Level 2 | Treasury bills    
Financial assets:    
Total financial assets 134,974 122,806
Level 2 | Treasury bonds    
Financial assets:    
Total financial assets 58,690 105,924
Level 3    
Financial assets:    
Total financial assets 0 0
Level 3 | Cash, cash equivalents and restricted cash    
Financial assets:    
Total financial assets 0 0
Level 3 | Corporate bonds    
Financial assets:    
Total financial assets 0 0
Level 3 | Commercial paper    
Financial assets:    
Total financial assets 0 0
Level 3 | Treasury bills    
Financial assets:    
Total financial assets 0 0
Level 3 | Treasury bonds    
Financial assets:    
Total financial assets $ 0 $ 0
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]      
Cash, cash equivalents, restricted cash and investments $ 320,100   $ 350,700
Available-for-sale debt securities 255,700   301,800
Interest receivable 1,000   $ 700
Unrealized gain (loss) on available-for-sale securities $ (124) $ 73  
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cash, Cash Equivalents, Restricted Cash and Investments - Investments (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Marketable Securities [Line Items]    
Amortized Cost $ 319,960 $ 350,416
Unrealized Gains 0 74
Unrealized Losses (49) (1)
Estimated Fair Value 319,911 350,489
Total cash, cash equivalents, restricted cash and investments, Amortized Cost 320,159 350,616
Total cash, cash equivalents, restricted cash and investments, unrealized gains 1 75
Total cash, cash equivalents, restricted cash and investments, unrealized losses (49) (1)
Total cash, cash equivalents, restricted cash and investments 320,111 350,690
Cash, cash equivalents and restricted cash    
Marketable Securities [Line Items]    
Amortized Cost 64,459 48,875
Unrealized Gains 0 0
Unrealized Losses 0 0
Estimated Fair Value 64,459 48,875
Corporate bonds    
Marketable Securities [Line Items]    
Amortized Cost 23,547 33,576
Unrealized Gains 0 4
Unrealized Losses (3) 0
Estimated Fair Value 23,544 33,580
Commercial paper    
Marketable Securities [Line Items]    
Amortized Cost 38,273 39,305
Unrealized Gains 0 0
Unrealized Losses (30) (1)
Estimated Fair Value 38,243 39,304
Treasury bills    
Marketable Securities [Line Items]    
Amortized Cost 134,984 122,757
Unrealized Gains 0 49
Unrealized Losses (9) 0
Estimated Fair Value 134,975 122,806
Treasury bonds    
Marketable Securities [Line Items]    
Amortized Cost 58,697 105,903
Unrealized Gains 0 21
Unrealized Losses (7) 0
Estimated Fair Value 58,690 105,924
Total long-term investment corporate bond    
Marketable Securities [Line Items]    
Amortized Cost 199 200
Unrealized Gains 1 1
Unrealized Losses 0 0
Estimated Fair Value $ 200 $ 201
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories, net (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Finished goods inventories $ 500 $ 800
Raw materials 1,702 1,746
Work in process 35,994 37,376
Finished goods, net of reserve 2,065 583
Total inventories, net $ 39,761 $ 39,705
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid assets $ 4,707 $ 6,892
Prepaid deposits 2,376 1,345
Prepaid insurance 563 1,249
Total prepaid expenses $ 7,646 $ 9,486
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 19,859 $ 19,846
Accumulated Amortization (15,099) (14,869)
Net Carrying Amount 4,760 4,977
Patents    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 1,860 1,847
Accumulated Amortization (1,307) (1,297)
Net Carrying Amount 553 550
Acquired intellectual property and reacquired rights    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 15,126 15,126
Accumulated Amortization (10,937) (10,737)
Net Carrying Amount 4,189 4,389
Internal-use software implementation costs    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 2,873 2,873
Accumulated Amortization (2,855) (2,835)
Net Carrying Amount $ 18 $ 38
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization of intangible assets $ 0.2 $ 0.5
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, net (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 5,264 $ 5,264
Less accumulated depreciation (2,066) (1,910)
Property and equipment, net 3,198 3,354
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 3,243 3,243
Office equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 631 631
Furniture    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 1,155 1,155
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 235 $ 235
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease Obligations - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2020
ft²
extension_option
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Jul. 31, 2023
USD ($)
Oct. 31, 2022
ft²
Mar. 12, 2020
Lessee, Lease, Description [Line Items]              
Operating right-of-use assets, net   $ 4,394   $ 4,498      
Total   $ 7,338          
Operating lease, weighted average discount rate   5.28%          
Operating lease costs   $ 200 $ 200        
Finance right-of-use asset, net   104,358   108,715      
Finance lease, liability   $ 81,199          
Finance lease, weighted average discount rate   6.19%          
Rockville, Maryland              
Lessee, Lease, Description [Line Items]              
Area of property (in sqft) | ft² 30,531            
Remaining lease term 7 years            
Number of extension options | extension_option 2            
Lease extension term 5 years            
Lease term 11 years            
Lease termination option term 7 years            
Operating right-of-use assets, net   $ 4,400   4,500      
Total   7,200   7,400      
Proceeds from tenant improvements       2,300      
Operating lease, weighted average discount rate             5.20%
Edmonton, Alberta              
Lessee, Lease, Description [Line Items]              
Area of property (in sqft) | ft²           4,375  
Remaining lease term           6 years  
Lease extension term           5 years  
Monoplant              
Lessee, Lease, Description [Line Items]              
Finance right-of-use asset, net   104,400   108,700 $ 117,600    
Finance lease, liability   81,200   $ 90,100 $ 94,100    
Finance lease, weighted average discount rate         6.19%    
Finance lease, right-of-use asset, amortization   4,400          
Interest expense   1,300          
Beinheim              
Lessee, Lease, Description [Line Items]              
Expected payments prior to commencement of lease   1,000          
Future value of minimum lease payments of leases not yet commenced   $ 100          
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Leases [Abstract]    
Operating lease, weighted average remaining lease term (years) 7 years 4 months 24 days  
Operating lease, weighted average discount rate 5.28%  
Finance lease, operating lease, weighted average remaining lease term (years) 6 years  
Finance lease, weighted average discount rate 6.19%  
Cash paid for amounts included in the measurement of lease liabilities    
Financing cash flows from finance lease $ (2,778) $ 0
Operating cash flows from finance lease (1,370) 0
Operating cash flows from operating leases (276) (263)
Supplemental cash flow information    
Finance right-of-use asset obtained in exchange for lease obligations (monoplant) 104,359 0
Finance lease liability arising from obtaining right-of-use assets (monoplant) $ 81,199 $ 0
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)
$ in Thousands
Mar. 31, 2024
USD ($)
Finance Lease Payments  
Remainder of 2024 $ 12,052
2025 16,070
2026 16,070
2027 16,070
2028 16,070
Thereafter 20,087
Total lease payments 96,419
Less: imputed interest (15,220)
Total 81,199
Operating Lease Payments  
Remainder of 2024 838
2025 1,141
2026 1,169
2027 1,198
2028 1,227
Thereafter 3,303
Total lease payments 8,876
Less: imputed interest (1,538)
Total $ 7,338
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Employee accruals $ 11,412 $ 22,486
Commercial accruals 20,078 16,216
Accrued R&D projects 2,665 5,503
Trade payables 5,672 4,327
Restructuring accruals 2,070 0
Other accrued liabilities 6,965 5,190
Income taxes payable 1,408 667
Total accounts payable and accrued liabilities $ 50,270 $ 54,389
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Payable and Accrued Liabilities - Narrative (Details)
$ in Millions
Mar. 31, 2024
USD ($)
Payables and Accruals [Abstract]  
Restructuring reserve, accrual adjustment $ 2.1
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Deferred Compensation and Other Non-current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Other non-current liabilities $ 12,292 $ 10,911
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License and Collaboration Agreements (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Nov. 13, 2023
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2021
Dec. 31, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues   $ 50,303 $ 34,409    
Otuska | License Agreement Terms          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Upfront payments received         $ 50,000
Regulatory and pricing approval milestone revenue       $ 40,000  
Eligible to receive a payment $ 10,000        
Otuska | License Agreement Terms | Service Revenue          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues   $ 2,200 $ 100    
Otuska | License Agreement Terms | Minimum          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Tiered royalty percentages on future sales         10.00%
Otuska | License Agreement Terms | Maximum          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Tiered royalty percentages on future sales         20.00%
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholder's Equity (Details)
$ in Millions
 3 Months Ended
Feb. 29, 2024
USD ($)
Mar. 31, 2024
USD ($)
shares
Class of Stock [Line Items]    
Stock repurchase program, authorized amount $ 150.0  
Stock repurchase program, percentage 0.15  
Stock repurchased during period, (in shares) | shares   (2,400,000)
Stock repurchased during period, value   $ (13.4)
Minimum    
Class of Stock [Line Items]    
Stock repurchase program, period 12 months  
Maximum    
Class of Stock [Line Items]    
Stock repurchase program, period 36 months  
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]    
Net loss $ (10,749) $ (26,206)
Weighted average common shares outstanding basic (in shares) 144,013 142,641
Weighted average common shares outstanding diluted (in shares) 144,013 142,641
Basic Net loss per common share (expressed in usd per share)) $ (0.07) $ (0.18)
Diluted Net loss per common share (expressed in usd per share) $ (0.07) $ (0.18)
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss per Common Share - Anti-Dilutive Securities (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 19,910 20,582
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 11,081 12,678
Unvested performance awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 1,503 921
Unvested restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 7,326 6,983
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based Compensation - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended
Jun. 30, 2021
Mar. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Unrecognized share-based compensation expense   $ 40.4
Unrecognized share-based compensation expense weighted average recognition period (in years)   1 year 7 months 6 days
Employee Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized 2,500,000  
Number of shares purchased (in shares)   700,000
Amended and Restated Equity Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of additional shares authorized 23,800,000  
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based Compensation - Weighted Average Assumptions (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]    
Annualized volatility (as percent) 77.00% 71.00%
Risk-free interest rate (as percent) 4.04% 4.08%
Expected life of options in years 5 years 5 years
Estimated forfeiture rate (as percent) 13.10% 12.70%
Dividend rate $ 0.000 $ 0.000
Fair value per common share option (in usd per share) $ 4.62 $ 5.44
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based Compensation - Stock Option Activity (Details) - $ / shares
shares in Thousands
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Number of shares (in thousands)    
Beginning balance (in shares) 11,556  
Granted (in shares) 63  
Exercised (in shares) (6)  
Forfeited or cancelled (in shares) (532)  
Ending balance (in shares) 11,081  
Weighted average exercise price $    
Beginning balance (in usd per share) $ 10.57 $ 10.63
Granted (in usd per share) 7.12  
Exercised (in usd per share) 4.85  
Forfeited or cancelled (in usd per share) 11.62  
Ending balance (in usd per share) $ 10.57  
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based Compensation - Performance Awards and Restricted Stock Units Activity (Details) - Officer - Performance Share sand Restricted Stock Units (RSUs)
shares in Thousands
 3 Months Ended
Mar. 31, 2024
$ / shares
shares
Number of shares (in thousands)  
Outstanding - Beginning of Period (in shares) | shares 7,807
Granted (in shares) | shares 4,491
Vested (in shares) | shares (2,225)
Forfeited (in shares) | shares (1,244)
Outstanding - End of Period (in shares) | shares 8,829
Weighted average exercise price $  
Outstanding, Weighted average exercise price - Beginning of Period (in usd per share) | $ / shares $ 9.29
Weighted average grant date fair value (in usd per share) | $ / shares 6.94
Weighted average grant date fair value (in usd per share) | $ / shares 9.48
Weighted average exercise price (in usd per share) | $ / shares 9.12
Outstanding, Weighted average exercise price - End of Period (in usd per share) | $ / shares $ 8.07
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based Compensation - Allocated Share-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 5,737 $ 9,467
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense (2,166) 1,590
Selling, general and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense 7,537 7,589
Capitalized under inventories    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 366 $ 288
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Income tax (benefit) expense $ 739 $ 436
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related-Party Transactions (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Related Party Transaction [Line Items]      
Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively) $ 1,150   $ 2,388
Other non-current liabilities 12,292   10,911
Dr. Robert T. Foster      
Related Party Transaction [Line Items]      
Payments of deferred compensation 100 $ 100  
Employee Benefit Obligations | Dr. Robert T. Foster      
Related Party Transaction [Line Items]      
Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively) 800   800
Other non-current liabilities $ 8,800   $ 7,600
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Restructuring Cost and Reserve [Line Items]  
Reduce employee headcount percentage 25.00%
Number of positions eliminated, percent 25.00%
Other Restructuring  
Restructuring Cost and Reserve [Line Items]  
Restructuring and Related Cost, Incurred Cost $ 6.7
Employee Severance  
Restructuring Cost and Reserve [Line Items]  
Restructuring and Related Cost, Incurred Cost 6.7
Contract Termination  
Restructuring Cost and Reserve [Line Items]  
Restructuring and Related Cost, Incurred Cost $ 6.7
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring - Restructuring and Related Costs (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Restructuring Cost and Reserve [Line Items]  
Restructuring costs and asset impairment charges $ 6,683
Employee Severance  
Restructuring Cost and Reserve [Line Items]  
Restructuring costs and asset impairment charges 5,207
Contract Termination  
Restructuring Cost and Reserve [Line Items]  
Restructuring costs and asset impairment charges 919
Other Restructuring  
Restructuring Cost and Reserve [Line Items]  
Restructuring costs and asset impairment charges $ 557
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended
Apr. 30, 2024
Mar. 31, 2024
Subsequent Event [Line Items]    
Stock repurchased during period, (in shares)   2,400,000
Stock repurchased during period, value   $ 13.4
Subsequent Event    
Subsequent Event [Line Items]    
Stock repurchased during period, (in shares) 1,000,000  
Stock repurchased during period, value $ 5.2  
EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 90 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 158 279 1 false 52 0 false 7 false false R1.htm 0000001 - Document - COVER Sheet http://www.auriniapharma.com/role/COVER COVER Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Disclosure - Organization and Description of Business Sheet http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Fair Value Measurements Sheet http://www.auriniapharma.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 0000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestments Cash, Cash Equivalents, Restricted Cash and Investments Notes 11 false false R12.htm 0000012 - Disclosure - Inventories, net Sheet http://www.auriniapharma.com/role/Inventoriesnet Inventories, net Notes 12 false false R13.htm 0000013 - Disclosure - Prepaid Expenses Sheet http://www.auriniapharma.com/role/PrepaidExpenses Prepaid Expenses Notes 13 false false R14.htm 0000014 - Disclosure - Intangible Assets Sheet http://www.auriniapharma.com/role/IntangibleAssets Intangible Assets Notes 14 false false R15.htm 0000015 - Disclosure - Property and Equipment, net Sheet http://www.auriniapharma.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 15 false false R16.htm 0000016 - Disclosure - Lease Obligations Sheet http://www.auriniapharma.com/role/LeaseObligations Lease Obligations Notes 16 false false R17.htm 0000017 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 17 false false R18.htm 0000018 - Disclosure - Deferred Compensation and Other Non-current Liabilities Sheet http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities Deferred Compensation and Other Non-current Liabilities Notes 18 false false R19.htm 0000019 - Disclosure - License and Collaboration Agreements Sheet http://www.auriniapharma.com/role/LicenseandCollaborationAgreements License and Collaboration Agreements Notes 19 false false R20.htm 0000020 - Disclosure - Shareholder's Equity Sheet http://www.auriniapharma.com/role/ShareholdersEquity Shareholder's Equity Notes 20 false false R21.htm 0000021 - Disclosure - Net Loss per Common Share Sheet http://www.auriniapharma.com/role/NetLossperCommonShare Net Loss per Common Share Notes 21 false false R22.htm 0000022 - Disclosure - Share-based Compensation Sheet http://www.auriniapharma.com/role/SharebasedCompensation Share-based Compensation Notes 22 false false R23.htm 0000023 - Disclosure - Income Taxes Sheet http://www.auriniapharma.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 0000024 - Disclosure - Related Party Transactions Sheet http://www.auriniapharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 24 false false R25.htm 0000025 - Disclosure - Commitments and Contingencies Sheet http://www.auriniapharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 25 false false R26.htm 0000026 - Disclosure - Restructuring Sheet http://www.auriniapharma.com/role/Restructuring Restructuring Notes 26 false false R27.htm 0000027 - Disclosure - Subsequent Events Sheet http://www.auriniapharma.com/role/SubsequentEvents Subsequent Events Notes 27 false false R28.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies 28 false false R29.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies 29 false false R30.htm 9954473 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.auriniapharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.auriniapharma.com/role/FairValueMeasurements 30 false false R31.htm 9954474 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments (Tables) Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsTables Cash, Cash Equivalents, Restricted Cash and Investments (Tables) Tables http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestments 31 false false R32.htm 9954475 - Disclosure - Inventories, net (Tables) Sheet http://www.auriniapharma.com/role/InventoriesnetTables Inventories, net (Tables) Tables http://www.auriniapharma.com/role/Inventoriesnet 32 false false R33.htm 9954476 - Disclosure - Prepaid Expenses (Tables) Sheet http://www.auriniapharma.com/role/PrepaidExpensesTables Prepaid Expenses (Tables) Tables http://www.auriniapharma.com/role/PrepaidExpenses 33 false false R34.htm 9954477 - Disclosure - Intangible Assets (Tables) Sheet http://www.auriniapharma.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.auriniapharma.com/role/IntangibleAssets 34 false false R35.htm 9954478 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.auriniapharma.com/role/PropertyandEquipmentnetTables Property and Equipment, net (Tables) Tables http://www.auriniapharma.com/role/PropertyandEquipmentnet 35 false false R36.htm 9954479 - Disclosure - Lease Obligations (Tables) Sheet http://www.auriniapharma.com/role/LeaseObligationsTables Lease Obligations (Tables) Tables http://www.auriniapharma.com/role/LeaseObligations 36 false false R37.htm 9954480 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities 37 false false R38.htm 9954481 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareTables Net Loss per Common Share (Tables) Tables http://www.auriniapharma.com/role/NetLossperCommonShare 38 false false R39.htm 9954482 - Disclosure - Share-based Compensation (Tables) Sheet http://www.auriniapharma.com/role/SharebasedCompensationTables Share-based Compensation (Tables) Tables http://www.auriniapharma.com/role/SharebasedCompensation 39 false false R40.htm 9954483 - Disclosure - Restructuring (Tables) Sheet http://www.auriniapharma.com/role/RestructuringTables Restructuring (Tables) Tables http://www.auriniapharma.com/role/Restructuring 40 false false R41.htm 9954484 - Disclosure - Organization and Description of Business (Details) Sheet http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness 41 false false R42.htm 9954485 - Disclosure - Summary of Significant Accounting Policies- Narrative (Details) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies- Narrative (Details) Details 42 false false R43.htm 9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Total Revenues, Net From Main Customers (Details) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails Summary of Significant Accounting Policies - Schedule of Total Revenues, Net From Main Customers (Details) Details 43 false false R44.htm 9954487 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Details 44 false false R45.htm 9954488 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details) Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details) Details http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsTables 45 false false R46.htm 9954489 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Investments (Details) Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails Cash, Cash Equivalents, Restricted Cash and Investments - Investments (Details) Details 46 false false R47.htm 9954490 - Disclosure - Inventories, net (Details) Sheet http://www.auriniapharma.com/role/InventoriesnetDetails Inventories, net (Details) Details http://www.auriniapharma.com/role/InventoriesnetTables 47 false false R48.htm 9954491 - Disclosure - Prepaid Expenses (Details) Sheet http://www.auriniapharma.com/role/PrepaidExpensesDetails Prepaid Expenses (Details) Details http://www.auriniapharma.com/role/PrepaidExpensesTables 48 false false R49.htm 9954492 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 49 false false R50.htm 9954493 - Disclosure - Intangible Assets - Narrative (Details) Sheet http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails Intangible Assets - Narrative (Details) Details 50 false false R51.htm 9954494 - Disclosure - Property and Equipment, net (Details) Sheet http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails Property and Equipment, net (Details) Details http://www.auriniapharma.com/role/PropertyandEquipmentnetTables 51 false false R52.htm 9954495 - Disclosure - Lease Obligations - Narrative (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails Lease Obligations - Narrative (Details) Details 52 false false R53.htm 9954496 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) Details 53 false false R54.htm 9954497 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) Details 54 false false R55.htm 9954498 - Disclosure - Accounts Payable and Accrued Liabilities (Details) Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities (Details) Details http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables 55 false false R56.htm 9954499 - Disclosure - Accounts Payable and Accrued Liabilities - Narrative (Details) Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesNarrativeDetails Accounts Payable and Accrued Liabilities - Narrative (Details) Details 56 false false R57.htm 9954500 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details) Sheet http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails Deferred Compensation and Other Non-current Liabilities (Details) Details http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities 57 false false R58.htm 9954501 - Disclosure - License and Collaboration Agreements (Details) Sheet http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails License and Collaboration Agreements (Details) Details http://www.auriniapharma.com/role/LicenseandCollaborationAgreements 58 false false R59.htm 9954502 - Disclosure - Shareholder's Equity (Details) Sheet http://www.auriniapharma.com/role/ShareholdersEquityDetails Shareholder's Equity (Details) Details http://www.auriniapharma.com/role/ShareholdersEquity 59 false false R60.htm 9954503 - Disclosure - Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Details 60 false false R61.htm 9954504 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails Net Loss per Common Share - Anti-Dilutive Securities (Details) Details 61 false false R62.htm 9954505 - Disclosure - Share-based Compensation - Narrative (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails Share-based Compensation - Narrative (Details) Details 62 false false R63.htm 9954506 - Disclosure - Share-based Compensation - Weighted Average Assumptions (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationWeightedAverageAssumptionsDetails Share-based Compensation - Weighted Average Assumptions (Details) Details 63 false false R64.htm 9954507 - Disclosure - Share-based Compensation - Stock Option Activity (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails Share-based Compensation - Stock Option Activity (Details) Details 64 false false R65.htm 9954508 - Disclosure - Share-based Compensation - Performance Awards and Restricted Stock Units Activity (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails Share-based Compensation - Performance Awards and Restricted Stock Units Activity (Details) Details 65 false false R66.htm 9954509 - Disclosure - Share-based Compensation - Allocated Share-Based Compensation Expense (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails Share-based Compensation - Allocated Share-Based Compensation Expense (Details) Details 66 false false R67.htm 9954510 - Disclosure - Income Taxes (Details) Sheet http://www.auriniapharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.auriniapharma.com/role/IncomeTaxes 67 false false R68.htm 9954511 - Disclosure - Related-Party Transactions (Details) Sheet http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details 68 false false R69.htm 9954512 - Disclosure - Restructuring (Details) Sheet http://www.auriniapharma.com/role/RestructuringDetails Restructuring (Details) Details http://www.auriniapharma.com/role/RestructuringTables 69 false false R70.htm 9954513 - Disclosure - Restructuring - Restructuring and Related Costs (Details) Sheet http://www.auriniapharma.com/role/RestructuringRestructuringandRelatedCostsDetails Restructuring - Restructuring and Related Costs (Details) Details 70 false false R71.htm 9954514 - Disclosure - Subsequent Events (Details) Sheet http://www.auriniapharma.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.auriniapharma.com/role/SubsequentEvents 71 false false All Reports Book All Reports auph-20240331.htm auph-20240331.xsd auph-20240331_cal.xml auph-20240331_def.xml auph-20240331_lab.xml auph-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 92 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "auph-20240331.htm": { "nsprefix": "auph", "nsuri": "http://www.auriniapharma.com/20240331", "dts": { "inline": { "local": [ "auph-20240331.htm" ] }, "schema": { "local": [ "auph-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "auph-20240331_cal.xml" ] }, "definitionLink": { "local": [ "auph-20240331_def.xml" ] }, "labelLink": { "local": [ "auph-20240331_lab.xml" ] }, "presentationLink": { "local": [ "auph-20240331_pre.xml" ] } }, "keyStandard": 252, "keyCustom": 27, "axisStandard": 22, "axisCustom": 0, "memberStandard": 38, "memberCustom": 14, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 158, "entityCount": 1, "segmentCount": 52, "elementCount": 451, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 595, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.auriniapharma.com/role/COVER", "longName": "0000001 - Document - COVER", "shortName": "COVER", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "unique": true } }, "R3": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "unique": true } }, "R4": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "unique": true } }, "R5": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-24", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-24", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "unique": true } }, "R8": { "role": "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness", "longName": "0000008 - Disclosure - Organization and Description of Business", "shortName": "Organization and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.auriniapharma.com/role/FairValueMeasurements", "longName": "0000010 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestments", "longName": "0000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments", "shortName": "Cash, Cash Equivalents, Restricted Cash and Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.auriniapharma.com/role/Inventoriesnet", "longName": "0000012 - Disclosure - Inventories, net", "shortName": "Inventories, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.auriniapharma.com/role/PrepaidExpenses", "longName": "0000013 - Disclosure - Prepaid Expenses", "shortName": "Prepaid Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "auph:PrepaidExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "auph:PrepaidExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.auriniapharma.com/role/IntangibleAssets", "longName": "0000014 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnet", "longName": "0000015 - Disclosure - Property and Equipment, net", "shortName": "Property and Equipment, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.auriniapharma.com/role/LeaseObligations", "longName": "0000016 - Disclosure - Lease Obligations", "shortName": "Lease Obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities", "longName": "0000017 - Disclosure - Accounts Payable and Accrued Liabilities", "shortName": "Accounts Payable and Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities", "longName": "0000018 - Disclosure - Deferred Compensation and Other Non-current Liabilities", "shortName": "Deferred Compensation and Other Non-current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreements", "longName": "0000019 - Disclosure - License and Collaboration Agreements", "shortName": "License and Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.auriniapharma.com/role/ShareholdersEquity", "longName": "0000020 - Disclosure - Shareholder's Equity", "shortName": "Shareholder's Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.auriniapharma.com/role/NetLossperCommonShare", "longName": "0000021 - Disclosure - Net Loss per Common Share", "shortName": "Net Loss per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.auriniapharma.com/role/SharebasedCompensation", "longName": "0000022 - Disclosure - Share-based Compensation", "shortName": "Share-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.auriniapharma.com/role/IncomeTaxes", "longName": "0000023 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.auriniapharma.com/role/RelatedPartyTransactions", "longName": "0000024 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.auriniapharma.com/role/CommitmentsandContingencies", "longName": "0000025 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.auriniapharma.com/role/Restructuring", "longName": "0000026 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.auriniapharma.com/role/SubsequentEvents", "longName": "0000027 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.auriniapharma.com/role/FairValueMeasurementsTables", "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsTables", "longName": "9954474 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments (Tables)", "shortName": "Cash, Cash Equivalents, Restricted Cash and Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.auriniapharma.com/role/InventoriesnetTables", "longName": "9954475 - Disclosure - Inventories, net (Tables)", "shortName": "Inventories, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.auriniapharma.com/role/PrepaidExpensesTables", "longName": "9954476 - Disclosure - Prepaid Expenses (Tables)", "shortName": "Prepaid Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.auriniapharma.com/role/IntangibleAssetsTables", "longName": "9954477 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnetTables", "longName": "9954478 - Disclosure - Property and Equipment, net (Tables)", "shortName": "Property and Equipment, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.auriniapharma.com/role/LeaseObligationsTables", "longName": "9954479 - Disclosure - Lease Obligations (Tables)", "shortName": "Lease Obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables", "longName": "9954480 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.auriniapharma.com/role/NetLossperCommonShareTables", "longName": "9954481 - Disclosure - Net Loss per Common Share (Tables)", "shortName": "Net Loss per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationTables", "longName": "9954482 - Disclosure - Share-based Compensation (Tables)", "shortName": "Share-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.auriniapharma.com/role/RestructuringTables", "longName": "9954483 - Disclosure - Restructuring (Tables)", "shortName": "Restructuring (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails", "longName": "9954484 - Disclosure - Organization and Description of Business (Details)", "shortName": "Organization and Description of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies- Narrative (Details)", "shortName": "Summary of Significant Accounting Policies- Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails", "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Total Revenues, Net From Main Customers (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Total Revenues, Net From Main Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-38", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-38", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "longName": "9954487 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "shortName": "Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails", "longName": "9954488 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details)", "shortName": "Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails", "longName": "9954489 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Investments (Details)", "shortName": "Cash, Cash Equivalents, Restricted Cash and Investments - Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:HeldToMaturitySecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:HeldToMaturitySecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.auriniapharma.com/role/InventoriesnetDetails", "longName": "9954490 - Disclosure - Inventories, net (Details)", "shortName": "Inventories, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.auriniapharma.com/role/PrepaidExpensesDetails", "longName": "9954491 - Disclosure - Prepaid Expenses (Details)", "shortName": "Prepaid Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "auph:PrepaidAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "auph:PrepaidAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "longName": "9954492 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)", "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails", "longName": "9954493 - Disclosure - Intangible Assets - Narrative (Details)", "shortName": "Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails", "longName": "9954494 - Disclosure - Property and Equipment, net (Details)", "shortName": "Property and Equipment, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "longName": "9954495 - Disclosure - Lease Obligations - Narrative (Details)", "shortName": "Lease Obligations - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "unique": true } }, "R53": { "role": "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails", "longName": "9954496 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)", "shortName": "Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails", "longName": "9954497 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)", "shortName": "Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails", "longName": "9954498 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesNarrativeDetails", "longName": "9954499 - Disclosure - Accounts Payable and Accrued Liabilities - Narrative (Details)", "shortName": "Accounts Payable and Accrued Liabilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails", "longName": "9954500 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details)", "shortName": "Deferred Compensation and Other Non-current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherLiabilitiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": null }, "R58": { "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "longName": "9954501 - Disclosure - License and Collaboration Agreements (Details)", "shortName": "License and Collaboration Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "unique": true } }, "R59": { "role": "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "longName": "9954502 - Disclosure - Shareholder's Equity (Details)", "shortName": "Shareholder's Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-129", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-129", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails", "longName": "9954503 - Disclosure - Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "shortName": "Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": null }, "R61": { "role": "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails", "longName": "9954504 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details)", "shortName": "Net Loss per Common Share - Anti-Dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "longName": "9954505 - Disclosure - Share-based Compensation - Narrative (Details)", "shortName": "Share-based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationWeightedAverageAssumptionsDetails", "longName": "9954506 - Disclosure - Share-based Compensation - Weighted Average Assumptions (Details)", "shortName": "Share-based Compensation - Weighted Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails", "longName": "9954507 - Disclosure - Share-based Compensation - Stock Option Activity (Details)", "shortName": "Share-based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "longName": "9954508 - Disclosure - Share-based Compensation - Performance Awards and Restricted Stock Units Activity (Details)", "shortName": "Share-based Compensation - Performance Awards and Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-142", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-142", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails", "longName": "9954509 - Disclosure - Share-based Compensation - Allocated Share-Based Compensation Expense (Details)", "shortName": "Share-based Compensation - Allocated Share-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.auriniapharma.com/role/IncomeTaxesDetails", "longName": "9954510 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": null }, "R68": { "role": "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails", "longName": "9954511 - Disclosure - Related-Party Transactions (Details)", "shortName": "Related-Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-154", "name": "us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "unique": true } }, "R69": { "role": "http://www.auriniapharma.com/role/RestructuringDetails", "longName": "9954512 - Disclosure - Restructuring (Details)", "shortName": "Restructuring (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-3", "name": "auph:RestructuringAndRelatedCostReduceEmployeeHeadcountPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "auph:RestructuringAndRelatedCostReduceEmployeeHeadcountPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.auriniapharma.com/role/RestructuringRestructuringandRelatedCostsDetails", "longName": "9954513 - Disclosure - Restructuring - Restructuring and Related Costs (Details)", "shortName": "Restructuring - Restructuring and Related Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.auriniapharma.com/role/SubsequentEventsDetails", "longName": "9954514 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockRepurchasedDuringPeriodShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-158", "name": "us-gaap:StockRepurchasedDuringPeriodShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240331.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts and Other Receivables, Net, Current", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "presentation": [ "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Compensation and Other Non-current Liabilities", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accrued Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r20" ] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17", "r19" ] }, "auph_AccountsReceivableCreditTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "AccountsReceivableCreditTerm", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable standard credit terms (in days)", "label": "Accounts Receivable, Credit Term", "documentation": "Accounts Receivable, Credit Term" } } }, "auth_ref": [] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net amortization of premiums and discounts on short-term investments", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r94" ] }, "auph_AccruedResearchCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "AccruedResearchCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued R&D projects", "label": "Accrued Research, Current", "documentation": "Accrued Research, Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r44", "r142", "r537" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r28", "r29", "r83", "r149", "r534", "r556", "r557" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive (Loss) Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r10", "r29", "r428", "r431", "r467", "r552", "r553", "r736", "r737", "r738", "r743", "r744", "r745" ] }, "us-gaap_AdditionalCashFlowElementsSummationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalCashFlowElementsSummationsAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets", "label": "Additional Cash Flow Elements, Summations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r75" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r400", "r401", "r402", "r571", "r743", "r744", "r745", "r799", "r823" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r58", "r59", "r363" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r395", "r407" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r150", "r225", "r262", "r265", "r266", "r817" ] }, "auph_AmendedAndRestatedEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "AmendedAndRestatedEquityIncentivePlanMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended and Restated Equity Incentive Plan", "label": "Amended and Restated Equity Incentive Plan [Member]", "documentation": "Amended and Restated Equity Incentive Plan" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r6", "r39", "r42" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r199" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfRealEstateProperty", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Area of property (in sqft)", "label": "Area of Real Estate Property", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r114", "r145", "r172", "r205", "r212", "r216", "r259", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r423", "r425", "r443", "r531", "r598", "r701", "r714", "r766", "r767", "r807" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r138", "r154", "r172", "r259", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r423", "r425", "r443", "r701", "r766", "r767", "r807" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total financial assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r61" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r231", "r270", "r525", "r749" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r390", "r391", "r392", "r393", "r394" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "auph_BeinheimFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "BeinheimFranceMember", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beinheim", "label": "Beinheim, France [Member]", "documentation": "Beinheim, France" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r33", "r140", "r667" ] }, "auph_CashCashEquivalentsAndRestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "CashCashEquivalentsAndRestrictedCashMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents And Restricted Cash [Member]", "documentation": "Cash, Cash Equivalents And Restricted Cash Member" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and restricted cash", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r33", "r92", "r169" ] }, "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestments", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails": { "parentTag": "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsAmortizedCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total cash, cash equivalents, restricted cash and investments", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments", "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments" } } }, "auth_ref": [] }, "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsAmortizedCost", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total cash, cash equivalents, restricted cash and investments, Amortized Cost", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Amortized Cost", "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Amortized Cost" } } }, "auth_ref": [] }, "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsUnrealizedGains": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsUnrealizedGains", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails": { "parentTag": "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsAmortizedCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total cash, cash equivalents, restricted cash and investments, unrealized gains", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Gains", "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Gains" } } }, "auth_ref": [] }, "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsUnrealizedLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsUnrealizedLosses", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails": { "parentTag": "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsAmortizedCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Total cash, cash equivalents, restricted cash and investments, unrealized losses", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Losses", "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Losses" } } }, "auth_ref": [] }, "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, restricted cash and investments", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments", "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r92" ] }, "auph_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r146", "r147", "r148", "r204", "r314", "r315", "r316", "r318", "r321", "r326", "r328", "r562", "r563", "r564", "r565", "r690", "r721", "r741" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r102", "r708", "r709", "r710", "r711" ] }, "auph_CommercialRelatedAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "CommercialRelatedAccrualsCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial accruals", "label": "Commercial Related Accruals, Current", "documentation": "Commercial Related Accruals, Current" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 18)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r26", "r69", "r532", "r585" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r101", "r295", "r296", "r651", "r763" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r704", "r705", "r706", "r708", "r709", "r710", "r711", "r743", "r744", "r799", "r820", "r823" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r74" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r74" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r74", "r586", "r604", "r823", "r824" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares - no par value, unlimited shares authorized, 143,690 and 143,833 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Outstanding", "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares." } } }, "auth_ref": [ "r74", "r586" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r30", "r159", "r161", "r166", "r526", "r542" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internal-use software implementation costs", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r666", "r760", "r761" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r36", "r38", "r64", "r65", "r221", "r650" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r36", "r38", "r64", "r65", "r221", "r558", "r650" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r36", "r38", "r64", "r65", "r221", "r650", "r723" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Major Customers", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r70", "r128" ] }, "auph_ConcentrationRiskNumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "ConcentrationRiskNumberOfCustomers", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of customers", "label": "Concentration Risk, Number of Customers", "documentation": "Concentration Risk, Number of Customers" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (as percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r36", "r38", "r64", "r65", "r221" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r36", "r38", "r64", "r65", "r221", "r650" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r60", "r677" ] }, "us-gaap_ContractTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractTerminationMember", "presentation": [ "http://www.auriniapharma.com/role/RestructuringDetails", "http://www.auriniapharma.com/role/RestructuringRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Termination", "label": "Contract Termination [Member]", "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [ "r684", "r685", "r686", "r687" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r330", "r331", "r350" ] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r88", "r172", "r259", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r443", "r766" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total cost of sales and operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r87" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r176", "r177", "r310", "r316", "r474", "r674", "r676" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r37", "r221" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available-for-sale securities", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r751", "r752" ] }, "us-gaap_DebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Debt Securities, Current", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Debt Securities, Noncurrent", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments of deferred compensation", "label": "Deferred Compensation Arrangement with Individual, Compensation Expense", "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement." } } }, "auth_ref": [ "r55", "r107" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid deposits", "label": "Deposits Assets, Current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r735" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r6", "r43" ] }, "us-gaap_DerivativeAverageRemainingMaturity1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAverageRemainingMaturity1", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, average remaining maturity", "label": "Derivative, Average Remaining Maturity", "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r361", "r365", "r396", "r397", "r399", "r698" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r718" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r719" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "auph_DrRobertTFosterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "DrRobertTFosterMember", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dr. Robert T. Foster", "label": "Dr. Robert T. Foster [Member]", "documentation": "Dr. Robert T. Foster" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic loss per share (in usd per share)", "totalLabel": "Basic Net loss per common share (expressed in usd per share))", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r167", "r183", "r184", "r185", "r186", "r187", "r192", "r194", "r196", "r197", "r198", "r202", "r436", "r437", "r527", "r543", "r678" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per share (in usd per share)", "totalLabel": "Diluted Net loss per common share (expressed in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r167", "r183", "r184", "r185", "r186", "r187", "r194", "r196", "r197", "r198", "r202", "r436", "r437", "r527", "r543", "r678" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Common Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r191", "r199", "r200", "r201" ] }, "auph_EdmontonAlbertaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "EdmontonAlbertaMember", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Edmonton, Alberta", "label": "Edmonton, Alberta [Member]", "documentation": "Edmonton, Alberta" } } }, "auth_ref": [] }, "auph_EmployeeBenefitObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "EmployeeBenefitObligationsMember", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefit Obligations", "label": "Employee Benefit Obligations [Member]", "documentation": "Employee Benefit Obligations" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee accruals", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized share-based compensation expense weighted average recognition period (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r398" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized share-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r796" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.auriniapharma.com/role/RestructuringDetails", "http://www.auriniapharma.com/role/RestructuringRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Severance", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r716" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r716" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r716" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r720" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r716" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r716" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r716" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r716" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r136", "r162", "r163", "r164", "r178", "r179", "r180", "r182", "r188", "r190", "r203", "r260", "r261", "r329", "r400", "r401", "r402", "r416", "r417", "r427", "r428", "r429", "r430", "r431", "r432", "r435", "r444", "r445", "r446", "r447", "r448", "r449", "r467", "r552", "r553", "r554", "r571", "r629" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r61", "r62", "r63" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r311", "r353", "r354", "r355", "r356", "r357", "r358", "r440", "r482", "r483", "r484", "r688", "r689", "r694", "r695", "r696" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r438" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r311", "r353", "r358", "r440", "r482", "r694", "r695", "r696" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r311", "r353", "r358", "r440", "r483", "r688", "r689", "r694", "r695", "r696" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r311", "r353", "r354", "r355", "r356", "r357", "r358", "r440", "r484", "r688", "r689", "r694", "r695", "r696" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r311", "r353", "r354", "r355", "r356", "r357", "r358", "r482", "r483", "r484", "r688", "r689", "r694", "r695", "r696" ] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r455", "r460", "r700" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating cash flows from finance lease", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r457", "r462" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease Payments", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, liability", "verboseLabel": "Total", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r454", "r466" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liability", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r454" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liability", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r454" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r466" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r804" ] }, "auph_FinanceLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "FinanceLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, Due after Year Four", "documentation": "Finance Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r466" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Finance lease payments", "negatedLabel": "Financing cash flows from finance lease", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r456", "r462" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance right-of-use asset, net", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r453" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, right-of-use asset, amortization", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r455", "r460", "r700" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, weighted average discount rate", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r465", "r700" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, operating lease, weighted average remaining lease term (years)", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r464", "r700" ] }, "auph_FinanceRightOfUseAssetObtainedInExchangeForLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "FinanceRightOfUseAssetObtainedInExchangeForLeaseObligations", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance right-of-use asset obtained in exchange for lease obligations (monoplant)", "label": "Finance Right-of-Use Asset Obtained in Exchange for Lease Obligations", "documentation": "Finance Right-of-Use Asset Obtained in Exchange for Lease Obligations" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r263", "r264", "r267", "r268", "r269", "r271", "r272", "r273", "r312", "r326", "r433", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r541", "r682", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r753", "r754", "r755", "r756" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r143", "r280" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r278", "r279", "r280", "r281", "r511", "r512" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Value", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r98", "r512" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r511" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r40", "r41" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired intellectual property and other intangible assets, net", "totalLabel": "Net Carrying Amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r98", "r511" ] }, "auph_ForeignTranslationOnFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "ForeignTranslationOnFinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange on finance lease liability", "label": "Foreign Translation on Finance Lease Liability", "documentation": "Foreign Translation on Finance Lease Liability" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r89", "r608" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r86" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_HeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecurities", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r132", "r242", "r267", "r758" ] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails": { "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain", "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r125", "r252" ] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails": { "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized Losses", "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r126", "r253" ] }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesFairValue", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails": { "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Held-to-Maturity, Fair Value", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r124", "r251", "r525", "r530" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r84", "r116", "r205", "r211", "r215", "r217", "r528", "r539", "r680" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r282", "r287", "r613" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r287", "r613" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r173", "r411", "r413", "r414", "r415", "r418", "r420", "r421", "r422", "r567" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Income tax expense", "terseLabel": "Income tax (benefit) expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r127", "r133", "r189", "r190", "r209", "r412", "r419", "r544" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r34" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued and other liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories, net", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Net changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r724", "r740" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-current operating assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r740" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r277" ] }, "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntellectualPropertyMember", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired intellectual property and reacquired rights", "label": "Intellectual Property [Member]", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": [ "r16" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r66", "r118", "r165", "r208", "r451", "r614", "r712", "r822" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income (Expense), Nonoperating, Net", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivable", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest receivable", "label": "Interest Receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r733", "r825" ] }, "us-gaap_InventoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoriesMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized under inventories", "label": "Inventories [Member]", "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/Inventoriesnet" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r274" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods inventories", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r734" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/InventoriesnetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods, net of reserve", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r97", "r671" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.auriniapharma.com/role/InventoriesnetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "totalLabel": "Total inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r151", "r668", "r701" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/InventoriesnetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r97", "r673" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/InventoriesnetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r97", "r672" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r112", "r119", "r120", "r135", "r227", "r228", "r441", "r442" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r803" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r100" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r459" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r459" ] }, "auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future value of minimum lease payments of leases not yet commenced", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid", "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid" } } }, "auth_ref": [] }, "auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected payments prior to commencement of lease", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease", "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease" } } }, "auth_ref": [] }, "auph_LesseeOperatingLeaseLeaseTerminationTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "LesseeOperatingLeaseLeaseTerminationTerm", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease termination option term", "label": "Lessee, Operating Lease, Lease Termination Term", "documentation": "Lessee, Operating Lease, Lease Termination Term" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r804" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r466" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r804" ] }, "auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r466" ] }, "auph_LesseeOperatingLeaseNumberOfExtensionOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "LesseeOperatingLeaseNumberOfExtensionOptions", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of extension options", "label": "Lessee, Operating Lease, Number of Extension Options", "documentation": "Lessee, Operating Lease, Number of Extension Options" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r801" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease extension term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r802" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r802" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligations" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Obligations", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r452" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r22", "r172", "r259", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r424", "r425", "r426", "r443", "r584", "r679", "r714", "r766", "r807", "r808" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r79", "r115", "r536", "r701", "r742", "r757", "r800" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r24", "r139", "r172", "r259", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r424", "r425", "r426", "r443", "r701", "r766", "r807", "r808" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LicenseAgreementTermsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseAgreementTermsMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreement Terms", "label": "License Agreement Terms [Member]", "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [] }, "auph_LicenseRoyaltyAndCollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "LicenseRoyaltyAndCollaborationRevenueMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License, collaboration and royalty revenue", "label": "License, Royalty and Collaboration Revenue [Member]", "documentation": "License, Royalty and Collaboration Revenue" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "auph_LongTermCorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "LongTermCorporateDebtSecuritiesMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total long-term investment corporate bond", "label": "Long-Term Corporate Debt Securities [Member]", "documentation": "Long-Term Corporate Debt Securities" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r221", "r693", "r769", "r818", "r819" ] }, "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesLineItems", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities [Line Items]", "label": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTable", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities [Table]", "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cash, Cash Equivalents, Restricted Cash and Investments", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r360", "r509", "r551", "r576", "r577", "r638", "r640", "r642", "r643", "r645", "r661", "r662", "r681", "r690", "r697", "r703", "r768", "r809", "r810", "r811", "r812", "r813", "r814" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r360", "r509", "r551", "r576", "r577", "r638", "r640", "r642", "r643", "r645", "r661", "r662", "r681", "r690", "r697", "r703", "r768", "r809", "r810", "r811", "r812", "r813", "r814" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r221", "r693", "r769", "r818", "r819" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r168" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r168" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows used in investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r92", "r93", "r94" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows used in operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r85", "r94", "r117", "r137", "r158", "r160", "r164", "r172", "r181", "r183", "r184", "r185", "r186", "r189", "r190", "r195", "r205", "r211", "r215", "r217", "r259", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r437", "r443", "r540", "r606", "r627", "r628", "r680", "r712", "r766" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r747" ] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "srt_OfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OfficerMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Officer", "label": "Officer [Member]" } } }, "auth_ref": [ "r222", "r821" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r205", "r211", "r215", "r217", "r680" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r461", "r700" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r454" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r454" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r454" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r458", "r462" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating right-of-use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r453" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r465", "r700" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average remaining lease term (years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r464", "r700" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Description of Business", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r72", "r110", "r559", "r560" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r23" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r153", "r701" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r144" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized (loss) gain on available-for-sale securities, net of tax of nil", "verboseLabel": "Unrealized loss on available-for-sale securities, net", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r4", "r9", "r111" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r155", "r156", "r157" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) gain:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively)", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r23", "r701" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation and other non-current liabilities (of which $8.8 million in 2024 and $7.6 million in 2023 is due to a related party, respectively)", "verboseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r94" ] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (income) expense, net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherRestructuringMember", "presentation": [ "http://www.auriniapharma.com/role/RestructuringDetails", "http://www.auriniapharma.com/role/RestructuringRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Restructuring", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r684", "r685", "r686", "r687" ] }, "auph_OtuskaPharmaceuticalCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "OtuskaPharmaceuticalCoLtdMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Otuska", "label": "Otuska Pharmaceutical Co., Ltd. [Member]", "documentation": "Otuska Pharmaceutical Co., Ltd." } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r109" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromTenantAllowance", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from tenant improvements", "label": "Payments for (Proceeds from) Tenant Allowance", "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy." } } }, "auth_ref": [ "r31", "r90" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common shares, net of transaction costs", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r32" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capitalized patent costs", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r91" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of investments", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r750" ] }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Other Productive Assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other." } } }, "auth_ref": [ "r91" ] }, "auph_PerformanceShareSandRestrictedStockUnitsRSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "PerformanceShareSandRestrictedStockUnitsRSUsMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share sand Restricted Stock Units (RSUs)", "label": "Performance Share sand Restricted Stock Units (RSUs) [Member]", "documentation": "Performance Share sand Restricted Stock Units (RSUs)" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested performance awards", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795" ] }, "auph_PrepaidAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "PrepaidAssetsCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid assets", "label": "Prepaid Assets, Current", "documentation": "Prepaid Assets, Current" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.auriniapharma.com/role/PrepaidExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "totalLabel": "Total prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r152", "r275", "r276", "r669" ] }, "auph_PrepaidExpensesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "PrepaidExpensesTextBlock", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses", "label": "Prepaid Expenses [Text Block]", "documentation": "Prepaid Expenses" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r670", "r683", "r759" ] }, "us-gaap_ProceedsFromInterestReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInterestReceived", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received for interest", "label": "Proceeds from Interest Received", "documentation": "Interest received on loans and other debt instruments during the current period." } } }, "auth_ref": [ "r739" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from investments", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r14" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue, net", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r691" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r218", "r510", "r545", "r546", "r547", "r548", "r549", "r550", "r664", "r691", "r702", "r725", "r764", "r765", "r769", "r818" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r218", "r510", "r545", "r546", "r547", "r548", "r549", "r550", "r664", "r691", "r702", "r725", "r764", "r765", "r769", "r818" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnet" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r99", "r129", "r130", "r131" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r100", "r141", "r538" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 }, "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r529", "r538", "r701" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r100" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r352", "r360", "r391", "r392", "r393", "r485", "r509", "r551", "r576", "r577", "r638", "r640", "r642", "r643", "r645", "r661", "r662", "r681", "r690", "r697", "r703", "r706", "r762", "r768", "r810", "r811", "r812", "r813", "r814" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r352", "r360", "r391", "r392", "r393", "r485", "r509", "r551", "r576", "r577", "r638", "r640", "r642", "r643", "r645", "r661", "r662", "r681", "r690", "r697", "r703", "r706", "r762", "r768", "r810", "r811", "r812", "r813", "r814" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r359", "r471", "r472", "r579", "r580", "r581", "r582", "r583", "r603", "r605", "r637" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r174", "r175", "r471", "r472", "r473", "r474", "r579", "r580", "r581", "r582", "r583", "r603", "r605", "r637" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r471", "r472", "r806" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r609", "r610", "r613" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r359", "r471", "r472", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r579", "r580", "r581", "r582", "r583", "r603", "r605", "r637", "r806" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r468", "r469", "r470", "r472", "r475", "r568", "r569", "r570", "r611", "r612", "r613", "r634", "r636" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r176", "r177", "r310", "r316", "r474", "r675", "r676" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r409", "r798" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payments received", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r410" ] }, "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationReceived", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory and pricing approval milestone revenue", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Received", "documentation": "Research and Development Arrangement, Contract to Perform for Others, Compensation Received" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r409", "r798" ] }, "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tiered royalty percentages on future sales", "label": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r409", "r798" ] }, "auph_ResearchAndDevelopmentArrangementNewDrugApplicationEligibilityPaymentReceivableUponApproval": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "ResearchAndDevelopmentArrangementNewDrugApplicationEligibilityPaymentReceivableUponApproval", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eligible to receive a payment", "label": "Research And Development Arrangement, New Drug Application, Eligibility Payment Receivable Upon Approval", "documentation": "Research And Development Arrangement, New Drug Application, Eligibility Payment Receivable Upon Approval" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r71", "r408", "r815" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r33", "r113", "r140", "r169", "r533" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "auph_RestructuringAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "RestructuringAccrualsCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring accruals", "label": "Restructuring Accruals, Current", "documentation": "Restructuring Accruals, Current" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/Restructuring" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r283", "r284", "r286", "r289", "r294" ] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Cost, Incurred Cost", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r285", "r288", "r291", "r293" ] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.auriniapharma.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of positions eliminated, percent", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "auph_RestructuringAndRelatedCostReduceEmployeeHeadcountPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "RestructuringAndRelatedCostReduceEmployeeHeadcountPercentage", "presentation": [ "http://www.auriniapharma.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduce employee headcount percentage", "label": "Restructuring and Related Cost, Reduce Employee Headcount Percentage", "documentation": "Restructuring and Related Cost, Reduce Employee Headcount Percentage" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.auriniapharma.com/role/RestructuringDetails", "http://www.auriniapharma.com/role/RestructuringRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r285", "r286", "r291", "r292" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.auriniapharma.com/role/RestructuringDetails", "http://www.auriniapharma.com/role/RestructuringRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r285", "r286", "r287", "r288", "r291", "r292", "r293" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCosts", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring expenses", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/RestructuringRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs and asset impairment charges", "label": "Restructuring Costs and Asset Impairment Charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r6" ] }, "auph_RestructuringCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "RestructuringCostsPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Expenses", "label": "Restructuring Costs [Policy Text Block]", "documentation": "Restructuring Costs" } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring reserve, accrual adjustment", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r286", "r290" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r76", "r106", "r535", "r555", "r557", "r566", "r587", "r701" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r136", "r178", "r179", "r180", "r182", "r188", "r190", "r260", "r261", "r400", "r401", "r402", "r416", "r417", "r427", "r429", "r430", "r432", "r435", "r552", "r554", "r571", "r823" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenue, net", "terseLabel": "Revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r206", "r207", "r210", "r213", "r214", "r218", "r219", "r221", "r348", "r349", "r510" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Product Revenues", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r134", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r663" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "License and Collaboration Agreements", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r134", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r351" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liability arising from obtaining right-of-use assets (monoplant)", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r463", "r700" ] }, "auph_RockvilleMarylandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "RockvilleMarylandMember", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rockville, Maryland", "label": "Rockville, Maryland [Member]", "documentation": "Rockville, Maryland" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r221", "r722" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation of Share-Based Payments", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loss Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r746" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r439", "r440" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r40", "r41", "r511" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r40", "r41" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories, Net", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r18", "r80", "r81", "r82" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r67", "r68", "r609", "r610", "r613" ] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements." } } }, "auth_ref": [ "r409", "r798" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.auriniapharma.com/role/RestructuringDetails", "http://www.auriniapharma.com/role/RestructuringRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r285", "r286", "r287", "r288", "r291", "r292", "r293" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.auriniapharma.com/role/RestructuringTables" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r45", "r46", "r47" ] }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Revenues, Net From Main Customers", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r362", "r364", "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r390", "r391", "r392", "r393", "r394" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r12", "r13", "r56" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Payment Award Valuation Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r108" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r48", "r49", "r50", "r51", "r52", "r53", "r54", "r104", "r105", "r106", "r146", "r147", "r148", "r204", "r314", "r315", "r316", "r318", "r321", "r326", "r328", "r562", "r563", "r564", "r565", "r690", "r721", "r741" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r715" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r717" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r219", "r220", "r573", "r574", "r575", "r639", "r641", "r644", "r646", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r665", "r692", "r706", "r769", "r818" ] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service Revenue", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r691" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r383" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r383" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r381" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average grant date fair value (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r381" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding - Beginning of Period (in shares)", "periodEndLabel": "Outstanding - End of Period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r378", "r379" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)", "periodEndLabel": "Outstanding, Weighted average exercise price - End of Period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r378", "r379" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price $", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r382" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average grant date fair value (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r382" ] }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated forfeiture rate (as percent)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (as percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r393" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term." } } }, "auth_ref": [ "r392" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annualized volatility (as percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r391" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r362", "r364", "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r390", "r391", "r392", "r393", "r394" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares (in thousands)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r699" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited or cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r776" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited or cancelled (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r776" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r374" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value per common share option (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r384" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r370", "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares (in thousands)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beginning balance (in usd per share)", "periodEndLabel": "Ending balance (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r370", "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price $", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares purchased (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "documentation": "Number of shares purchased for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r797" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r390", "r391", "r392", "r393", "r394" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r375" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r374" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r361", "r369", "r388", "r389", "r390", "r391", "r394", "r403", "r404", "r405", "r406" ] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Performance Shares Activity", "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares." } } }, "auth_ref": [ "r15" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life of options in years", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r390" ] }, "auph_ShortTermCorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "ShortTermCorporateDebtSecuritiesMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Short-Term Corporate Debt Securities [Member]", "documentation": "Short-Term Corporate Debt Securities" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r95", "r170" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r27", "r136", "r162", "r163", "r164", "r178", "r179", "r180", "r182", "r188", "r190", "r203", "r260", "r261", "r329", "r400", "r401", "r402", "r416", "r417", "r427", "r428", "r429", "r430", "r431", "r432", "r435", "r444", "r445", "r446", "r447", "r448", "r449", "r467", "r552", "r553", "r554", "r571", "r629" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r219", "r220", "r573", "r574", "r575", "r639", "r641", "r644", "r646", "r649", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r665", "r692", "r706", "r769", "r818" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r178", "r179", "r180", "r203", "r510", "r561", "r572", "r578", "r579", "r580", "r581", "r582", "r583", "r586", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r599", "r600", "r601", "r602", "r603", "r605", "r607", "r608", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r629", "r707" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r178", "r179", "r180", "r203", "r510", "r561", "r572", "r578", "r579", "r580", "r581", "r582", "r583", "r586", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r599", "r600", "r601", "r602", "r603", "r605", "r607", "r608", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r629", "r707" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares repurchased and cancelled, inclusive of transaction costs (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r11", "r73", "r74", "r106" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.auriniapharma.com/role/SharebasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued on exercise of stock options and vesting of restricted stock units (in shares)", "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r73", "r74", "r106", "r375" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares repurchased and cancelled, inclusive of transaction costs", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r11", "r73", "r74", "r106" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued on exercise of stock options and vesting of restricted stock units", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r11", "r27", "r106" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "auph_StockRepurchaseProgramPercentage": { "xbrltype": "pureItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "StockRepurchaseProgramPercentage", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, percentage", "label": "Stock Repurchase Program, Percentage", "documentation": "Stock Repurchase Program, Percentage" } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramPeriodInForce1", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, period", "label": "Stock Repurchase Program, Period in Force", "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock repurchased during period, (in shares)", "terseLabel": "Stock repurchased during period, (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r11", "r73", "r74", "r106", "r565", "r629", "r647" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock repurchased during period, value", "terseLabel": "Stock repurchased during period, value", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r11", "r73", "r74", "r106", "r571", "r629", "r647", "r713" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r74", "r77", "r78", "r96", "r588", "r604", "r630", "r631", "r701", "r714", "r742", "r757", "r800", "r823" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDER\u2019S EQUITY", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholder's Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r103", "r171", "r313", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r327", "r329", "r434", "r632", "r635", "r648" ] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r8", "r633" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r450", "r477" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r450", "r477" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r450", "r477" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r450", "r477" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r450", "r477" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r476", "r478" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r748", "r805" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Net", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r121", "r122", "r123", "r223", "r224", "r226" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r312", "r326", "r433", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r541", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r753", "r754", "r755", "r756" ] }, "auph_TwoSpecialtyPharmacyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "TwoSpecialtyPharmacyMember", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofTotalRevenuesNetFromMainCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Two Specialty Pharmacy", "label": "Two Specialty Pharmacy [Member]", "documentation": "Two Specialty Pharmacy" } } }, "auth_ref": [] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.auriniapharma.com/role/RestructuringDetails", "http://www.auriniapharma.com/role/RestructuringRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r285", "r286", "r291", "r292" ] }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryBillSecuritiesMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury bills", "label": "US Treasury Bill Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r816" ] }, "us-gaap_USTreasuryBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryBondSecuritiesMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury bonds", "label": "US Treasury Bond Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r816" ] }, "auph_VispSwitzerlandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240331", "localname": "VispSwitzerlandMember", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monoplant", "label": "Visp, Switzerland [Member]", "documentation": "Visp, Switzerland" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average common shares outstanding used in computation of diluted loss per share (in shares)", "verboseLabel": "Weighted average common shares outstanding diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r193", "r198" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average common shares outstanding used in computation of basic loss per share (in shares)", "terseLabel": "Weighted average common shares outstanding basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r192", "r198" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r721": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" } } } ZIP 93 0001600620-24-000051-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001600620-24-000051-xbrl.zip M4$L#!!0 ( .LPHEBRX(Y*A_< &QX#0 1 875P:"TR,#(T,#,S,2YH M=&WLO7MWXDB2-_S_?@J]S.YVU3E (8FKJYOG4+9KFF==ML>X9G;>?^:DI<1H M2DBT+B[3G_Z)R)2$ &$C(R"%<\].M0%=,C-^<)0$U ME9]6,%&""57^X7H_K">BW-HD&+O>M%;CMYV[L[EG/4X"16MHS?BR^%?O3.VV M6K1KJC6C:W1KS7&S6>N-6[2F:NJ#V3)Z3=/4JX]GX[8Z;H^-9LVD#VJMV6B. M:STZ-FH&)5K[H=,BJJI6S;,6:30:FJDV34*;M/?0;34>C!;I:O!9[_4:[+V3 M .8,\W;\,\MWFYK:^:TR"8+9V:=//W_^K#\_>';=]1X_:8V&_BFZHA+=\.Q; M2Q?_U.-+U4__^^UJ9$SHE-0LQP^(8]#X+I,N[F*/]ZE1?W2?/L$/<*^F)X^' M'\V5:Z/GMS_Q'^-+23B;+ V%A)[E6&0V(=Z4U UWBD]N-G1=39YN6\Z/K.&K MO5[O$_LU/1#KI659F6$8>!NO[GV"7^,+UX:P_%S\^8'XR7.MYR#[:LN!2RF" M\E/@$<='S)$ 4(RS;M0:&B!H\9!-;U3UU(-2[ZP!@9;NB0GVTFO55JW1K2V6 MV_<68Q\3_X&]$[Y,4WPS-1"ER>KZM4="9NM/BWY8//',)L"Y%>K4OH\J_5\G ME)C]7Z6J-_A-;3;Y5SUPF BVOW\QFLM,$__58)Z'/PB;WW4_\__N,_ M?@VLP*9]!%HMAM*OG_B7OW[BCWYPS7G_5]-Z4OQ@;M/?*J;ESVPR/W-);!W_\D..%L8#[:OD& ML?])B?<5OO&3-[0K?5R*HEYP"Y>[YO(K.I7^W]2WO^#2 0K-S^$5'K&'CDF? M_X?.DX=W*WV0D&H;Y(G6>/M+SD//6UJE2\>\ (6P3"(3OJE-X2F3FDD68^A5 M^JI6T]?G^&D9(AX=4WB+0?T,9*.@./.9N(4!*DQXG06 Y]\JOC6=V2A!V'<3 M#\>_!.+ZLV\"Q-G[%B^)WNF[H<<^,1%X%BT"&SLN0OP]9P M,=%,X7$^_)_EY5^]N1]_M?ST&4-)_ D$KQ?@8C,DUAHJ_']\W^*W9)AFZE*= MK?KR+_'G^"6?EN:=O0R: ,O -5 0S:R56H3XE^UF%CH6GY8/BI/ZRLDK+,VOM>V81/.DC*A7^T827/<]LR["";W3Z *\P+?B5F?B5R&(XNZ,V M&O"W("_F]VC)$ /-&/_+//W+X-D"CLBZAS_YUT^9+TS6)AG7 6&Z3("V), ; M"+ 3!Z3E!!@X(Q2="17 5(352U_*U#\)7.^-(F7M?OSR@CKNU'*R'KNM0%]Z MQ*?ET;\JT3JBP0[\CK-;SS5#([CQ1M1[L@RZ#*[HU^)Q)8#!TI7DR":'OCTY M].+(T2L/.=!Q.+N"CXY/[]PYL4$F.^:Y:]ODP?68ZW]'GZ@3TI-D'+4A2542 MIE*%,.X4[W(+3W1 MA??XM:7%' V(YU+PDGF,YCWYI%EY87U\$P2^" M,2F<5RRJEA"!6,+YS&50*2(03CCO6CC](P"5-.$<:Y&4U7[V K2]>\BGHG_V MM/YE]\R/[:4428NR>^P']5**7/BRN^J'$OQ:<9ZA5G:7_!B"O\CU+[MG?FS! M7R0MRNZ$'U3P%[GP>W>HCS>ULKN[P&GEB39.R$N\X9C2S/X,W[ 2\=Q%H>@.)76'L=R*Z,?MWG@RLH+ MNY=\[CH&Q:.2+#O4\G]\F7^ACC&9$N_',NI'Q*9^E#]Z35_+R]YE '@J=T7C MAWX $LY;NWC746 R[3?R;]>+W^"G4FGO?[JC&34L3*2]9:?*C==.G6SU0A'R MWH^SZ:L+&R>1?/ ^^> X+EA3N'#4 4X52%X\#B^64U4TA0L"2A:1+"*6%A$N MW(ITN2/.8X0#1B;+L:;A]#1EE'"1U"P"D.?3)8"P8=6OED,8&_&, MR?P*%(.]++23BX;.+ Q\=H5:EN2RIK!QWM,"A%8:0 @;;"Z"#'IAF-@W.L4! MA+#I7^^(!L*&PP^A+'<'Q,()\V;H7](OKF..J!%Z5F#1TF2"-X6-!N]IY:6* MSH)!2[A@:+E4](E(@Y9P ;]WL_+"Q9'*JHZG4^KA%;<$UK\TY!)*A,. MRN/_GG0T[' *^(V@% <'Y0V'E7WIVR<=@CJU+6YXZ#WYB&UQ8T8'4$CBD*%\(9M2IA?N M5SP66'*]+6[LYJ0 L5]!720@Q WBE,)S$"/7L4! =,0-+;T?&IQT6.>T\TV+ MA(&X41V9;WI &(@;U"F%BCX5:2!N@.G45_ZD8TJGF6]:)/E/.I9UFOFF19)? MW!A:R=1O.09EB96W2U?)*I,."B-_]L]Z6C8B>>;%HF# M\H;#2K_T)QV".O%\TR)Q(&X,JE2N<.EQ<-(1L1//-RT2!^*&QDY^Z4\Z+%4> M)U7<\-"[\A'%C1D)GV]:(!EZXH9LQ.0& 6K2]DXZO+)OFN6JI+W$9SO1K'RA M$):D-YJX7G!/O6F2$7!!'X+R'?;IB1L/>7']KUSG\1267]PPA+CP+U+-B^O^ M"PO_(I=?9*_;"NB5]43-H0/S>[0>;#KP?1KX7^:\ 89-_)7VA+= ""0 OMWA@'U1NXX^$D\NG)G M::@BKB\NJG@J4#FH#7%]\%+(IT)I(:YO738!52A9A'6?8X3?VC"Y@6/B:;89 M/B.K7=D5)3Z=N+8YG,X\]XEU@BZ-&:4VA/6A!2="H9P@K">=BP@WX[%ET.22 M\O" L(ZTL,M?*/J%=:1S+?_7T -E'GH4+OQJ/>-?)5(#PKK38M.@4#X0UH_. M18/8/"VA'A#691:8 $5R@"JN\>/) M N_X&_'F0"!SK^O=V 7P(4A'MMC^'^,@6>LIR\"B_3#PSO"'^.;X^_@SWKWV M)'@Z7ZQ_N3-LU+SV5+9&JU=M\XI5< CGQ0L"CJ6=< :/[7;"&\5E+ZBJ<+Z\ M(,39DZI2A7/;Q5OO0C63MJ:^!,%"9ZA'/-MUGMOUO^;/33"OZDW@$$?:-3V&H+YX2+ MMMJ%FC'">=RBK7:11HQ62O=Z[ZLM0/:WJI72N?U"+6="K>E7CS@&+8W4T81T M5L_=$$;IS0!P\VLRI:EUO@E"_P>YG1!O2@P:!DB&<_(T97GUO'#*\HS[% M?/X!8!CS]5T6-QQX0-='!H!S6$&/&,&]>TN]L>M-O[K>33"AGI^Y&VL9\ 8Z M>/0HNQNS/?<0AU\-?&S+N(T"?0]-2$=<8FDG+*G;8TDM4@D(&60X!I;PO7>( M%_XR_/C-#&&U'O"4"P#(OH2PG:H_O]0H8;)6C+ =I< M^VT%@G;O4=O8SF//BBR$:AN^F6>_8!EE78YG=GNG-)1X!H_;EC>WFE:8;IP@;<3I_.1 M#!==N#C70>DS@OD0A*^#),5[ M]K]9W=Y^L[I=TQN%T*DI7#)9PI,_B6>N!^B6K-R][I"M+/-.\:BF<&&8XRZS M".JH*61@YMX*;'HS'CJF]62989RHAS_QR@"OM1Y[*^69)%RU.D8D=R]YK"AG&VHMA?J4,]D+6..3"GEF.!Q"/H]YTVEPD; MCBD!S8[%9\*&5;:BV=!Y@M]<;R_UP47@J9:PX13!Z',D_FD)&X>YHS8&'F\Q M6>_>(XY/#*2/_V6>_B5EJU]X=RX\*[C_ZOI!<6[!AG&D3^!'H:$O((#'5G#S M8%N/#$OE<0E:PH5^) R.$!AJ"1<8.A ,RBJ]A0O9E(1>Q[*&A(V\L*!6: 2A M9SF/YT "OO='O:=-^R#@R._I>+P0E!(VXK(UI9(\?^J!.TA.-\VQ)6RL96M: ML?,72U>?**F$#;&,P@>?_A%B7!)=OO4-X)4+]D^?YO;T:;XA^^&3]7SF4=\- M/8/Z_..$$I,-WK2>^K_"/XQL5HO DFNFVC0);=+>0[?5>#!:I*O!9[W7:_P+ M?PM['?XZ&W>O5NRT= M1Q[ $@5F_.)H4G68U*?U[WO=>J^1_5.CKK+O/['G>?&/T9KI,RQD"_? 1'!E M?JOHE96Y1J.'*Q73#7$M_@*$^CPCI@D"Y*RAJ/",^ 6?V,2SZ,27(G!G9W#] MYZR%QO?'E\-P7.\,7X3O&@.::F,RM>SYV2_WP%6^PC[^Y#/MP',8::*9JQKBX_OU\/[R0AG=#^XO1\O@> 46 MQQCMZ/+\^]WP?G@Y4@;7%\KE_Y[_/KC^ZZ5R?O/MVW T&MY<'W$*VE93^,=@ M]/OP^J_W-]=5Y>)A_Y?F_C;-)L4!;(!;X>G/W3?D5Y++C M.M?A%!YB*)'XOJ-CID\KBD-05YK4.KMPC7 :J:X*D]QCN*"O-FI_8])]\93^ M^Z-K)$X/JC% T=4;7-GE41E:O=OLO*@QME8^S7H/5=;KRF>3IHEUB39[5E:T M@TW'ZVO@SK8'S#_@P?AP_\U0X6N;FT'^%H(Q13U[?D=GKA=4%);B$8"E\QR< MC:UG:M; #D]X2*OT__LOO4ZS_7DC&P7F,19P.X[K;;6*?_L^N+N_O+OZIW)W M>7MS=Z_6[,NR4)CEO;E;&[$4 MTU),,SL&P\86AJTVR^DQL?U$4#X'@V9.!9 4G<$$B6QI X2 MW,2B>NRYTR6+40E<15SO8+OIGKO3J>5C$$L96R NG1 C3V.WA\NGXD1*#A%Q1TKBTDKQ%=&,VI@7-A4+$>Q E\YGS K[J/P MTRH6QJT-,"Z%H=5\/81:X*.*M;3X_"N'A5AW*T,BZA=2S:TP,''. X.,[2BR M_#E65\V;G[OFLD,#(S/.J/E(/&Q>;/"K%LY,!Y08<8A)7A8Z6QAMRZ'N-U&/ MDV(C_0HET*OA/T:@#VQM%;!J7-P=5/X-8MLW+99' :*.[9I8:5JP2[U'XEA_ MLL\?OTH\[$ZVN07Z1$[V%,<2-=PO"!("?(6O8 M6764-?B A:#!_IN1N%L=RUN']1P7_K'6E-$?MG47:D474 M?M!R3YZ'T5X]S[9>=CRPVV*OB\T'U$Y;?]&)/RE!'V$*[=<9F.:&-2.V0I^I MP]A_:X^JBM12IG'--HR/A0.D(\"QY%?Y922#N,C;;9@NG+__ M_DM74SN??26@-IWAI*/X2!4\02QB TRB$%AE6#&3GI W^+:XQK]#'WANON^( M9C-S-S? ;!GY_^#?, *]GE\)-.(KH.1@H]]D@ MV"")'RB]AF*2N5]7_OLO:KOQ>?W?O%K[//0\> V/PL.[T0P+_41^M"K]?U)_ M570LO3!"9$$[#MO!ZCGG6XN$]*:5OW:/OBSN:8L'9!O@F*D5!,!C(/R-P',= M-'CLN8(IZW-EB((BR>,0L]/\1'PP]W(5S9;+2B2&-H M*A;,[]5 +>UC!_\*4@->(<7 M*S[@E2FLP+R*A@0\#+0OKMFC\NBY/X-)_',=[ K*1F;2L>6PK4CFW*%5JL$D M-XR/_:Q^CB][]8+-XXLO1&,BNGC#6.,K+8<+-U5[J&FQ>92VB>H[ :<4&PU: MH][2\Z5T;/I>J[/%_-20L?B<.*OJZQ M3*N @#$LL+#]WRK#ZZ\9.\MLM*R,.N_I=;.8\3("86UJIAO4H@>"R@?S"I[5 M2/"(1]V;>K6A]JIZNQ4C,QYK?VUQTJN[;7#[."!)92EP@E!ODVK5/CPDJA7$ M]MF6AP/*$J'7F_6.VBTD&*ZVZUJOF!!]LU5O=UM[BH8?,FUOFQ.(?&S AE'2 M^5D(AJ2'5U7ZK%=#(JF85"I/SN+.D_<($]2C^?3!M=_/O..35S0V%T$._9Q8 M+*DI%E8E3-TMVL>.A/@<3&S&)HG>TOA1SI32=EQE1CSEB=@OG!\H':YV7<"( MOSA[):NG5_J#[[>_RV5:Q5GLO?&SGVO[D/#K\AD)K0DB#*R&:^*;Y _EK[;[ M -[]-_ I::!<79V_'N_<)2-;EG(KHI3;2KF]FEMRUGNA: ;[%*-CK M&XM;R(/OVF&P?LMK-?ORU@[L)+4#)]Z"-1]I[<&CY$>-C $@9\3^2>8^+L!! M"PP>(]5[\/UN>#T<*+>_#^Z^#5&W[^,AA?#P=WP MJ'7QMIO-_>#+U266F#B_N;Z_O+[?/.)R.B2=>C>G/[+Y>[W;+,0=Z:IUO=46 M;%!M&-/+"[6E62CR!MG6IL34,DTP 8]R9N\6A&M!]GC67E_\;B0UYRQY"/OU^'UX/I\.+@"-8Y5/0?WK")L\<2.]&1D:BM@PUFF$C- &<[N M;T67_?+X5DAX X^K&PA>7OE[(K31*_UA0*>**N7O*0;/4HV>G M3B^HP5LM187*2STC/6U+',, VWB47]JL)V.SMJ7-*FU6!$)OH\V:]C25[ITCT]+ MU #"M!**FC0&I*@I0-1HK2U%#4O.GK@VO,*/2NLIEW^$5C O0,9($7-Z(@:1 MM8FF4L2\)Q'3W5+$G!-_HGRUW9_99DMI_4=< "8/2SV#96%>ZJFL]D\K\510 MC99[ M+/.&4CH!N',LME!,B01L&LKJM86BB ,06NLL$:R-ZB#^46_6G*!H1$ M2R9$"4F;7C-*B-)D0M0)2F,D[S?BD$6;X2\GR1&9P8.L>>^Q7RS MA6Q&X U=]0/[=5@M "0D8*Z6&&@]J2D%I(X*E:]8*):EZ+Z!$4UH^_? ML,J'%; 3G$SLPA=V_!FEMNWZ(18T&3RX81 ?V;VS_!\"0$**XH*Y7=O1HY:R M>&_4B$84+XUG,-:J+<%8#84LH6S,=:^^2D M[(D5SV-"4M$/CF_O?+NWV?E94R]H@R%HBL=4Y.QIX(=?2&/!%[ MRB(6Z7M%'XG-K5C6BU":L2?(Q%+$"DN=I.C 0,K8DY2Q0&",P2I?B1&XGA2O M)\C 4KP*2YVV3&$X:>D*]/WNI*KACXC-&R!$QU)2-?,Q6OO=9S6J(W-7"N,3 M9'N ]+7L5PO)80%H+L4N 6SM!2XHE*G MJ8F4B2 %;M$"%^G[#>X!JW=,P=A-)8$)0&\I: MF92EHA:5.*Q*T+2EH3U+0 M GUO6#_5H<-;Z,"C!*"T%+$%,[$4L<)2IQN)V+84L2PM"207NKI,3I25WOQD.A1>Q:^1M_BNAEBGQ?9SI # MBS4 Y*GZ[)"Y]GE#&Z3T1'(LM5[)F'>ZUZA6?,/V+6<=)<]F%C5Y\WS;6?,5 M@,Z=YLFUK3R_N;ZXO!Y=7F#?RM'-U?!B< \?O@RN +^7RNCWR\L76EGN?1:O MMNQFD_A@.4HP<4-XA.E_C$=;CK::C7J[JPO6PE+5ZLV>:'TU85!ZZ^65*C:$ ML9\NV%N>5ENJ!Q5QWSX-QT,V M]R"5;+%[[/55AM+Z'GZ6CZ0(P?CYX+?DPM M&J]A4 HNU)N.6!]C^H/1**V -A/_U:F^UD]RT_U;-9I\Z\,/.[C<:!FS_Q,1 M+=GNY'GH><#""O%]FK(_\Z!F9BQ4J>M6PH93!#_G-UB7)-,3TU#Y\JU-Q^M9XQ M_//5(P:K\Q8Z5G"'<:#0-RN !0='S[XP:@ (DQK6E-C^;Q7\Y) IQ2MKCX3, MSA!R^+_+!=[N$JCA#P/'7/XB=65%X1NNX!H_!V=..*V9+HM1X>L B+!=Q#4^[M9O59JOWZZ?E&221DF-PW4J;IC? )98N6\.F&'5;9J;-)L5I,.V& M@'$.IFT*Q+1JI=_L5KN=UAK3'H=Q"C(%2V .C":N%]3 K9LJEO,$]%R.319M M&VKYUC!3HIRTKKR@#\$B73ZRV/.R$^8*MEJ@!/4R*\$7>&H?2O ]P'?O6J,0 M^.J5OMY0JVVUN:LZ* A"[\<['!@&S /\08\:%+3Y@TVKBD.#O8687N*H;4W, MDU8(,47 W&(9J'<)8?QK&KR1P["R7;?::T@G2:+YH/IA+VC&O-UFM=%=1[/T M'O:+C"&X#$[@>J#KWZXFWH/AM7S<@=A&2 MOR K:JLD3R&9:_][![OPE88.=K>J::7>1,X+DA*X#>4%_/ZW%W8!O%[I-[5F MM=MH%.1-[!5T)Y^M?NTZM0/Y%UOD,&LS+?,2)$"/F+?V(D QVZ"QL[^F5]43-84*:R$C+S7^M1J7?K';:Z]'\$ND0Z5J43X<4BV(\&E_M=:2/ M<6A$\)J=5&$+4G/'M="/U(3T,XZM)9 P5Y3X] Y?<3/^[G,&R\M<&CCPC288 M:=+1D" ^M)(H"L0Z@KA;[:BR>LK!-R7 HR !C#E#2TAGXLC;$S%MBN"Q)EIA M>F_=ER^1FI"^1/G41*$@;B&(FQE!U5*[$N)J!YXIO9\,Z?TFB9:_TN;V\Q=% MEAPH&SROT&A7^BVU76WKI=9])4D#/UFN+J@49_FX^D I[WFYN@-Q6&^WU MQ!L!.>N$#6\3_?$.6Z2NPYD,MT0M\9$RW)_=6@G;UC&A?QM MBSQ8-DM9/68/".'N?S\!J*1>XXS,64,GW-PFAN&%U-P9'N_!@S]8_<9;3J"! M8PXX>:X6U'G;@;56%Y1XHZIUY ZWQ/1A;<[]8;J'AFE5W[V6HUA!JJU5R5$A MD^C GZL7,-7\;:[59/I2L^2NW MN@_=260/6&9945UUO31%J7>\W]*K/'I$#:\_4[L':'6\34&PE.NA?'#'RL^) M94R4_\R#JM82JEJ9!WC>:F^T$R!I^:#>/LB@]$J_4<]*25KY0@$ZVCADRV%= M0)GWAUTP%6]*'/ M4.YL-;?QT'Q5;4E'4,+W\*->.GPET@I%@AB/V#>K[8RH1:D]O1+HAD5N\[)VD+M) MPB0UKS/7&O]T*_U>NORLS.$C6XWLPN ^>]?AV$=JM]%6MJO5.(;0M?<8R&0.% M0;B'Y?NJ/?4D6PH)'I3F&Z&"N(DEW1$ZY 9H3M[J8E?S5J>JEKN^:RY\E,"- M+"G0#[GUF1?HV 2]TZBJC:)RZ 7:]-S1S3Q2B19W.K5XVU'F6"$08/34,9C+ M>.T&5%&[^_9$MKA_VZW&O!+]V;?.',O^K1)X(5T_$IJLSL QS]-KDT!:XV Y MD15I%K B>K(B)U\0:_3[X.[R]YNKB\N[__Y+5U,[GT?*Y=^^#^__>'N M/Y L??7T-*N;R<*OS5T>(YDKFY@_]/V0FGFM MIO8+E"AF7#=AX >@_X%3\@Z.G7S1J^U>UJG>53*@B9%S*J]6;2AN*MWO&W M^G(@6L:ACUUE)X$1DY-OAW@/(PU5K=&I]KHR%BUA?. ".X7!6.4P;E0UM:CT M:9'BT9HFAM.SH9@G#!@7&IM5$LNL68YBD)D5$%MF+QVM?&="DUL@R= YYP1) ML5Q>%F,]QUK5IBH3F"26#ZHGBLD>6?$HX MFW1L&99L!"F ++ZC 8$WF9?$N;5+/_T6A?X1'/EB\6Z,W\<1Y M@1$9YJA&I+IDA,K+7]U*7V_UJLW.^I&"$D5@2M+2\'V@?N^QF]U1WP/4=SK5 M7H8K*2#R3BC#:>L'(VS+UD]-BM=L>+DIINY#NVENX^ 4217X= M,HE_X)@[2S,8WTGT)2X<44=R'-^O3-FUL_'IRI1#GI_O#!GGB&6X^6\3)B-&8I32BV-'6G M,)HYYMHY;H#FDH?=3A4+QOKHL90)+U#2$E/_XFB15:P6@3%HIMHT"6W2WD.WU7@P6J2K MP6>]UVO\2P5G([IIXBTRQA]I[<&CY$>-C&&"9\3^2>8^(C4-2\#DRKJO+AE? MF/ZO#]ZG?M9HLT&N:H=%^2;+JM/$#8+O=\/KX4"Y_7UP]VUP?OG]?G@^N!HI MP^OSNC*XOE!&W[^,AA?#P5VZ)?CJ[$29S?G-]<7E]>CR0H&_1C=7PXO!/7P8 MW<-_OEU>WX^4FZ_*S>WEW>!^"!>P"9[??+N]N_P=;AO^_5*YNAD)/4W&&A\L M!Z2+&\(S3+^JT&>#@E2>48^[;0J(&/(QURR8;%X(#:8+8#8VF?GT+/[CLVGY M,YO,SRR'C8G=]#E"=B1ID$U675M\'_\YXJ!>I]YKZPP5,%UHT5>]$I+9 M\G#3BY?UUB[+,/8Y]PCE*-]//$J5*5PW\14*EH>Y1=!FRP639-B:#,D)C%*O M?LH%W_80MN!TP?,PVT0Q=Z['O.1NK3M4>;PM\9=4WQ_*2Z8V5.WD6.9#Z)#0 MQ-.4RUO^AS[Q>XP0T=V>N\_+^P7@^WQUI'3!(7OKN69H!(K'H5M5'%IXQM_. M"5GEWWD3,LZ]^]Y9Y^4X=R0/OWKN% N#X!/_8063\]"'Z5'O\MFP0UR6@>]3 M^'^390'G#'UKE3Y&OCM9)Z'+MIM6@OTPD7FUH!TM(7EU]SVI[O%Y5:_T]695 MUSN"'+K:3Q4>.R=V,(^-&5FE M8L_JOW=\D=*L]+6JEG%(J$3:7QYS$U!=JHT]@'L=OWC$;>>D#0$!)*@Z?%NR M[5%!R_-M]^F?;\7URXE!92N!N[NN4X^OZ]J5?JM1U1NGX.K*FM"E5Y "<$2' M.93-1E$-V,N!2D%U:PDW;!9]]^@S=D[:8R/Y+>[?0UO?4QF94$!_:;]'JVM; M- XY*NC/79_E&_L@365[R:-9C$B&FW&D)7-KOB[XC=5.J]0E.P6,XI8=M?LW MZU9@NX[,7J7?U';N"24@-@351B\$?\J@C4;4AB\?J\HC=2@>A\% /C&GEF/Y M@<=.J\AJ<,?247_E-!DXYF")(I?<6LZKM=0&R(9.M=UKE5EM"1AM+3N0]Z^V MBD:RRF)QJE9430J1T"2HHBNYVW5'?X,CW%*#^QX,7M.$1 * M%PMZO%4B:" 1JJW6NN5;(M4FH-5==A0?(M!>)(RQ,K:>V7BT_%@25+&5W(,# M_ 5>: 2A=Y! >MEMW4.HM04],%SCYQ8"S4J_76UW2[W1+*!A77;H'D27O8C= MC-9_*=BV$"1=3=4^2Z],>F7;[0"S#A0?+%:._F.LO8Z>9B6T&"B@\/DK8H!1 M)=F;;5.NA:[ M4!;PZ:+],&D;.\&]Q^#>ZZW'!$X98\%67\K8Q?G2=HR8?EE12 M[,/WVF0T+]O+2,"\4D-KL-T$K;4N-7*[7L<7&.\;>05TIMK>7RL >BIZ<-56 M=Y<&E*6"GJ"ZJN2[6T.LL$;!QXN<.>G+":&SEN5%3*0W;GIKV-J\JF7L=^5N M-7I\4?&^L;9_3^I%K+VX/Z7I1>]/E0-M@BJFEW:N1"_;EV@EOG$EMZJ.%4:, M";&\I^ Z21#X#?M56A/WJUI:J2.+ FY]E!W,A]-MA:*Y5>GKU:ZZ$A;E)(KU? M&%7Y=?=(T\OGP".PMI9#O/DPH%,?Q R^W7/9>@BG<&N$8NT/?3UL47Z4"*I[2NSH M">G4BE^[(1*30=I5K;&N MF\J+R#(JK!(Z2_R$&'9Q]^@$[!_KB2H?4(-]5!Z)Y9SMS77:XOX4%G4 G.F& MV)9YM\*<)S,TH8"_>Q^6XZ#_N^-1&,N?U$R#7L&&*T_$LK&C=PUD<0V/OR@^ M-4+/"BSJLP.4>"P&8PSPGS?;*,/KKYF'N<[3_+A0#(-X4%]=;P1#&B4C6BLO MG9&JT5XH#&T7'^I8@]8K?<>R,P($&R(&LC'.L>WL3;!(( '$]Y<@,3#_'?H! M5G@!B^AF# BY=3T_>6>'!)EBG4!.,\HVQ9;CM()&NG[(C; M?Q#G"$##UC9%G182"6Q"6!C[?/5[N.H]>"Y+[/[VH-O[/O9R0&,@0SS'HC=W MP(.G070S!/")GGXY700>,LI6) 0[+.8&7LE[@:"@FJN$FT1?B&\9O%"N986 MP8\?<\$QF\C$QD(F=E_VZ@H>"&.CK&'T*OU&O;'>AOO$=T=.D\UW;7M?3C9_ M@U6TD;L*9J]FXXU<7KB\::K(Z.IZ+><39W313;(2!A/^P3Y0LT9@5.21XH[H M%(#-[#%?<& M*J=7SB35F/@#3OOKUXXML-]VHR=8%IR]#F@\?6*[B7%& OP37STEWJ/EL-7J++.F0?'PU/ZXD#WQS K@;<;+ M?*FQ:K 3JA #31[BS-$*)_Z\BGR*?(I>WQ*)!2: M6KV#IM))2E_L71HFZU6@3&H)EJTR2T27L/W5;CP6B1K@:?]5ZO\2^L$Q'=-/'B M&/$I^U,@8)GA&[)]D[J/>2%,.R+:R[JM+MIEV+^% U0ZA72= M)LQB\/UN>#T<*+>_#^Z^#Y()0JW^"ZB:]<.B8UE6^L M6[VN5A6M@0>&C@?\K7,-!)?_!)?T+%E6)+?MU?TV+62+1W31A/7!K'O_\*^N?PCM(+YTEJ>UFF#["7Y M0FSB&%0A@7)!#8H9!;'9HPM9IDKXU)5BKJE7 MNQFGE4J4P562DJ[[!;YP\J6X5/RU^9>4X;..*+["[8S/(VW%]51N'N^P+D^- M1E7+S(B77"ZY7'+YGKEESPN>?P8]2Z:6U8;R.+V=8;N M81VA=]#H0/*2Y*5U7FKMP$OY-&>K4>GWFEI5US3);)+93H/9\O#:FMHJG,/4 M2E_O=*J]UGK]16F;+K'X>SA2S:.6BN7[(36QI"Y]IIYA^10/"/F(-L6=L<92 M[-3T$_6Q!2/^B#VC/,O LT+\.H3U4:N[O8-P='L+\3!DM+P(/5B+6QB6&QU) M9#_><&)>1E0V=32Q-,(CFT]%/T9\2O#.LC+?ANV_$SNDQ4!; M!VBK554OM6*4V!;2A>KD<:'VBO(F1_E.;4@DR X$LO_^2U=3M<]2_DAH2&A( M:!R^->@;]-&ZRFF!RBGU3EA!R#VM1+;L<_A10,&CL] S)@3KBF#@P,#L-MNF M9E6Q',,.63EXK$'BP;LBF!JN_\8 PGOHSY'7"MU#!.%R.K/=.>6,?QO1]]:& MX>>V0ML81M [L@=,J3%6L!N_$5^YX85I5CK@JX M6XDO:^%DUI[(+SJY71&P0?%U9:[URFU?=-E[;QH$.O?NXLR K?$,H?..:\=P(0]D_7G*5%_1_\(+=\*Z(AZ3Y9! MN5J_HX;[Z+"G, V?6Y'W*OU6M:-GM362G" Y00I)"0T)#0D-079W15.?[894 MG^]DLYBM['?'HS",/^,^7(!F\D0L&\LWUP Z-9]@\6=JA!Z BOI5Q:%OJ[/S M?H-AY=,D,DXJH2&A(:$AH2$D-/+MKG2W3'QG=0J72A3RLH2#V!X H$6<:FBE4Z9 92"2 GI9&$ MQE[V>L411IH@PJB@[5\.GD:&_\D^6]AS,#BK]=:;\AS5(07B,4]4;@2?N'R6 MT4H)#0D-"0T)#0D-"8TR02.?P=_;TN('PX^;^-@2(?>VE0[&>Z/::?;DF?I3 M ]!!\-,4!S^GM>WX:K.% AI,[;O30AEY+.>I5*UQN#8+[19OL]#NK2?;E\C> MR(6:LA6X?-?5+4^UM.5K3+Y[;EP^LK;5%VJ670KM;Z7\PNYE^UUP>7"]@+AU0F_DQ4;3(&KMCD;FU.KEF3VR=GU M7Q^\3_T9 2):#OO;X,?8W^W*&$8X#6T24),M!SO:P/Y:.M_ OOF R2L?%9[( M(A>,+]@%'5N&]6XYZ]X-(J9B,CGRG7]AWW />FEEWEGZT 4UZ/2!>K$JUV0& M44'QC+P91*\TSBPR@ZB#!T>;6E5KKS>UD+N!)=G*R$;=J6]EY.2UK)V,O7>H M[>!1R*K:;57UQOI6OV0PR6"GS6!KW=8+9S ==^"KS:[D+LE=)\!=^7;BU_K3 M[&TGOH/'.JJ-MMR'EQSVGC@L5Z_;W3BL!9JLW01#<3W=6_*8Y+$R\5@N%ENK MJE4X9[4K_29F6^LMX8W$$^]8DMH04RS6B ;KI-*HX2HVT?21W(K+.[&R=IM/ MU ]@:O@CW!9XEA%0,[H.@24+W.PW&KEV[#Q'E\UMV^IV.I5^)\.XE(4+2H:A M+ '_-@"]U)8YI_SO KBJ'77]C*R$EYCPRF6CZVMG,5^RT?<*M%ZEW]XQ65UB M[&!)QJPLCQ0!DCR2/'LU -0=VE(6(I>[#0Q>MO6=]P@.4Y?&M/R93>8X4+H9 MC?*JLEUU6OE$+_CV9E'M2-]#*>@BU9^LU"W)(\F3\Y3E*Z5\1.LKUE4K_5ZU MV5[O*R;1*"8:I;"0Y)'D$<'3%$Z6:V+)\O>P^YCJT_A(+&>/?1K?;W1(!N\D M>21Y)'E.DCRYG,M7#)+#-^?JZI5^1QK1M4RQQ;]YV=(:-+\Q:O=KW7'])?Z7P=I'UE[H= MWL&MH165G%H$78\4+#H:9(4+%&Q_;+C(I2DI%V<98J^P\.Z'BKM=5MFI!ZR; MT<1)LJYD7=[TH:>Z3M)(Y)7-*YM0/5RJNIX)Z[36JK8;D7LF]DGL+,(G7JM 5SK-: MI:\#SS8S>+9<-C&+)W]BF2_P7]-ZZO_*_N&CQTK_R4SB'^.YK#4OV!\TV!// M\+B!9;P,%HUWW:$*,? X+7'F6 O+<0-X'_'@:T>Q8*R/'K&5&?$"+),53*A/ M$4,F=?@Y7(>M,/:!4,:60QS#@LO] +Y@AR'J&] MM4E@/='//RTSF,283MT8$;ZQN(4\P"#"8/,M!US_%U=;7UZ-]+\X6F09JT5@ M#)JI-DU"F[3WT&TU'HP6Z6KP6>_U&O_2NI7XIDG2-G!&'FGMP:/D1XV,88)G MQ/Y)YC[B-K4.4\N)!Z1WZQJN^^J2;<;S&@6GQ'N$!S)6T[):=!Q^4Z33Q-XD MW^^&U\.!5(!)[= M-!N&F?.;ZXO+Z]'EA0)_C6ZNAA>#>_@PNH?_?+N\OA\I-U^5\\'H=^7KUAM9+OK&XX!H;R ADW@+YF/B%29ODYE/S^(_/LQW^.D-CKU;LM'<$8;=U%+XYP6HMD_Q8_:LJG<+@TG>VN795B;(O;Y M>:%)79X./T6LX>EU9],:6O. W>PBL;3RC!-:3/TMD$R;Q^Q5K_A_L%#'ZBUO M.6"0NB$\P_37_/^WBZ130<"'T"&A:8%I_C$/$$XB'_Z<^!-E;+L_?25$1P6/ MX\ZH1UB]7W0_G]@YA[.]YG$Q [!.9&#;-ER)'>0 M3CC+5>R\P.!<6!>H;EDVQ:@G3G/@M_FV@K?62E26-K#T967I'< Q= MT!G@QF*%CEC+#3+%<\1_OKUPYPNJ)D^.NM"YYMFFRDZ6RK) 3I,EMSQN5?K- M:K>Y7EDJIN=QSKK),@8B&A1%EC%81NTZ,-N5?D?=N>#984R%X]>,WNZJ(BV> M9IMO]:XJ+/;9PBWEX*S6R]@D.D"$<7.,(*VQ< L<,#BUPBGO( 7+9<#LP4*" M'_T)7%D+J#<%0PA[2S';259D.*!#OE*4T3 \RJJ6I&AX,[Z(B39PS-N(FL,% MP7(KQ$ZEKXMQY%'":\\.[E'PU04'N-I6"VB0*\B1VG+X+NP$9D:_ 84^X]]4 MNB_']2K]5[>C2D9'P/:PC4PA^M4:CH!+/ @9'R^=F(4E+RG:=5N'^ MMA4C M]+!)4.1"21OYZ'&U=8:+J/="2 +K6F;T $51A+.YD0;,$IEL9E:Z6=$LDND-J1/ M<1H^Q=:(U3(1*[V'@P349V3.H^G$,+R0FBDW8M=ME_=@D!VPQ,$ZA\5$O.4T M'#CF@!/Q:D&YW&::CNY\J]<\?@A5XNPXM0,.!+0F;OFH.TE^ 5T!X27_36+M M+^?([G-SO>SVTU&E?$*PU13'=99J@275%>#0DL2.*)([!WC: !X1-H-.JXGD M"UE/K]5P403H*%FVGI&'+3F&)0]O/??),JGY9?X=:)GBN$%"R-RF$?:1[((1 M7ES/#3&[:KP#0!ZXZ->^$-FM]'6UVNX4D*"UYW81[Z_**J]\(5"5U=VK10LP MLG=5F?4V](P)>H/N>.="*N\A'+/_5*Y;,F&A:96M;9,M!4*3P?8H-D+H+0&=CS7JGKOQ,)XVTCLX^W>@X4'0S=] M9>RYLO*5$ 528I)\!8J,"(N1?R,!LM7\9EP(J[&-?>S$N'[F7>[NOV=L[[]Z MRO[!C3D [4ZUTUX/0)[ (7R]GJE/Q$T/2_L#,P^#D\&<9090,!UFJ&JD:W T M3;-JR+%$&V!1,T3WG\:)-EM7P-#TS14P2J19I%MR$F[)!C2OH[99Z>L9);%+ M[7:43U.W;OUOJ&/=EA3,*W[\EJ MG4J_V:MJ^BD<$MP:024PZ[/:S=C:$A"2[RQ5@>U3\-J\ MEC!]RF2:0NF]SSLZ2T4J#73G=C#Y3S["XQ>VCFE7<&5)"VM5B))\A26XX12XC4IE9/*6# M4%Z7R.4+'4JKO4PJ80NHYC0NFMAJHJVOU_PMM=TNM$)@D;T/T?FCCTM[4UE! MOK?M315D@I7TW.#Q#[)^C2GY]IB\CED%K6JC54!-@N,?9'W?@#S:WE 1.&P7 MI"/VCL7WVL.^I*D95E1P0_E@1B4W/N*)7,S8J/*\#4R8?@(X.E$O&X_Z@6<9 M 78XAM^%S-H06Q#MW9M"(83_NUR0[BZA&OXP<,SE+U)7WL+P77.]$(MAA[BD MEU&OTCL2T,OQF!I!;EG683JUU5VOT%8^W^WX2OU]\](AJU,(SE9=;!VC=@K8 M1I0%+G;U+;?3G57E@3Y:CH/.)IY38A"1>T9[4YO-/:K-W.S:J_2;W6JW(P_# M2I@7ZZ9J78%PWFQ4^KTFZ*7U?/M2;WR=C JB6"Y[)^7S@@6ZWTSC(ZY[MC+Z MS[VEZ&Z-! Q"5K ;P?/]R_PO( .2V&ZX8--UU:J)*-[#Q;F*)S- M;(II<,3FAB:>DU$LAW,-@;*>'^1N="JZ T:6'(%[W,/7@8 F 14'0\ MBHYM[>SHE]B#R)JB*';!0?,%AQ&X[B+$92EV'11[>UVKE\C&%R?25F:FV]52 M%YGI#IOZN,YU.6UMEO78ZJV'OTL=%N3Y\*7KILI4-NO&S=6UX4ZI$I#GXAOG M[9Q=7&*5G35%4:3'WE7VD('J'C%U"T"[ID&.\S/-EJSP=]!8G,AL6%"X34@V M/$RCVS5&7&NHYAV1:+2;$:&UOOC2J! MJP03BNP%)AN>%8&_6 R7X"4/Q&9'OOT)?6O/>5'#58*$NX1&5O8>NXQPR0A7 M8=O@ V=U1VL0G!//F\-R_)W8([:FE3KV6H3 1K&B1N?,P^]+% MLV>WTN]VJ[JV7A2\U$$QH1%_)\YY)J'S4O>N\=;R.M:R.=89IE?IMYJESJ 6 M)R1T,DC=O_1_ U1;#3"].NMVEZSQL"^"W[MQ;LH>3[+N8!Q&645\C583BW8Y MCU=^EZ^0I1%%')U6QG3K)#*F"\29H*[G*4J7@ES6DY(N)Y:"W2HL!?O(+,XL MK$^LJR3\U[2>^K_"/_%PI\1[M!SVWLXR>QD4$VOV!QOVQ#/6\;R:J3_Q=$BCU@M F/03+5I$MJDO8=NJ_%@M$A7@\]ZK]?X%Q:K MC6Z:)#NG,_)(:P\>)3]J9 P3/"/V3S+W$:EI6 (FHP$UHQRF34N60C!.+EJP M_J\/WJ?^1IJF;])>P'W68][\L -:=ITFK-+@^]WP>CA0;G\?W'T;G%]^OQ^> M#ZY&RO#ZO*X,KB^4T?7US?SE2[F^4\YOKB\OK MT>4%_C6ZN1I>#.[AP]?A]>#Z?#BX4D;W\,6WR^M[\2?U(71(:%H@E#ZNCW5+ M+FM64C<=9QIJ(CVYJKP.I_ @8STO:UFAWWB/Q+'^9#OBYXF A@^@R&_!*<9# M'?CQ9OPUEMBC1&!?6+YANW[HT7MXQ1>;5:F/E;?.;0O+":DY"*+O< 4%/T, M >"%]"@TC_5Y#DTBO!0@(7,%#/FL6Y E]"'Y[C+W9UE]8YIC]\ M&='TCN#T+,V]!@ELA[ $C18Q4U8(I/:H,(] M-"BP6RJ989'-P%5FU)V!;08_XD\_K6"BD#!PK>DT=*AB6CX6S?'Y#Q.8 !BV M4QHH4VJR-SF8G5R'82O_EP UO+FB-32UFAXV#I7U9H6!7'V__9]_7@]'>W%< MVPBQ5]<^PZY!>-1T=O>J=0F3QP6 MYP?*]_JHKGQU79-SE!<^*@,3+ L+7 3.(!^^7@P^*F2&95<1#VA!ST ?"SR;8N-U7/EQ=?V0OC@41 MPQ5:I*$1* 9,A"&%Q_\>0UAS%V"2*O4*5_OA#*85L''$& '(/E';9:W#L5XL MH'T*ZCQB#7P9^BDP&S:XF\ /?ZSR$T"P7E6N A-XBE\ (T4> IK9!%P1OCIH M2SO48RN1?BF?U'2*988!#W\F&4W)$"V'#?DRQ(;G (GO#EOMR^] G_]+ "15 M?-]/:MOX7[P4KL Q_P]PF^E.J\I=Z/L6J2HCF,6?U+/AG57EVO7 5JPJ7P"A M7NA7E:%!^2]7%C4F 9CZ ;6X /W^PR. %>4#SHDR$MESCHYH3>ZI!Y0"U%#_ MXV;K7UA1>>,H7^F#QX2+VJJB@&DN"QCB.."'HGR)DL<,&]0()Y4%Z&5L0!]! M3WOTR8)1S?!8A<]CTMS7]8'P6(0,G^$JU)E$B6;@=DU<&SQ6Y0GWEZN8J<_K MAZ$W1I_9FX IF*1E""IE8PC#":B-!JX: M)9XQ883/$"_L>Q!I]!E6BZTLL6$I':8F^&H1 QQN)BG@F5JCP5^\F3!/KOT4 M 3,>'0#_8X-BP)PM M0 ?"!T49_$3AR0;(; ,%*\YF2H"^UI_X6W)HV$=M >(N]% 'L-5"*>2"M/+H M&*'C@@B"R:@]$%#I"950?$1L](O/H _L!PM$8VT$&I)Z-/D62 _F-3.J@'?^ MHC8;545MZFJKIJI=9?!$'10!E^84WHJK-; !R %([W/B$!,D;>M*:8[:"RT% MO.$J$Z9RF)).283HE:GW=3K*]QE0$F9M_%#.+<\ NH]"T!<*&-A5]O63!4*^ MJGP#8<@5@M8 1RG6*LQI>"'"(SJ1D !X%"IB)E.9A9X?$LX8R$*Q>P"\Q*]A MHGL =L:'B!8?ER0!.\'2^>PO]_ECP330"28WC?'!U\0WR1_*7VWW 6@#R_L# MC-P/_-N/( E-RHTD?SY]<&W@_=O?5Y;YTXI3DLNU[51>I]:1/'?M;2[O"$!E M <*!> .#*1P0'[?@^*)DRG!D6QF.;$M@1W843J=HD8 Z3TU56KO,V7 M99//6!*MDI,27XAO^3?C%2K,^;\9E&BOK?DQ,+DQ:IZ-4C9))$8ZG%(^.;@6 M_$_"9GE"_*!QP%QYH!1<&X^"=\.:;K '>R8S;)G+]$C!Z2$83(!?Z(QIH05\ M9[SYEDW]V+Q<4C+*!Z;0_CH8W'Y<5)RPIJD!I4J3<,-J?0CX6,OA!@83Y2#G MP329*FJC]C=VTP#]<="#:@.I>\<=2'SBJ/:_)51T0[Z4[LQR(F< 'DD>&=VX M4U, ^;F/ H]"M]/$";/OJ^Q6BS7-QC<[2!T;ZX:$'C=V%]?R2TUF'#D4G244 M=DCG,;$\A%7"95ET3; 1F\>OG^=!!QD&]0WM<[[QJ*O,]'_).&= M.7@^6'J28LS5H.B"+2VSSDD%*Q#: 2-%Y%4@6R8QHHD'/B2:OQ,_>E@6P="^ MPI6.D6.Q@"5&#)DC%;G \:N YV&-P.>B+)P3OPOCG'S4\ 7Z32[S5L8AN"(T MJIZY:NNNJMA60-V.M:A3OOJ V^8F@21O_/*BXG6GJG]2--0@\1?RX0P&[C/( #VQP>\>GCE(4K7HB/ M#*^_KO6NB<(@-['S/N+/6<[@ ((;F,7Q$^0KB-PD)M)8(+);Z;L.78N)*-&X M2J@E=T$KPBA23YRH3(:;&/#U?!9-,2;H9RX+4!8)M.TX8@@$@/$X2PC^!40/ ME]VH8,Z'I4;R>J6^/!1$<-[F R^R618*5@EG[AK>_$@L3BE!513' MXA\)F$@H!$%#^9'W"DH;$VD25;!AA5+KLB30.;> '*5:]>I MO3:L#\1VX[TJ> Z8(QX/+C(= HO@?XP]?+;R/+K"EI:]?;P8#LR*LMX/\9AP M%/%[?R(UB<&M@;KR+1Y65*P%AQ6]$#!#I_Z&EX*L\<#"6U\\C\WX:_1U,B9. M;C;IF-Z6STPV9PE, @89F G.,F@3YJ"R;+B8)5(VB[9$UM!)PJ=+>#'U?(' MOBH?XR6I@O)?%3UK#G!FR"2O<'HE V8EN^9=9#6UBLAJPCKR^\MJ>BWM:'-8 M1,L,B^CB&&(Y0Q>OA(]*J;U3FM5/32\=7HBC8\P60V>!B[_(PPLFKL_T^)/E MAKZ-D@SS1![VYOPL+W,NO^&.LHT!K-%V'NU*_P-TTSD0 22BM]&3Z(GJ2>0$ M\"W+[@B4:!U*B-A_@!&">_0;-F5G'ECQS(G%5 5P4\'D#.9*E'03[[0M?C Q M\<)Z" /7XS^98$$8 ;_?#0&)SS5F)<6)!WRC/HDQ1,#QF?E)_PA!E=BII](5 M_,_X^O-TGCAC U\[H3"Y#P,P3EG[AVBMNX&(PL:$=S&>8B($NH0%6B<_MWB@9:9[4>XD>7U>$ MQ$[.#.X[(*+W%.T2LZWH,*8(K(3[DSFE9\HQ0/,.GP"[L"\^R1JR'4VSI_?YL5+@J^"6^%B"\Q^,X;\TN^8 M=,4VYI;>P4SI*5]*D.8.2V.*8D>&36!UDLV\V!V(9H?K[K&+?!\T$<[1YXD1 MW*!%TSD.:_ BRFPN'ZST2]&MFY$Y^V4%M1]9@"IQ4>8OWTD8U\?1K "4WO+# M!.6!'!I_B6P)95-49\#8@!E&*6(;H1V%B!$+3&B$ :SNGW%N31(N9'DYRI2" MQ<#AE [U; #OAG>#'\\RJ*)76# A@WE6FYBXJDS)' $(@OK?Z$7RQ#?,-[*B M_#%K/6R[PEJ 6CN1A$!1E@>"N3L6AX[G/G#LX'=DR9X"\PA$.K&7^2/^9(33 MD/LX[$(F\]/"W0*-AX87D\R1@Y\.KM:5P33F"DX-EJF'"YFXNS&MF=R(<_)P MQG26Q-#"F9GVAZ/V1Y0PN8 V&[,'V2M9=IYI6E&4);V#]$#1OX2?GXAEXX*4 MD5'2MOZ_0Y/%YY#(R9Z#E4@]7)1LG+)TVRGY$>'47U#!7\Z+B^\"(QML![!E M,"42:$'2:6R1Q:!,K>=HEPZ@PE(TP=EE)%_8(PR"F,Z"L)D#C%D,%3LYL]C3 M7STZ"-F?G+#9#$<)KJ9Z1)/XB5M\L+@TG/*::-57YM8VK*J M8[H)^ANQ,D(1$-I!G$5G6F-,H8J\F$RY" 1$E<.>$F^"P*3G*UF-+%CHKY.8 M"S.#;2XQ[XFDHUBH&V$-DEW;B+%83F\(:S.!IHM5$&BU)?G'1L C## &$O/10%C4C X;=094;;:(=R_U4!57M&2 M=]L)@T5\Q>XL_\3 M0[.%'G+ :N8AMSW2:>S,JLE.BO6I/"75"<3U^OK 6,E9U*: <,,;7HSCIS@ M+W,&WH0,7^9WL442[\;=HUA;C]ZT,\*0;6V=(^^Y"$;RD\?(DV%E4F*3C 7* MN;K T CY4+C\CT(I",:GI%]%P=FZ;47/FT[/X MC\^H)&TR/[,L;!&O9"_O,B-%QO\/!P5"8G>G/T1HP5 M # M^JI7"BQM67'WQ9 MVA(<1X!^^>%)QS3F[3L(8ENO]'OKQ9+^ MJ^AJAJ=-V9Q5M#90MEX>@K%#B=W=;]D@-(C8%,'80O04W[!"- M#0L1L,U&L6S8JO37Z[&_C0M/G'R%2-'FRR?Y7R;?*PWETF1M;^XH=PCB[EW$ M+M<>+":Y]0CGTW"KE^\,X=:(MKPA%.418;B89Q;;Z?W:>)^3.JYQ O0'K6J0UN M='3KR@CWRY/\@6I\EBG::$_]@-N(?%,,YQC7[>"1=O[@I=0PRTEEA\6GH?@> M)WP=$ >#&UL8^6&*'&;/78I]XMO#;(J4'S#/[T?,G4=BV6P84,OF"J+KO,5 MCO:9#;91]=/U@@D_E8_-OI(1XE@>79"+#MOE]I*CF_RG,3 R4*W*@6+BWGX0 MI8JQ[8@'SR4K(^*/\)!J+M:GPO-D<6TJ5D@C>3=N-GMFG,B!J>QAE(V2I/?$ MIX/J\:'_C&GR"D!Q[ENR1XF;%[@PG&1LYWX))N)L MH8A'%D/CKTTV3&%Q@0;\ 9;KK.SPXR;PS,6D$8OPNF"8S,$I$QT@6%Y$W-R: M$-S636_#__2L@-;<\7@IV6.QH*Z7'N NV;+W6'=AX)@WN)L;Y3O[=\FS>;;L M0FET,K99.AD;GV()U^R-TGBVRF*Z;/?G[)BI@,H@(_<-=][9 9 X:\?RV#:5 M1UD=++R$Y5TM00N/464\:Y$]Z]'H8%8BGR-9G(9T5E:J$V6%(Y]$^X(KVXJ/ MP&-,S'S@A6NTCR_D.$2%![,2 :I94^!;=+@F__GV(O*M54:(USWFA04H_&L: MG//=Z.VJ.;<7_-*M]+5N?=V)50 Z=KP#FVL:S6-,HP?3:-;7HRSQ-+!2$RC)N%L7V MHE)&Z13$Z PFEI>"QX YC EMXU2*9L2@F=F!EL_S"5GZ52I9Z8$&/VF4>LZR M.3&C*LIJ!-$PM5 U/KK<=MGAC-E[/!O6WGPV3*AC7EF5;5NUY@LI/9W25']= M.E(1G:>DUHQE[L[(G"DREI[[@-G!-*F"8+/*@&F>7238L?S?)#-9"?VD"B$7 MP8N,Z91QR/R1\\OS*_ _7)/:=>5[4NH*O^;?5EHON"Z97+C\\EF28=FA;8[BR\6!E8-G;X)E:O!)9.6* M\Z,0R6.3?.\T:<#[L9XB2>L0YI.N'>G)M(C@A29%O6JQFIDL-]U)C0I]^)>0 MAW[;2VEVKQDB&045!O'+O[K>A1L^!./07M>0 >J5 MOF/9&7V!5LVFS<5U-MO"KQ:XRY=[AZ7WOB#'(K*HX_.*Y[.H#/J0!1D!B[< M?G_%"^PT2^GOL2G7V)R5]*2/>_8KK3ZBM$)E,#I7[MT94+&C=JO['E[.\W3I MI5-JRBA@Y3%37QZW*C>N':S:QVIRUHU%A+@62Y?RB LG@/$<5P(VTE-+*B>L M'8 S>=4MYG*#SD;9BL5*6#7+&K\:Z^>8&)(RF9*)Z_VFSY^ZGK\:3\,S?W[F M*):5Z^+U\3>/'BHY5BYC86H\\IJ:6$[.IKR"YQ/E]<;X :W,H4<6S_(Q(T9D M=Q9%&\$O8$(1-4LTTP^W _]C-=U2D-^# AI^O1M]]WD%H5D(0H\5L5^4\5PH M-RQ7KUS&U9$9QRJWT1T*RB+EP^7H]C8J*YI%$&:T+<:W3 ]0RDEUE/65BPZ( MK9ZXY2<3/JMRT=LW/3I MF"+J@3&7>ZGL,5:M]C>=X^^T2JF%)^<0J8G_Q$$]A,SB GL@#882%!N!L0[5>X3!DWM89H:OCR&200+-2% MY<]>>84X^I]*VR21$]@(KQ.!!9B#;U(C2QJ M5BD&EM7&>AEA &MB<(LG;NN1G/%A*B;>2$/5GQQ.Q D4 M6>F.)R?LP(3!H]6 MJH%;A1D8%%B8&X_DI&<&>P18NK3I&YV! M3^JMIC*SD@3!N$C2Q*+C5(,B#)!CJZ':E/S @E^W*Z^,O"X,*=DT51\F?B4# M29H-[E: /3[G19@BFWVGAZ9[[44)=2F/X($:)/3CJ )\ M[4] [M70H8^V9>O*Y8;8<[*Y7 .Y4\.,.1"R#RC:0!%'[P8_8='M)0G:LO)C M?E33,=ZF3Q4*P=_3)3K*J6%7T\5Y#"Y6!LMK:7%W*:/J^'(>N$_I#Z8>H_9Z M/(834=!]P 5C8+"<68B[$5/>4(S5PEI>;M\%7XPYER:=86ZY$ZS5CN+[&/@V MRUE[6^ADO"_(\,AA7N%T%N4U,]-SXOY4HI'A82D@]HRP;J\\JY@5I\M>#9Y= M21!*5NRH\KI/#"\\%I2\#KA$89U#:G#O$N[!./!P3YKO2/".#(LZ@?&.&HS$ M123_&07AHEF&481L0=#4DY=JIFR)VJ5&7WH[$\?\*XL1ZJR&%QT)V4A7K7W$ MCL0KRZ7QOFA7V%53496:0LR(XL#D MX+)PM7D780Y'S(5*">QM.O&]XY2_3AE2_EXT7W3)G05RIP;<.>0LF:I"N\R5 M/*,+XXT+-HXCFXP)TSPXKRK4"G@OV:C2-2O6&'^*J_S%>Q'+KV(5Q4"O@0.9 MS=\94@'UT?I3%G)BFT?&STJFRF(9[#U;63H2E$6"4@=0?L^P9:(VUHN$TT5, M@&_0)0:.^]-)6QV['%):%(I+O, !@]' ,5,;QY$G9]XX=W$3/=:(92KMO'#5ODK')H MJE4A,SRWM^RR-'$IRMLU>_5.IR-:);E&O=43KN:>'-3V@VHWM!64M5)F6RY;WH(JQYCE![:9XX;P#-/_6%R=L?)5*LI>G\C/ MW:9NA2Q8EUXR32Y9WB7;ILR?7+*X!A]65\XCE0LO/WB,DC]?5PSPLVT@<_!J M='G@* ?W)BX68&0%U9M3\+\=P?GN/-/-C0XV+'FZ15>XRK.:#44L&98MN?]S M=8ER33$]-0^?*M3<QI:]WJUI3EQB6&"X6P\4D M7+PH@WL-*8,E?O>$WV*R$UZ7P3U5RN"W.P0EWB"X]]BIO+GR8-FVW!_8(RL? M(+.A=QJ9#3(V)2)^#Y4*T-,K?55O5GN=I@2Q!'&Q(#[ )FU/;M)*_.X+OX?: MI.VUI!!^GSL$"X?@S0E#TK??AI?;!]BL[IW&9K6,38F(WT-M5O[0]N4O=@X4%1,;^B5OJXUJJJJ2M$APVEB7B675RYO>:]BR_N)-6=YN1M,AS5? MDJU?3JVAB1S4MH.2K5_>;ETF7;NC[B_+C1ED]Y=WTV1"=G]YXY+)[B^R^XOL M_B*[OPC7QD3HP95I9._I%(3L_E+<6IY&,>WLN>7:S#K0"5J]T:STF]UJM[-> MW:VT2;^2+4Z6+?9_)E=OM#;O\4J6$ 8VDB4BEBCFF._++/'"T4#)$L+ 1K($ M9XE.,:=EMS">.H(93W*#L0RG3SD!#!5S M.'D+E8<%>/5JI[N>Q29Q= (X*B8=\D59I+Y0!%=BZ 0P=*CS?ZHJF"QZ5[L> MLCO$_V/O39O41K*%X;^BJ+?[CCM"Q8! +/9$151[Z>L9M^W'=L_$?+HAI*30 M6$BTEBHSO_X]YV2F%B0H! (DT(=VVX!2F2?/OIZ,H(X_=[K?VU+9TE@73XM# M"0Y54QVU U/&.H>)VN_FFP&V>'0!>%1-8'([+]K2%;7%H0O H6JB>#OP(KUF MO.B:'(CMM(!3D=,)(H"]ZB* K0QP:GRIDUAO=W/4T31UWARTB72(BG2"8 MT6N#&9>-0Z<*9O0F=6-&U^1!;+O'GXJ>3A#4T:H+ZK0V>QUQZ%1!':T'/+FK MJQ.M+D9[BTB5(M()@AE:&\RX;!PZ53!#Z]>-&;49GDW(\*RWWMWV$Z]I6OXE M=NBK@-N?JA92JZP6LFVPV9)O2[Z"?$\5[=4PVMOMJ>->2[\M_;;T6Q7]GB"\ MK%4>7FY)MR7=JR?=D_EL1R!Y]6[AR+=FD6_K7FD;(#?W5RUX3]U?6G"[C]$" MN+FYJ=]T3\L*VO]$06C/5J>7(!KY_^9,>>TMX,VKOP2*:&*JV&X0^G ,;%UF MNZ8368QZENW6V4P)YT:H&#Y3'E&46$H4 !M6_HP\_ 6 XCL+E24\P(*..@>]/?DV_,)'[SX#_A_Q5%EMZ@0WOF:Z4T/B.&[?=T$-A M&M@@: P2M+@U^AL\,PT- *NES'QO 9NW?>MV:?CABHZ(S\/5//+#?LL<#5\7 M9N"?/J?I&$$ .X.5GVQ8UA6WHRDV;,X($*Y+V(HWQ?6I?;GM+J,PX.!?&*OX MZJ;,-><(=V5E,P?.'/F/""P?SNHC3$+?L/ #.P@BYBO!TF>&!?].'ER#FL]F MS(/N1X@6B8/:$792#GS M55\E '$,AGT:<)O& X/E%P!S?!_J.*A=1(8#[P[E'@&R K%BK-8RT'V"[2O& MV[ZAUI5Y.;N]&&72':!$MFXCN<54=Y'R)" M9O%X"4J8N<+WX!B&D.%PFG4Y Z#<=1D*K@,O'6;N'FX;$YW#CS5:3" MKR' P? MY7^,Q?*5\MGS_+\$]"-8(6%%!?C#=W9HSCNQ MWKEE&D"]N/-'X#L^L^Q0 5T<\,%QO"<#J>[)". :3%1]@2H(W\L2EI&Y-%"I M8=NN%P+-.S80#'T9N< ('-BPQ3< %VW@]4=.B*\T,KNS@*/!W>)S+N):S-]2 MEY_P>S!#$J:*+ A^""S&EYR;_4 <0[8:T5IP6-=; 7@EX++P$?P=N+"^*G% M0N8OB!<3"\0EI5C!O:0V"V=%$.)Y [AF$@!N"$S !FC@:QN(+%^0)^,-? 0Y MJPQ4YE#8RMWD$6,*EG$4;GXDU\7[ M3&@\7H-/ZD_<+4HH6S=@#YK5&U@&&[#)=*QWIZ9NC#7X=W\RZ?[? 28>&CN MRQ,L01S>3N&ROM\:,SC@2\-Y,E8!:O-I^@;B7H/[.L@X8.[^-O7_>E>TV\W< MXO0]T FF@P[G_OD_MZH7.>TB19?OW3>@>]^[UN_$BU'_1+(.5U]C31&^? W: M-=#$-] O@7JXCREQ+7V#5_WJ>.;W6/'H=[G;"JB!6?>A^ PWP@+36"*:^A$[ M@)FLF6B9RUNCQ&1/^/Z"76DWS1 ,]WOI!VGE8&Y8RD_[#]+3)1X9T7+^$B\& M_TM=7')M^ 7@3?:#U"_ANZ]S,%J^@:1/7>QN3LIA@F<]&L#7R3<+4> "'#P> MPJ;4F0=U/[-&CMG.:..9LZH]J4R%1K^:L_@16&D=/X@60 XD$T&?])Y []L+ M":M NMC#_6C8#O*I=Y[_%0Z2,"KD9,F_2L.U3^.CM\"U,EPZ^E$&%#7OC#V*4I[D-YC\Z@5!W0B\&:.3D^Q#*.[E &JAFQVIU*\'N _G(6N#M#KRWPI5M*9BEHU":SM7-M3OR?*W#,_$:EFM7C&K[YMHU M)9NN^-2E#/1GZE#^ESG6-T_&7,M:Y$DV77]XF&2TB"@RBLF-Z#RZJ.__K.0@E5!A+9,+W1YLSX5OJ;ZF_ MI?Y&43^:/&6H?TMGLY;Z6^IOJ;]FU!\7SY16\B>MDM_6XYS[5Q6U&ZP)\SO> M(+MK:,MT.!.=/-.WLRH'R:![* MV8+7T&O_<&+6GVG'6YG.CFG&8U4;Y<5!@VBX'1=Q02ARL;" 'EOHDZ& MC6:ZI;"E =[ %NW/:9==1MN"EB9J3!.E;+F3FG+CF[M!!>&7%NWJB'8GP+K] MS;^)4$5Z^:[F+=N]LE@.F2Z.YSZL6R.IX6D8YSEGF.=J.<-D;^,D1_3#[LU= M;]+VC:B16[-%ZR,8'WG$Q_R$%NU;M+]0M"_9+&RH783-W1+%E1-%ROK)XSB6 M?G<;[6<]=X^L*XW+'#$84=9/ M-!S0[#NUU^QV@TWPD[;,H64.)V<.R9 5FD]3Q 'TAMO.+>W7BPJND_:KB$$> MC_CY@*4BZA]>082RI;Y+I[X:$E]I37PD-/$V8KN+4T/N0.Y5!VJO-IWA!,^G MH-0'4%A>A/-]2\VS:[?6U*V==F!ML\8;RA'PYC=5S0(*9N4?&6QEH: MJP6-55IG-=S2LJZEP)8"6PH\=M8E;**EP)8"6PH\28';J-<8A;/M/M)V'VE' ME3:$D4T&IS&81S@ KZ_JH^&A_*L8G>M>"=ZB477E;Z,^R,(6C5HT.I)A,ZC, ML&F1[(*0;'_=7>>R;YPOWVH[>A]/A6Q'9Y[*&!Z?2(?$?G,3M=^MR@:N@5NI M1:.#T:C2N,)H2_^V%LGJB62E:A&.@V4;&J*-QD7%1FUOZ]JAT"DP:'_]<2+D MWL%&;SO%L9WB6#=R&FNGT1['V"U,T]21GI\VT)KUUXM'>[D@Q[W".L(6CUH\ MJL0'.=[2TJI%LNM%LKUUR'&?2[]QMRX!N&MP0K9C!4]%3\,3*9$#(*.NKDZZ M_9K88BT>U0&/]E,B]9L[+>\>:O&HQ:-JE,AAZ\MND:Q*)7(DI)_6$$_D^;,U MF_VKJW#TMI/NZG4A95C@B;)7Q^.;N[[>50>]JJSG\]>ZM*AW%M3;SU*8W-R- MJDIY;5&OCJA7*HGAB&FR.=R;= _+86BQKL98=P*DV]O:F/2$T!U7%6BKT>B! M YW9EOW8E.%JM-5VQ-HI$]SURD:L3;3BL2-UJSEM4:O>J+67UCOI%VD>+>JU MJ'FWI-\HTG]^+M=D M='-W>'.KEK1;TKYDTJXB2G2&L5N3 ^M@6[)NR?J2R;J&5%U:/Y\(_7Q259>; M'92VUY5%R M(B#7*)G8XY#21<=\0-M*0>R5F[J%5]\&\ (EB'>L*BX+<9'0^)%%&E5YFMOF M7#%\!O1K.A%B"M"N 1!:+#T7H_SP'/[#9W/F!O 4O1_?B3@#@"1&3.-P@A#^ MQQD /.0MF6_@08*.\CKR??@<7YC&-,N#<[A>2$P%CA-ZL&O'R;"2<&Z$8G]P MY'4X*$LOL$,B!G+!PE(!_,:QO\/I,N]Z J)1I@R.#P+09\G+\$?I%TX9@!!_ M9WH@,58$-^"?OF+$H[I,#_C?U CL0 )P8:QP<=CJ0KC].\JW#$T%@&*80 'L MV.*'PA>#' R"@LL%\*;W!+\NH%]X.; 8!6".:1BP50"1BZ]G'>6+7%"@B"]7 MID?L!0XP\K%7FK4WU^BL>;D!?9&N;#31\&XA>08)"W H-+(,-V&0ZUKM34S?&&OP; MM,7N_^GZ3<'+%H;_8+M,0IB7?.MB_Q$N MP?-7;^S !)*#J_@&/__5\5T[6+V'Q+Q>@KWEJP%^VFGG28 @E)A4>,IUK 0<$V +$%(LBU#)^S:.1K M"P92U(+-/:Q(3BHSVP_"6QL$!O^;%PE63G2%2Y(8LQ3!H1T/."87@D!*P$=1 MEG)V3;HO;2#+[.$*[9#8;T"$2?A SP?P)"4FH/19^IX5F2CB/)0=($=1NZ:7 M@JECNP8]%/D!P]=/HP" $0395RV,[PB(6+;PR\7=RCT@$-8W 0(.GA'OQ]/# MADB$ N]_4#S8@:_,0 OQ?, [!$=$K,MG#YA6@>L82W@:CJ["VES9P??"#PS< M^8,2&#,6@K1GLQF87.:*@,M^H.+!=0(.")(\'NH7LG4GJBYRC!P)8&-J.R!. M\?TEY(W F8'6&>F 5U)+>,G?^LA>/=E6.)?&>.I!87QVDT>,*=Q,%&Y^)#>M M\$RD,5F#3^K/>3Q.>FD\L-LIX._W6V,&>WUI.$_&*D S.,V3@2&O@7#]])M9 MS7,,IZZLA6@#=-68>BU!+H!Z=HKM(/5\^./S/_[]\?U7Y<6CAVP>%##;_07( MT7:=E52E@91M8$5+PP^14MT(:8JK6[0P*,,^[!>>Y42!M :*W -#J@+)8;@F MXWJMX8#\(+Y!YK>+&;G&U//1Z&-(0<@TN.HG]-6T.A(ME[ IP*VB;8*BBG@M#;< MHAG@JQYM8,L!/P-B YHV*4C =YWJE)"ZX5.:3QNH>Z/ZG>=JR44P RP)GR$^ M((Z _61[)"EBRT$A2P;,"P8FY9.+WQ6)([3Q(H<6(=<,^X%WCL++0V8&JZ41 MNJ/LYQ&Z1U2V#3J2C\8"O)7YCXP6F\%7P1SM#\^S@@S]P+(,[MM!M) U8,@N7/BSL R5D MU!0/;/,097."J1R- A!W)N@^U9!P*37[JPDPBASV:19#3O@8OB$9%*C)U.]TN>07J7_BS>+K#GSUU_SG^K@S M'O0*O^IVRG[>'P]*/;%I4[UQIS\HM]2)-C7:NM0SB9?U+, O'J#]@JP<[ML, M? MVSOGO.Y9"\785-U(S-JF)A0??']E/! MD3KJ:CD=5U[7.>BNXB*-4V8P72/!'WL&;FT)_N@M 8Y \!,B^,'!-0"G(+IK MZ)[U+\__KB2.Q'9.PMF%*][(>_ M8IW5Z40H<)K2LG) QU'PWQ-9(.$95N4V41FT19EGE-'V8=9Z)Q9'#[UO%9U ME7'2;B:!O2B)=VN:7R6%"..B0H0S) X6UR(,XZ3(G7*BJ!#XL\^6AFV]_;%D M;L""? )4;YC/\^\-\S4'9SBQ1+1;Y)(OM7%'QS(0<2)%'BF^[,("W5+98V_8 MC/D^;TL4I/)]Q2OO7>L3YL#?!P$+@VV%'+U\5MF&O&<"];:ZEU=G0+_B]#0) M>"8 _VPZVF8"XH>R70N8X.*[NV2>%MTUY:U/>VI2WRTS=:E/>SI#R=OYI M4T>:2=7 N(F4N0:I'&WJ7INZ=R9O5]J8X/JOJ*LH;<6"C34 (S;?OZ1!'J\V M4Z^.S/(*Z/NX7<,JH>_)S=U0'4_RF;@UI+%K"+=)%<)B5+K>9N:=+5+T1MS M0?2E=3&]HBA[J4'RLTW%:XYDJ!9[>YBVW1]4%<)H<^]V%P!Q[X@VW>Y<$D!< MQ7MY$T44HMWTJ=K@X F=;2)=R42ZY5I8 MKDVD.[__\!)S8TXE'$5CZ) M3"O(S-/JG)F7'$ZYS\:K#T_-2QJ[875/R#[8C\Q:A^:&'F_:SMEX'+P%0%_K M35K;'#UL(^_U#B<*:;A^RO\UE@ ZPIYF[GXXGBB05R@ M:20SDV6?>P+8EN9^.\&F$4E[@U%'+YG5=H+\.+TST(J_:C>5W]3VI7;,)'PF M:6SKSWKZ+HF)-;JVCE^-L+,,/ES9X/6VBMS[%30 M>OI=#G?63H;;'2];S#"2&:5],-3!<3S,C^)KD..V%+(T+2FT)?.&D'FI&8T' MT'E*KTFK-*4IGUHY]@LRPG>?"]T27KU0\#H)[T1T1[T#=] ]1%EODNBP^N4)P'0\,VV..)X)#X^L2HT MP%*Y\>@2;*(:^"\N')/+:4+[HW)5FI!.R*WG*^E*>\U:W+H0+KG!,30$G3D_ M_/7Z>."AWI]#>T==>X)\6U5SAJJ:RI6J$7"3"0B>2S"=V@J;EH%<) ,II]$ M=%>TQ24GIC5XXL0*97]C=4E;X5%/?"JE-!V"4%5I M30,J\1BU)1Y-P*Y3(=<><22L'^^%254C B#.NWU0X-0*Y3X=8&=\'XYJZ?+W>H9D0V3#D1>4$ MEO2\75+JW]'[Y5\'*!@X,9VBJM5FFY+8-=-8*74H?TIK")E2,>H[D = M#TNDR[?DUI);;8Y^&FK;PV6D]]!E-!F5S9>H3]9XJ7DOXE(&6F>$6=\TWQ6> M>>DSX%$ TB39^^?L_ MQTF[RB#&%SLNWW=LU&*X??_,C$ QEDO?^P$4&C)G MI?Q4RIK,, M]G5FDM_IIMLXO=F,6PX19P UU._DY]PH V<&=XJG*;?^T^^_C M_O,>%;E_5?%9L&0F<@)GU5G#WAR?*3'7:5#?N4[C#D?-_)_EYA5]%B'QSX[A MAO>N]?;/R%ZB"WS;Q"=]D!\^I _R$Y\^I^/M\ MPTV-JJB)JI?1M68.BG&U(M) M_JXC;W\7^7#)D;]3*Y.K3)FL@JD_,SJL6A5J2#T$>@6-QAO$\]OXME%#*_5?A/(AN>F1Y06HT::C=W6D'=18.8?ZOP MUY+Y/],GHCRF]HLQM9D*?^EA$Q4]OU=?NV8SS9-Z)#'Y25>UX6 C1ZW<9+K$ M6S]Z8G'%MZ[O=.M7HA)^8$&@&$DQ!%S$T@?8[=R\\RIE[O$G/:3J4]ZD;@3^ M[C#\"Y!!.@5U(XF4I@ZJ'^\.\S5D;<>/VO'8*FNESH9P.,1(G?3R3<5.CG!7 MXAC>DDQ[IBRCBRHQJS8!Z3)JS\YG&.Q1>3;$K@5J;W()+2\KJOGB*Q>\;WN)ZYG*OK[-F8(Q M*\-=*7,CH#)67N<% %4<@HB70.3EKJ5?)RULHQ5?VB&\SMSAS/^TS=#S;4-5 M?O7MT [F $G6DQMH[K3;;2@3G6Q[UTE+EG1NEI75>XCWW9M0Z':&M[4V%,, M<<=8PNSQ5$4X!OQIN\IF.'64-[C8@_*5+%-"U$)[;GT MK5Q4_ -I#"%@^P'\TT[P.V% 6^IK, V:<]RQ\$DSDN8(3YTHK\)]#) N8F9P3) M&K!'YBHK9O@YJ4T\A@[A*MZ2K@8YRH^0B3O<>''TFP ^^C_^W#.7^/[C.WE* M(UK."X\(FP)N^6GV5B[]B58.\@>%NXT/FK_6_LU=^.3E[[2::W#9D^'L#O_! MS=W,?F2W"/X<]&%IV[, ^MA9A$@1F]@@=4E$JF+/N-E/L]?P*(*B<-NXNV3/ M^LU=KY?;+"$0(0NCRG2K&'EB@2!.]L^B17P&7!5>LCOLAUMQOZ/WMHVYM[K&$\YF)W@T!E/5Z:'P#_ _X>B#? M8="PQ#U@-EB'60!Z(OPMYR$Q&;."=[ZW^,9<]!NA58J'*0U+ MT(&TSJ:BN!@[@,=;%O7W"HC'QPI0C"V=YFG#B1I'TI9T6P AF6-<1>YIQ .Z M'>5?KY/O_"-;, MNG^$3Q_8&P&1+ZBQ@PU!P5J!C[=:@I XXZF Q?\,Y!HDIO(,E &7[!#9> Y) M+W4#JO+ O ??6,[1PPCT_"#9G%2MN(5:2[0M:9N^M=#$QSY=]PY<6UBAK^;$ MENDG,_2R'I--MJDGK2V.Z<"%)10.M#V')[$]QWT:23(J$,D[FIXV6I[/*-?# M(UJ68[!L ON'4FC8) ZLG'W@HP6UFVVPX_;+661CG5MDFPSB4%GZ[-$ M@D8 M!O3R':X!.6R0!GY&5GQ$K0"QEFN,6LYQ%RL3"6>64!$G$[VN%RKH0?#) M(/322_XE*." ]>1E6\G^'9*JX_ S!UF*)Y]DH#P:<'Z,.4G(!T)7D_^0ZIZ$ MIF#SB-0A*D?FVN\R3D[Z*9*;<(=:>#/2&\KOHV@#],@5W ^>?PU)!0!FF9O; MI\UG@6M9>0(>7VFCSRRO> U;+ZTA#TN6,QQ_1Z/B=J.;#2*\G:D7SJ7#::<6 MG@+5KK(U<*\)K8$I;EH43>W7IZ]F24WV=\_UEI@(T4Q6&=L>H$5(O=1DI/JH MB18 >_ORZ8_$;W1(F^/>:#NW>4=2B%7A0QJ/D3!&G4WS/=*N) /VZ6/38,^U M$LEQB&NIQ#GW=RQ-;NXF@\ZF3A%Q-V0>0+5Y1@!HBP&ZA!X-)V+2" 6BMQ?1 M8MWVGX(5ZE*@Z.\17#6)/$J#_;&TR?X!S43K]DM9^_R]13:_$2;HA[LM;>UG M8#[8!O+];/U)]^9NV.GEAU?\+&&,3HH3V_T;&4H1?][EN5,SHF>B&C'K$?V+ M7>L96I5NTCUTL][X9-QI@C7]W6>'L" K+,< M(+3NWA=9?HA1"C3Z#A%*F]Q_01C/E3CN\=Z+U[WE;RM])+ 9>P51%7FD3BY; MLDQBIS ;OZ%3(I_1.1GE.O W17U.DBMY:WR?">6*:UI/0LFX-;B6DN+)V_?O5@A[Z_.2@(O :=H]/Z:O%G?1K M>0T[/%^F16S-[TC:=XHP\)0X:*3PR@ ,OR@O**2RRS"(PV#67DC^0J3)K:#- M?1CY/%]77+L:M4_9&$7E\PHJZ:!29RS;6N96K)F62__(1YE[SV>B3L:93*]< MK5%[NT@.KR/V93"CW)U_Y_/.Q>^-L96AQA.;D/72Y1.(?!K[[8O2/OVN+,WH=SZ5UR;7#0Q5ZM[82835>(8O7U> MKU;MGK\R+P#Z-F-E'11QWUN(9*BC^@?*0+-N[N;6DCM/*U5VI8[N U2L3 ML/4=\MMMRM)I3=;69*U QF9S4!*U/,\=<,S,Z#*&S#09W:_/&"V'[I7A M^PCP?9BO1SG7C!OY'@F: <\4:+A'^MS/7Z"&42PS,ADL6.KC>!@WP9@)8#=I M':$/ZW,L/Y*:T>CG+ROFMCU[,M.X531=F(8&_)X";^R'.3?3Z)]=3,C=+>H3'5 MQ*M]/9^WV+QA4JV#JG50G=Q!52W);G=93:[=977V&HMT\QS?ID:]W'%%5TW= M=W+*Q.$JPH4:]]?GRZK0E;4+KSF@,4G"=7I=[#ZC]B:-5A%:=UP=5(0Z4^SQ M8U@5D>Q6'0'V4,>\D?RHQDS-6]M>=*V]J-:0]J+]PO:B@V>**W>:11EC_^]& M&/GP_^)V1CI.EMFIG='H; 5U[Z(0O8\+?A";!87)VYN;$.U;7%?9<>&2)LX;=8X' M^%9WG!M?,Y.JHCC)CH>OB[%UN'NDOWN^8*Q)2MJ,4?73[)V-)M2_J3-'2;\( MMIK5U*Y>-&>A,7Z14NA3TZ#*SAV7KHWVKY?\MQJ4S["!/*6#/3ONYRO3+HC, MJZ#TR[(RBL$.>HU^--U8*P>K0FYVT52]5:B_B=A'6.G;$W,>V>\>=CTI+=)Q MKO50[194RS2(UNL3ZF@QNU)Y506&8]]YM3?(CQFX/@2_!J,_/7FEB7AT"6*J/DE[+4)7+:;V1>PQ2:=AHS--VM2Z,M)I MU%I3M99.V$.R-!E/+D$^M694\U"ZE'S:![6U+DFH2:.=@:W]5$9"C5O[J'V)?@P7U;U-Q'#43MCAM-SJTAU3"N3?996K"I9HH[B,$_W M,1:266]_F'!S]S2RIS07P%0.7=6T M0_ISMP96 ]%JJURI#+THH4(OR%T_5V//*S%SSC,<(CO5 M,I4!J-Z!74M'VGY2'5\9(.J4Y:3]+LW=R.U?TGE M>&=B)#LT9BINC92TDN''S;<-VN6Y(UP1K?C2!OW+-K=?&K7E^979+GRP6%/6 MMC6CVJG!SHD14).$NJ%'TX#"Q,IK;P'[6BES Z>!HW.!G R> IME?T;VDJ;* M&JZES R3M[C,S#OC@VD51.9HJ<"&(_@=-C1R'V ]TU@&D<-?'=@AP\;9$KZJ M C2*ZX1S(Z3WNUZHK%@(#&0!;S5A)V+R"S;4QBW8 X05$7L[RGV@+ V?9N+2=P\^H^[O*OU3GIS]6#(SA)4]V/[W5! "'C.62]_[ M 3PG9,Y*^:E4VS8(U82D,\YP=GKF 96GP:3=WW4Z^4"X#ODZ>72AY5H@KVKH!'$"S M>@/+8 ,VF8[U[M34C;$&_^Y/)MW_&X%D>[:EU^GU -Z0KMN1QRK5V.W>)"]& M -B-E'KO6O")'R778[/@33R?(=_?X7O66KZ='BA2_MZB.OM2ZW=T MO!UY8$6[T5XI:&>_SD)6_@JSEG5N2P3[,\Y#=TU.L/=NRH M5R\1&(-^F0*](4"?Z;-W==WTAEIG.-#JUKANV!D,^G7[LUJX4;==Q49+/-:X7"&P9:WY3Y$A#]J^M@]W:Q=+P58UQH@/+9=K"K0Q>K M*_6726S\@GVN,VK;Z\CW6?E@8!^[V_340:]M6%-#15[!S((%W"7_['6"Q?O5&6OOI/E0=M6H&'RH!K<'71O[G15+RC) M;*OWCY8J[!L6D^&JUBHXFZMM+4I-U[(O&?60C(:C1OO86I.@.2+@&#BLW=P- MU'Y!$YGKL ?.5CH"(CST(YE4E_,6G:U$OM:4=5S#(',E!QK: VSGTG8=:\V# MDYH'NV/PUL'"@T%E@X5;"V%G)/B$6=!%26RML7"V.A:\DGPNY;XR0;^Y&ZJ3 M9KN,6GNA.3+A2&@\1+.W-]E4;7#I)L,YD.&]:WH++('YP>*Y2M#4A?V<.OQ26"2XKTB=@%[:5;5F^]PJQ*HSV677R$L. MS9>^1%YRZC!8E;Q$QPR)@=H?YWL8-8N>RS7^J&^]+S5NH.(]#G]9P:=FJGU] MGB2)+0[\3'S-] +>^Z%4=X)^<6\"B7\9;SNFY/B/I1LWZ+V;.ZV@\X B>S9@ M 7/<#^/)#N>VN[.6J'B\?P:S8B ->'7360IO;.J]DJNU[ MXVV(N*$CS?9V-3OV:.C?Y%8\>2^&7C6]&')\$9@E>04+>S-\]%R3\\U\PP!= MRW=IT+4:=VEXPV;,QP8XV!H&4)&C)>(K#[C 86_%:7=OVK#>],A& N.XN@4Q M-[1Z(/"=K9'25KZ;;B;D,Q/%E*5X!#"TA1:N^#D^U]0'U9\MI(LO=-$I).)0N^,U_U5922V"?)?F3.JJ/@;4NA ML,]Z>5%A 7P$^9D9\O-!;#PPT4H(NS]-5XH)2HP!X@U! PC&?C SPJW!1F8V M?!FD-Z6,\9T]37F"AS&E_M&6$E*912##X$,OA/6Q&"L66%/FLID=*MX4B$OT MH,)>5SY;P)M1[-$"Z4Y2O!66W-L2Z,BSJ/D4T!F!+&"9Y6@_@!">8),/2"!" M$'LFOW^3.BM%;GQBOF&0IBX*XD\ND^VM!"PD!%3EC0^"V@/0A\JWCO(.]!KF MJ]A#"T4[@ !!;<2*$';*6HGN)WBZ.?S06"X]VPVIZQ,H2OB67SW#IT.]L8'* M0\\GU>$K6X:\38 F+KBCP!M]V*Y/+ ;%T=! ,=&3()[QO4^ M25WDA51,6* M\IGV\ TN/.!(6TH7$.QHH'5&V#5EZ04V_N8EG1"0(VF6\G.6API5NYL\8DQ! M]XG"S8_DFC:OV^FL 2OU90G\9QOK+W$]4JP=V._69\?V61HF]-)PG8Q6@ MJ9"V \ (6 /\.LPV2[FZMK72]E.EOB!51NR=[RU>"P7W7\ C7H-<]F"! @U) M+]"0]!IK2!^ M8"*3HS]-78Q G.4L^E[V5QOOQY6=.K:&)BTXNX=(S^%0?3= M4.2=ES0QZJ;(?7)CF4W,&;AY=ZUC8J9/)'H!4XB J.%(-)%(P66E@!.*25S. M G)QO*3!I!E7,-K_Y6N!F(%E'>7#'Y__\>^/[[_*+H]BH6^@+M@@@D!?Z@AI MXSBP;&#Z]E(ND.G\&&3.D>MYF=JEJBQY&\-86N&3]R[@K0/R:NGY)*KAK0NE MU[W]1WRJ%3- (7%1PRA6?3KE4: IJ+-;PTW0&QB(8PM;C$;+F0_+*J81S&7' MR-)V04_3GG6_4!$4F+)O$J2[3S1+2;K?O,_,1T4*[I54\B!M"KXU?)>5[ABI M8Q),]]F.FX#:2&DQ'N5I"&D$43:&7TD@;3"?9#IH%1#Z(K96&D:CF[O!3C#R MV0,VE/7\%<$#S B37%#86/012%.JL_ ( ['K(FM(FZ9"_0^4@"WLVQEH\L$< MM5_?LR*34"]F-D#S@M$@6R/'X.W2B0(P? (;].M@;G"/H;$T3&R,*]!^X;G> M$DPC?F/BMH#SV,1H?&]E.-P%";#%YX$"%LK&JP3@ 0O)WV;&H'S_\5U5U_F- MMOF%=KF"+\UTV/]62ZX,Z\/S%X90*WT6_:1GV04UTP?%\MV"@R[Y>LH+BRT9 M.77(=A,R:24\K7,;]BRY6@!K XJ *3WW'"OX!1]P61AC'WX/Z+6*99#A>-+0 M1'4,7PPX'N-VTF,74!+=+:()%:IRGC.4L;R*(LX.7P=W@VY\&MB5;WG-;ST7L46D]?.CVDQ@( 1UO9 MA7=9?D3L!O@S!].+CV_N?R&V_>BA5Q14 ^Z9H+L(P8 *Y54XT1+8A\N6<\ 1 ML*]??/CX2^)&^#OP$1=]!+\C5PI]8BC_RP!WYZKR >XE O,=L>I?S)GAG(F7@,M\ ?.\3 M\+ZE[:7'ZG$9@[[J/P#A[@7C+RMQAMU"]I65-X31L6B1$%65I[EMSA%XP.1! M_BR-,.E 'C",H8"@=F8(/1YY2M&QXSV)@-ZM!4<+4P)!< /.!3QJL6Y$+G;J M;2!!O9,$ .R.9&(X#X1>O,E5F/^\G],^&3]*(QR%[_(%P/N[E'O:^/RGVM .79XJZS4=F_J1 3*[-Q <+\] M^,:"0G)+,G7/DRY*1RNK+4PRVL*PD)2^Q&?]S(]Z'X5SL!M Y>*S1GNE-02, M1^O/:=IHIWJ+!5J="/- ^E($ P7F.YO9F"KT0%<'1YL!4T856:C=XH= JH!N M3\#1X:I(\=ABC#9!)]B9#K6)I,/7AFM8-NX&9:),=Q-N,X2/@0-D,6B^6)+L M\L$&9+/8G!2@I++NT:M@(Q7 I0CDP&M)BSL@C/C'@DY*NH3ZW32R:ADKLAA1 MA7L'M(72'IXAML#.E]K&'A[ 140Z.P@B\EH#TXC"(#1(_9 (2QZ6E;)=?/6+ M!5C186S/>N^"$66R+,D!KI@OK DE?07<\?_A(Y3.EUI_HMJ+3R'[>],6X$%@6Z\? Y,TVB"7DY MZ&,P*'F3.3C1"EZ_F0AA29YFM6#PC6L'"^'R#NV%5'L-XMV(R*D5PE2>!1_2 M-<5S\)1,3/I M="B?A^'2X!:^-'1!31U0%X"V)+Y29JYMBC6)\.BDZ.P"5L:/F8*(S;-ED Y? ME$.(CZ()HBATY$V^9Y'UO8W;Z MA=@I]US$L]%$1P7-V4F?:(A?XS+(&V8\];7NJ=S;,:Z70WEH;0K=1,G&^GI-,&T(5 M&QBE]892I#FC_"I6+*E C=%Q--CL.$+SD6NY?PG6M"AD^.6TQ.T>I6VG^R>B M>NG#3<@8W'*Z%PFG2#$LD:;/';%$5T$HE4B;\LPXN0()V0%5P__"N04^E^6# ME@268+">CS1D!)0;AV$9$7F4D$40T-J M$.08_EX)4_RH!0#0ZI-&M7W,KA$ &B!96#:F6EH4^W D@-)\C.>L+I;T*]!* MX'@V,83X"?@028^_$*D-BTT>F,*MBP+K,M'?.\I7FT^A320&.A11/Q#;$5FA M/+\79#/73@(Y )59:O$9XLT36P#\1JXRI7/G?]=Y1B??/,%QG58(LAABXWO: M,,YQ5(0^O3S](--T<4MH/?+[8JY'13MH301)Y$MJ($(F34M<<&[VXC8_6YL$ MG&.RFY. SY#/NYEC:1LG4G/4N] YFZ->9]3=/CWR#",M>YUA;W+9FWH6Y@4% M[!)7@/VPJG]U:'>29R9+[O?\Y'C=4<[**XL;5'S+I2/LXN8]ZY:Y;1N/(SV@ M\6\Y=*H:>^O5AV&'T;6"684J9LXS0V&4B[L&DO&N9?\W'Q^XX.O>Y9@A; MX' ]@.R? .]J)?V>[[XH%,%:M2WY**R<=DQP.R:XI/#9WU.+. 7[A[^M^PD M'7E+4/0]E6UN,](P2U8=#?+EY#DI6,T5M;-YC\Z@+IVXBD]=CKA.0UTX^6&H M:MW\B,7+HJZZ*QK/&RIU5#3^M>[MWNCC;L<"5-/$0<+[WG+RF>WY+'RDD M\6DFO/,\)OPIN:O23&1PH@WG=DIQAM+;Q5RKP4#M]O+==2Z@&6<-FFI>#'&6 M[ JY =?/3)W#4^VX(O+$9O,#31T.\C4]-1GBT#H^:JJ/?-P8WGW!?F"L7,2* M?TK\J?NY4@^WXRZJHW"U+I3+Z"B\AX-%ID]LU9:TC9;@>A:&D" QC^TF/':\ MO;=QQ1L1PQJ4O6<_LJ]QU0!O', LWE@ M\S+I+?E,Q'S6X5C+Y>=Z1L(&.,(SQZ M:G=<%,=H3%2Q4?#J&@RE6*S(CDK8]82,)\21LYI.M::SBD3+J(ZB M971S-U+[6C[WO$&BI9@4ZVX%U1KE*Q(MXSJB_/CF;JA.QGEMZCQH5\M8RPZJ MT=;8_(%I,,WG]G5$?.RR-E$G!0,O&L3LJ\6^!I@@ETIG)TGL/PNA3;H8B5'U M<7[.1^.0?4->4:8M5U$GKNTMM'=K:3C6=FAI>([TH U=#O7]NAPF\+V"N4TM?/G\"1Y+@G/)'IGS&YM0O,#,,__:+G$F% MG0L-RUN&8H%XF('HD)B\)DCF6U#2VM\CEXD9+ 9UX>/M#EUJ>V[(.>34/!Q; M4S\\^.P!9Z' IZ6-@\ES371CG$\C1VI.V*^K'%G%E4,L6@ M;(/:"2 18&T^.A(WJ!7EMKQ/;<"'T".LW4R7>.[#_T4,K10S*!'"U(Z?&AD' MZ6BV6A !4%Y\O@]^4>4@FP)'CO+BR]<_X"TTXT+T1@]8&#J\\H:FK,I1N_'6 M.\H]SJ#/XL 69"G$K^SOWRZ6CK=B3.$1^L^R13?'6GR#\O;KY\\QVJ8P#A?* MHUQ9%!MTCXUB!R,6%O]W"J8.9/&*=RV.(8;=1-,MZ?^,@('-5M2NV%5P9(/6 M?<4D]#EF9!K+TT]ZKT3SXJ^,@W.@]64ZZGM,;7%IR#&?PO7:LY@RC4*X),"2 M)?9/7YNC''J99%CY^DR7=SCB[1]P:;#MK\C2@NS/>#=T5,!$;FW^B+D=Q^W? MEUX0-T7/0 KG4'!:2\8^6,RQ5]*E]<[SZ>/22#S H!\"=$Z"F0B9GGXAW:3<*PHX)"Y!>WBPG2_S#&/TBI5W+J(^K261 M7=RLH&_B@N0<#L["V0_F4X?\>+($%0]PM"-6S ?_.BS !PQ1Q0!&"V++AJD4 M6UBFF% \!47)Q24MT%'LQ8)9-I_& $NA#N#1KRRA7Q*Z<50LF-DE5!!^'@QS MT4QN,/>1,+B^)?IUB[E?R+%]1C,O:$U)8V*^3Y90>6MJ4[)XTHF!N$@=OY6J M59 R9^1(YBVS*.O(UG)E+M39&Z'P*PYEN?UJ@OJ'%\@Q0\Y=7X!R0,P'X8[, MB!>_&+:?'7TB82PX!P>\ 0!?B"_H=5+_$Z.J'SWLV8VC?\4L!YSG!3\#=2"W M,!_>\&BS)Z&91DO+X%HJKN6LLH./Y2B60)D#YP,-SLR^3XQ\RB(OL$]Q3#F' M3 QS%'H6D4&R"'^C;P??;V>8T8]*#:KM-",[/NO64ST9:Z.]5S9SL.&/83M4 MF@,?/P#R^WS:]Y2YYAR)4IEZKB4T',--3SPAU(6KP9^W;=6WMU77F]!6G?P< M1=Z/?D.\'SY;@+Y#E7)@6R"3#OGPJI@:4OP_2RVVI X:U"U&+-&<8V0?N!SH M6<9WHE87'1>KQ)92+ U9< M;E#7D<$(%>6?O'ZMCTZI[,@_0@9O2W-M2LF/GSFP8^ULX]/=@9^<[4 5H.F%*8UKKHO?/ M^.Z_@ )1-"1X,KRY&Q4U2VI,_LQQ"W3.@V _MZ1Z[/2;#:1::UK%W.:#ZPN: M32_%M_SS83+^>=6FCC+^2[$+KBVH.YDL'QR5/^#]OH/K?2]N=R-;&-_<#3K= M_+#A!@GQ*HJ>FB2JKX'>CB"0:T)P$R*X@TO+FX#T1Y&WS;2IWZZ'M.((JZNL MF.$?K][P,%C6CV>6C"(@ 4^?I_'I+C0N+_$;\Q>]3%X0',9\:44^7J4D]6&W M>W.G=[KKF;OM?>_#\S?<=[TNO+?KA5^)E?%61)\HC6'&;,H,:.V,D]H9<160 M$2WGU>H\[^)+W:#M#+LX+*_?:73#J29H6JUY<7;SXKQTAJW=M(*LXPO$]=:J MB _]QL9$?BQ]V5>F7D/[AI(R];G!LE56SNS@VI_4R%,&OT3U^^ 9TJYA7Y23_#[A ]^<-\6XL& M2=V*^@5>.3T?.BRLSO1<7I+O/&FK=@0]0O?M(!\+/V,3SNW-9@XNJ$B#.EU0 M<0\'?[3#57$1Q; [OH B"E%D$"U@O[!(D"J(X,TE%$- (2Y,VZTF(E_[L+4L MMBUW:,L=:E'N<-A(J1HF\,,H9:_,2]@BH:%W7X M_*-+![Y4CN+RP;66!S\=VY>^Q_BYLVD.!+%/J;95M\H;9C)"7UGM6##BK2/7Q2><-FD1_J+BQW M^(:RABV.A\%1_0XI]I"+(G"I^AF%:H&_H=<%OM#M#!L]R::)(Z[J&$'YC7=@ M:#-VSMB(OEH7Y&^^%P0%ZD"O=W/7;)JO3]3@6M'[>&&SX! W^[,23[NY&W5Z M;\30=^XOLJ$EQ]$%PY MTLWYZHZ:XM5.IFJFV)!XM;?D&&"RQ3C?&[Q!DJ,F([(NP1\K,N*Q":BOF-BZ MV7%2,J:\&_9Z=/^S7-7XXIOBA?@D=.(^L:Y<5<&]NIWG/7Y59AL+B=>X?RJ.4TF,OB0GBC QO[&U'MD?/I#Y@U8;IR3T5";W*I%0EPP>)^JZM'* 67MCJAK4ZH07)\6YW05B>TU0E7 /Q<=4)J M;%%;GU!L=$DM"30^!Q4HM:U1J)6&,0HYEQW)E<_G^=Z*B;^23I76RYQW"36\TE+?K][2\O!S9VF:EH^ M$;ZMPZ@=5C9+6&41N^U&!H=22NL01QAHG1'F)2^]P,;?O/29 S]^9$DZ\L]9=46PM6[RB#$% M#A:%FQ_)Y=N=*=N\-UQ385)_SGVYFR5@X^W49\;W6V,&FWUI.$_&*D"@IU/' M;?=V#8;KQ]_<]3ZN&4A?3SPAO0=R>U.:^JC>92[$%&YYV46:;1C_@*L&O*RQ+V5!?T>\VMKY"UN7X MS/0>7'C8XEF]XIK,]#4Q?DTE"RRH/B/_>1^+=GAU1[!S#493"BY&6D>;E*UA M.'IM0Z\S[$UJN"GMV=*4^I8C;O8*[)BQ?EUE'=]R+(,$8.)+V,%5?M3;:H*] M4KK>8M?BB0NIDZ.O.X0!. '];-[6$P<2L8FM)V')E7;S]'J;N M](85M%!MZUAJPLHNG>PJF.,]&&X/R1R)V#1,.M G^?G<=2L"N1A-Y, VL^= MY*_,@0\?5.6!N743'O=TP./[ /N;%F0S MJICYZ#/ER0B4G\I@>[9$55]']K>+I>.M&/O*_$=;]/C.H7R<'L\[P7_S0L-9 MSU3]Z(7_9O!2F&?YK;YERQ WK&%#^>LG2>J@>TH1C*DR@5N)4=49=4B(N[ M,I9+W_L!APN9LU+*910?[4)XG? [SQ]ZF9L!I#5?6I&_8H8?W\6@>W/7 MZPS7B4G!'P5K_>:WYO;O2G)%J>FX#.['U@V@/\WJ#2R##=AD.M:[4U,WQAK\ MNS^9=/]OK-^D'CJY2BLR^F.XE+KZ]RY@+?MF_'AC!Z;C!9%?D/,]Z'$*!QC# M]8?B,UQL+1/\]">7LN465::76K^C8^8T/Y4"QTKY.M>+0K(75H0"Q74)_.BU MJUR-T]S9;,9P/@!30N.'X@-#"*I*8[=L6-N'AV:^MZ %9\RB>&D0&F$4>OZ* M7HC860B']E;EL9H=E]=(!3G_OYZ-4<:8O77.YC9]HYWW0$OIY'WRR\VHH345B M6'(R=E9\P$NB4<0H(%X62$4@0"TB34@"06PW'B3SG\BW \NF;0>X,#R1QA]4 M]EP/'YX%+%2F0)OT_90##"DUS,RXL21IAG,CY(-G(@?P+KU <7BGG#P#V;> MV3-0^]UP;6^[R/D=!?3XIH"^:U"KM$&6C_:3Y5^XJOG9\,/5-] M XZ^!UX)_PR5+YUE'>@F^/$*8]^_:L'"CQRAS%.Z% M#^DE7NBS!? XG*!$"Z3?BU\;,1=,[*80KHCX*\K.U'+(R#C"/,#;Y?0KSS0C MWV> W]S* M?SO)!M(NA@3QUC4(?M-R&,BZMG'@96NGN>Q1]9==9XO,O> MI&\6(T$.!Q:&!B5!^XP7\ T#4]+?V%?C7\# W[L@EVTKRCJ:2CG# M4QED;1:+'&FC"^S M0DU\TMM!$S^7VCW>3^V&JUW8(6^PX (V")W!!&K=IGGK!4XUO-GIF/8"PXIASV M]@K*K**\0#:8Q""):S87,-TD2;L!CX=Z1UHXA!DHRGCPF1C$3,8D8B%*6*0: M7K7L^0^&:_^7&XQJ\@/8=#2#OT0^@B_S*\)GC\ ;SFV?BU];..@#'GX+1/@O M-H:%51>3S6^\1LE9J<+YE]JJ>(AC+/,7MK CHR7\ 51C8S=+.@_JB_8,G?3& MPHOP62MB_'?I!S.3HX%OT)%FF9_@F>A;^"RV]^,]<3)'<"#?$*^B1^+%8B4S M'HR=/13RNL36SK"$4.P8'1(87TQVA!J,PV+FMAML2\06K[)OV&ASW[#=E< > MUGN=L=U8_33/R;X.7^PN*!@-Z)["-RHFI#^G?VH%^J=68_TS<]K]]$VM,?KF M)U _V-2/#'^E]/0BGQQH.1XR14NJ7J8#,HUS.PJL8-TJ>P L0NT'=D7Z9\!Y MKW"9HSH$9^5\D+ES"LQ02LO<@A8H*F9;N_I%1"0/N__C2[W83?66MRPHBQ(-O+.ASGGWD> 19PP%0 MNB3%.+0, 7"M1"U!L6HA=O'ZV.N M%8=X,H0&'R)/6C=X]NQDN>5808'HTAO9@_*98$N6B$0\/J!POX^JJKB1.)"& MJ9E[])4LADLJV._U]&[SW9UW'E3PPKZ0QZI_]\YDANW-0%\ M;OI"%5TI2__L#)TS=[K9^E5AY?MC;AJS_) N8S[KD4B1; S3;7C$_8O6JY-/5,%59%ZKH7>%DN(U#C0ZNZ#@(7O07T! M.P!4TM>@HS^P'2LUDAQ,?8C%D5H[_*#B3@CUJ5 _&[M\+5WX*??V(;SQ&KHE M5<%,GND,6(J9Y/D%#G?K-7J>4@V;?+7*E0B3FHB/YY\(=_$\XID6@0?RB#'H M%'JK4;0:1<672&6RQ]$@KK$[1=OCY@P];HYIRTUN[H;J<-QO,N>M97>,HVAU M^_2ZJ%<,Y@V/KFR,9ZF;PC 'UM6N^4MRR>1; F#O>Y@I=K)] M]@Y3!T^V3PWX5:=(3]PY*9_B=G%0#RMS/==E_,BB:LT.,K%Y@]?-.Y&LC+,S M >T80^,D7 L_L++IN%B@S^)2#O&XS$C$7#F?S>$Q#/EC/6^%.?\]+ 6I;>Z5 MUMTO]^IK- W8GQ$ ]"T5_>6CU,-^/L%JV*]Q@E5R)(6?::\D*SIB,X3!.TP1 MOU_ZMJ/(^JAP3IGYXM-^-_XX71N%0?EEY)MSRHW=,9]HPZ!R/=,I_/W'=SE$ MPZ9&7Y+W<0G&&&QR.6&\3$!DAC8F3.85:;?_Q,_O&XBOSCR>"8V<=% M7*\;B[<&926_!WU!T=)E1/_S_XVUWNA5H&!><10$,M7^'CC$*K!)LW@7E_V\ M!D7$CM/QOU!/$OK)IUCYZ-2RH&1CMA(7LP\J"QDB!QHO\5%64F0&/ MGX GI9L%.@$/EJZ+^'V>+MLOYL>!S]%@*!LB^L,1-0=S1\&)\;!]W MZWC>=P17LA_Z0>^55'"I!10S7%$B\E5HR-KH7N8CPD<@'*AZYMXDUMR;]/O4 M7 )$"N:3J,J+_ ]_X:T3X@5[;PL6?/N#5Y>E5AX4K)S^V2^J:.2W5IF'OQ.' MQX154!_\J>?+TYIPL:%,[L-:M8#O*Z"W/3$0+,9&X*5@+]1F M\$/4LV._KT?#=FA? *'LPK(9QV9,D7BJ*M.(=QS"'8%#O1J52V MZ3*'IZMC,9A8"I8Q[:6H2><)WH:%_4==+%FCO/XG)EIDTH[D9@VJVZ1^6"[# MY'_\!^&6N"VL>X_7Y/5?:ZZ<45<%J8'?_332\:\<[ARUXW=3Y6D0B03R,(4G M6$@+2B$O+YM%B/D(,M&^@2>+4P,:F1!.-8D@TI092"5J:_E*X7<:HP,EEYL, M#?*X:XVLDR/6[:T,A\B85\T12&3-')<-G\(@^FXHGX'E+ R31>0_#$ P=Y0/ MH=51%=@2_TU'>0^< 5N%F8!A<"4K+T*M%#0JW,YLM8T"01)FBG %M%-@)0AB\#8NU\Y[QJ: <$D1P]P\&I1$3Y[GI/7 &*7/YW MWPZ^ _YE2ME35;.2Q7!1"Q@&6!IA22]B/Z\Q%:J4BF1/LH8<+YSOAO,$64".5>*\SR72.+H(J'^4% !E%Q> 0[;M*_:"]\44N?S;8/8O MP7"H#8N+KAM SF"AGL 7FK[6:*N\!$?4C*D]T'TD+6 M7OB22PILA&68*V$1<[,76+TAZ^YMV([H&!;"ZDSJF_C3X!7GJ7AI[S\K%-_@ MRL:C@6$1*E3R2*K#UM$!P.BER6])8TO53W-^G=XK-X/1GN70:*;!Q&U0O4!E*(&618? M^YNKP:5#0=8T,>O5UL--(U](=V%F\$HF.$YRNNTK' *>;>N2'QNK#L7&@!9N M8U7"B M5$Y@F@%@5 (P 0Y7=J[C%F^W'I?=(_JDF;AWR8U+IP,,\I7VEVV$8 MX=KU!D1Q:ES5SL6+(8^'Q,Q[&3D&Y>"!+Q ?S 7[G M)*7X5-*&6Q%BX@NLJ+SCSTE! 8]C/T;EO:J0UZ!W+^^;.DMM[JQ!5@YHJ++E M'[[OC\[73MH6P]W&AA8UH^"FI5=0(DL_II6>,7U [P7MF#13(P($X1]WE-]L MCC&[PX[K2L)21Y8%FH>)_0JPG0*0@TT7[,E%M['\>R?PU&=_ER!AQCC(6V"> MRSLK"_/6$OR!3'2 .:S:4?Z=[)U<#'G[G;HHH)8<@Y9ZR"!ZP)YXBY"8>@4- M9H4EB>FM O8IH]USV0=? X51W2=H%^0[V:J"I\>47:PIUHZ&+=7B8I("W5RYJV44=]^\+F?R/:6&7..*)0W. 6:Y$+/B\&)]SB:CT+,7B\@E <+0^.-?S&%+0.4+L*@7:-7 MFUS&K( LQ;\;+K%=8+D]HB'8(15JP_N+:_S55,K%NS?WMV2 /Y)2C+8N[3)I M0Q>B+"))35$H;&8M['>Q.X,WN/_PD7B%M)FH[9;G4L%XHF20VIEP^Y3.X9%V MAC(ITYR@H$8^?@UJ&5)8"?.:@CU4(COUA*,%U1?J016WU4M6%/%VT2-!>EE2 M/A])G6+Y;\P'X41C6VO:7>J:&UDDK2M.WKE"TR^W <21FCJ\0R=EY)/ZEB@Y MF/,UX^VQ/WIPF-Y$53+Y0_4,4VTENX29($"(RZ(*9P'X;>P8"Y?S^N-[A5B_ MAUP0C33LP4]HB"D.4VQ';;$%4%?HRY:S]H+;'RXVPJ/6AI[[<(O>/]"30JYF M '9_^ CW!X^30.+1[ZGL%D:L\_??WRDO ,NX98;_LGF;[%2(0$H(@SL6?^'N M*'B79Z,8^A7EXMR>VB&_9<<$(.!UJ0DR<7("7%N%J"XQSOV3'F%33-CA_BS? M81'\1'G_X59+.;OH9]]N30S$H!SDVA@7F-ASU\/4JT[R1FH5$OOJ'-)#L7?O M?W'5L?_)YMA_(\+X]6$. M_TP4,Q'WX>H4$!)ZL)$E(Q$+G%:1-LD+2;,\%IY%\SJD.#1P), #\&K8*?HT M3#ON&&.NXO=@H;\#@M'AS?:!EM"@MX,%+6'F=*"8 Y%'T(AU+AD* ?Z#7C7E M@7HATN/ SQ(?U9)B/W)9G_V'Q:DXL29)-NR#1V84I6-3JT:> (3A@]A[*JKG MG;2V;+N6 $*05BNB1P9T!1]]QVUY<;@>54X<=F*:AJHL P")$>#/_#F+0)Y[ MZ/4$N>3SA^4@&>"C-FK;@".D@0J_%6?2,:R6-'\%-7=A&@ :H;J$<0SBQSWE#Q7TM1""G^IJ(7QCR,^5-HA#5NK]I\2%> M9]3EK[&J_(6KRI^YJESGABDK8>"&1?,B:OQ/ZB!+_FC*Z R, M1Q[H(A8YTG_FPHM256XH 9B_ I)*H@L*146HO MO!2A\+(XW OPG+>CB]5C;N>F\E)CD..(FB6=OY>"QQ, <1X'BM+YO"!XUDPT M=X;Q73/V&";=LD6COCCK96?CJJ\J7Q/#'%9Z^VM?N-(6;XHOC'O[::".)V.PK+8G&?WV[DO3LH>LR#=2 M[AOR-<8]HFT>P\=( ';4LPAS1+I8/)%WOV0C/%84;,TYNI4I1Z#@S]PU(OEI%/"L2! M; SW:2DQA58WXN]PP6];HW+@#Z# 1![C[ZF9A+^/;(>DDR*MS+8MBM+.A__ M\47^"%E1KI<:KT"1U$!F7IIH<_!H?$R.RS0TLA,:T]!(A1Z#[&0%7+B2>0JU M9/T;$\0WX);H8?M%)(_6\DQ;T>E?F)?L.)OZ-R=S?#&D@H(">,9*6J,Q'L5? M (<".3"-N#:#^B+I-OQYSG9OB?G(.(I,4N1Y9*!9A)C>&F2+:.)5F<@T(:CG M61OG: JQM#BSI!/?#@_!RK[#*$<#D<@1:X'DVR3>*G:B>%.>Y4XA(L])LEUH M%>GO"U=+I#02F1VRQ$.<3M03 MDYM'C/\(DE(U7N=NBDOB^<=TEA=V^J6H+2Z-53J!7V+M+Y0 &8^L6VU_TI#3 M,$42G.%F%ZLI#6R/>&:2$#ALPA>['<,R(7QS' &(57+.6JF&L MG'*];L' ;.5(E"EB+$;9#>\&VP.]*/(5-IA[O )F$^FJ,KLG/?J*>Q5M$>VV MURN+<@3%4Y4$_X-[9#(097.$\;TIQQC*I,EH)*AV^X'A9*DB]D!'BXB'1.+2 MC0PCE_.MB!^3:R">.DLEIV!H+20MQ',7*>O/!E4XIF!1=0&;BX< X9C<91QH MXEE!,3\17=5I*!_W:I#6E8SG2PIOMR;R-)$\OA:HDXJ=2LVR8UZ'0"G&4\I" M61C?!9X&R2T$&?L()^1B[@3JMYB=G';52R-M8?\@5F2:?L2VT64*!6P7HPMH MF0:>8ZWSP"")HB)RK7 ,.D53[6#)J_-2.@DY]C&%W>#YT\;# YC5:/;*$;_R M &*B'&8XB,-NDS7/;#$-B2*537WN#!TL>DO/=$(^($?+Q2E^7)O*Y"G"WK7QNP3.F8HH!BIT?ZS1/AV8IW M,3J$A63CB;*7XGKV.+]S0^O_@F'5!0#;R2E$'6T:,M9$ZW3U43QDI/P>EZEDWC4&3)K2=W3"6 MZ.!+VKE5Z*L<"M<*/CO.\'G^N-<#KWYU6-2LL[^FH.0.IS\_!SLA-ZQ\5L(Y MNBF+P-HNG.# +O,;GS^*TC=[9%*3$;WX*BX#T8O/UA^H_?ZH1;;:7,@E M(UNOKX[ZPSHAV_D5K2:;5RGO8J;#_GDR@0G%/M@FANO5M0X520?)E=3RVAEV M^_AL5*W?;9!:5,,I<4U'C.)[&6GMS=3S9C2UIX_K=#GGEY,U=)346B>EJ8Y' M]8[L1(/9P7/[C'*LGT#5NVJ_VT!'0S/F^UTN-FVTY@?=27NCEW.C/5T=3P;- MN-'S"^,F&]/GP*Y/N;&*;=CRRG9V?D*KH3;.98/6T?2:$_!K,:6/BLO.J937 M6K06J]XC=:1KS=.\&Z:-U1HQBN]EH/7:JZGGU8S4?K]6EW-^D5=#G;V\T-2!-LE5=;01HM8F+9\ 7]P:M35/RT6&5%WO-4B0MC;0Z;+HRD?T MV]LYE2 %!;@[VEV0MM9I:YUN%J2I_MI'C] T7;$M%J-#=3AN4GY%:_&<[%[& M6D][U5Y//:^'Z+9.EW-^^=<:I0=D.E"'N1>VBRTE?Y'"].RYC+4FS UM0 9J M3]-KHN!>Y\5L2/2>=%NCL)Y7 S0SZ-6%9LXO?&IH%-9:>/'\>S.=ZT/.5>]T MZ7L[*)D-S;O=8#;V55T?-L]N/'\6]W5CTP9CIJ].)GM:,^V-UO%&7PSZ)9R\ M9[K*\TOG&IJLM9;T'[Q 3.3Q\JVCVUJ[ RW77E_5]'YI-?S\'/BZ;W-3QLI$ MU<>#]C8OXC9[P_TS>UNQ6@,#NC&>X/?8#):!*2ULYM9DKDR\JMJXA'1M[9M: M7.81HJ/ME=;Q2AM"G^>7B#4T6ILG77FDM8VMEJN>476M24[G-H!XHGOIJ^/> MGEU VLLY]N6,>F6;W[7QW3:^FT*@CRQ4'/3\3MG,\YF0G4IH_*AI1+?V&O F M"[6K=GO=ZE3@,Y@T.^WE^BY\DX]85T>C9E]X:\.FW<1PG\.R:6ZM(5L?0[;6 M,%AL:*M5KZ$-[-2G'0K=L6EIKN[:V:X'M M6K6=NJ,V)^:5]P$#+2_"Z>>DT1V@]#9XSEJ5H*D+V]ILR8\&Y?O55 &:.AKY MUT@MA\[/ND1JV>0&&:I:=WBIU-(21$L0I=U( [WLU,-:$L7YE=S*%>:_A@: M4PYF2\V86QC^@^URV&I9JOM/%(3V;'4\=*(57]HAO,[*,RUF*7\CFWA.-7U>ZJB=;4!+9#_O*_".X,E,[$%J[/J- ]X_V** M&?D^7RI,=SI5/81!]-VC% M>(6 +>S;&;:VG<-=+,7,:US.V7EHH@)[Q\L5ZW]COF^'G@^[;^ 5?8.#+ '. M<$?& T,0A>E!5P%UAQ#5.)'/+\Z$'7MP.8'RQ'RF&'AKCN,]!2\/.S_QO%CV M<"%"M[$,V$OYEU>27]HNG88>>B76%P()$\369 B]D'_]ZLFVPCE*P4Z7)*%T M3X@WBZ\[\-5?\Y\/)YWAL/BK;J=7\O/^>%#JB4V;ZO4[>F]2MTUIG;[>?VZI M^LK@S4ZK'<>*;/W9)/>S D4:R9+YM?(Z?-L@TA206COXO\X Z93UM*MB6O,[ M0*5A%U_CP1-[+@=>_3UPLW9\IW)G.8GI>2GV([[%AB#_I_5SO M869U V,QMDXFNX"Q@>SCP/R4L[&/UYLLOP-8QR[Q[\-@64,&,=J//UPXK+:6 M S:(%5R"%_&S\-$TVXV(&0+2VY1Q) [&G5[.D=@_KB-10:>/[9H^,P+X2P [ MLP%R<&K%@GV%'JR3?!]W6TL[X. WZ [:ZLM3% MX/R&<++!F8TEH,4/ '\(-Z-H:F\T!GD6VL#^ .+D:/2-Y0J=;/#K@CM'A^4" M)""LC!>76:ZGCOJ]4LOUUY'#31Y'?!4W"F<8#,8*LF\\)QQ%_ H@#L(8T7;! MV_/UX&YQMR&S"0>P4!(>P09^,79Y^+')[$?\U X1^[WH80YPFWO! M$EF'1#/$6.H,OSN19 $V& Z5SU_?!>*%\&'9!0%DFU%5H,= ZXS0*;GT @+8 M2Y\Y-%DM\47^?)-Y4'@RN\DCQA3TYRC<_$A.>IZ)"K3>FA:6^G/N)RZ;!W8[ M!2S[?FO,8+,O#>?)6 4HN]*D#G2^!L--QT]S!=BH./S=WZ8^BL/\AIK 4.YC M G-6*G'9 GI)N";7UX<^*$1;*"?+G9WF%WMOP MZWX]HQHEU8@/,KSS.A?>^2+".T+#J.5I=SO;\Z$KTCFTCI95.;HI'>0T&H?0 M,^#HT+:&I"+,1Q^2('YO&$O2,<)4\%\X!@REPZ)KP M Q&G"^>V;RE_1B!E0-Z V+L8I):3K[]F)E_7Z4 [;9^KEX2:H\YX'36/'%5_ M7AE.F&I>#W[QZ)D.Z"0>(/ O2(#1TH$?4OP9MVHL/-!M_IM1<6'C'MAJH"S- M4"JS_3+^>3'XNPF2+)9K[0WI#"=,-UQ3\3$_M MFII=)1$IGFG\6VJF\7UFIK'R=KU=>)W.N_UTO_V/L5B^NH\[GL>W3N+QI\&H M,]J7::9M(\QRVE,Q *,HOTL3C&!462W)"7G:"'H KR!Q9-3K3":UR]'H=49# MO8Z;&K>)(Y>8./([YQMOD6^0:7Y(\DBE=U*O//8-)3]DTG@1K&$%N5*&-C&F M38QI$V.>;= [J@V1%\<9P9HW?(J?@)8..(/*ZM)8D0[+%DO'6P$?G8)B.[/# MDY>NJK!G)!:D].&[%I5[X\:Q&?KHYU? M#&)LZ):MZN-)G2ZG@6RVP=KL)Y[]&DT=V^01-W=%8=A 56:&:3N8U2+^;;M! MY&.6 /X5\RHY0PZ9.7=ANP\K-9=DL/1Q<&(H/$9_1O9RP=RP59++N5;4\4!K M$.]N=>13=8M4QUH[Z^!J5>1OOO'('%4)?<-B2C#WGH0O8NFY@4=%:&>=5U!K MBMK$:D?=UHE]U8BQB=7V]NU0UK+:$H)ZS^>?>^82^PL>&F.L$C1U(=X-<]Q& MZG"B-XBM5W@U9]*\KY$@#XV%7B)!%L-$[ZH];<\!>O4BBIJ(X5J6US_?[8_J M6U:\E-/V**-&:V7X0KI5H#52Q"=/SEQZ5./)=I"K!8N<8O;K8/\:[ M.])*P?_?WI5VMN+R"(@KD0C*K,4IG@F8;$1>P!K#'JX(3W"6XPF(4-_VFD>SD#&[ M8^ ;?PUF;&XH&X V[' ,2]RQPS%4PLSNUP#%6SP0=P M1>Q0P2NIBT;QC1/*0'5B[0VNONZ3QN7E^BE8$:*HH>Z@#:\0VM!IV/91C;R' MU0D*U9G.7Q^RH=MH=]9LYKS5SK57D@HV@(]P+%:23:-?C]]5:(B^*J-Z:')U%>GKWI$YYLM71T[>& M,!;GR?:JM#DUE+DU5FQ_"93L-6@P"SSF[89]M$+WXIUJ^5R0V4;O9%7[?:=: M;HUJR5 N2DS9*8ZK52$XJ5,)@IW:^%R57KH[;^@NX[]"(8E=QO^R:])K]'IU MPG%5,K=YQX^[A/_-5?.QUZWF4RVFJ,@IO##A_U6V>6K/9C97O\W3PDSVLKN7 MN>^YEWQY^(;JXS>+TT@6^>0,2,4J.5%_@QEG>46\!T">> MF>DLP&.V_[,4+O69G8FRJ>D?F>_YLHKA MP.&VSZ 2PRJY==2"3Q=W\+[#[KV@C3K)N$'_4]7&6R?0BBJIE;Z;"KYJOG/X MVZ,B89N4!)>_;?=ZANILF8W>5GLQ]JP_>?!5G99M]O%,K3/ABLE0Q&6]QO.. MA:;24K!(45'WPTR8[^+>A2#H8VP]K^I?.LAV?NK+$O%3;&Y(2P6SHLO]?*#( M-B"^).]SC'\1<$ M:/UX_5^"%M83MU&J3%_38D3"PQJM#C?WML0(3AZY8ZS0 ,'@(K"P RZXHII2\"L?5 P)N* (?S'+NT8SC MH>K-3'X']@UPP(8 M"3WF_.PT9\U%0J%1Z$C-+.?^<&X*;\$UE"ZLAAX%O@8_PVJ\LY?[X2AVE) 0 MLW?,,<@0"%A")*FPY)S,02W%8>,LI3T*@>ZM$9#NO4"&G>.7I=2V5^G#[M3% MA_TR2A@>+-9Y$-U9U]D$WYKKQBR7(J-')X2)*+G5& 95LWH^UO M78&7WG'SY&BU"BC/4$NEWSSN=ZHXJ(>KSE0I>T??OSVE5ZSRLBL;2K2O2,;# MAFJH/)G6MJ=8R*ZXRE.*JVPHO_LQ[H*%>Z'$F2]@I).>L)>QNVT? \NW/@J< MX?V[M7AMF8S>)>Y_.E568&2;Q$'9[6:[5V5B^LIV/EJ3VC3=M+1^,JZF74>U;FMV9A%&_ZBS:KO5:JE"RPF.9X@3+7:8Z'R&/971 ML:]3&\KBQX5 US,5>=U&1-R&BL-N%2)N0* M(1=X*'H-^W@%E>F%^6'IMD_'#V9U5"Q9VFZ;,0\9\E#Y:3,6@40"](V6.RLF M49AIIV\[MI&1NM*#'LP=5>#'-7,L2RY4B9;7,+(WWR+.1+X582;>6,XPNB5D MC37*8L(&>7[B9DG"P,H;)]:I7GD&]]R;:YCD2,E!1EQ,)@.644SWQ,CW]'(X MX#I$T^X:V<>K/JOS(%*JD'2<^A/:N1'.$@2/EW :ODYYK.NF*18?E1C]DL5[ M37M#&^86R:3TK9@6;!MB9$9C(7+$["!X9&GET8BS9!&<9)G43MSU*3 YWA#-B599?=:FJ)E&C821"2A M^$G3^FJ^^$3E2P^!1J!*W&B/N*: MDP01&0XE:J=)ZG!2,T\-V0D?9+D6 >FT=T[H'U%48IT/LMPN2!;+T(/Y<, MCK C^@:E1:27:"B7**$E=K M$-85877IDJ\*W970&^SW9%)CS9HPS,A\1/&)J-_S"*C8;@%=JM,;43Q2T5T MG%Q;/+;MZHI'YMVF]<\,M!L_Y?[1N*SP0:#^QET)(JQ8 2P[!"+!X_4'2(@K M/_E10U;XBLB\W R" Q K'D2H=1%M3WAV,H1'#5>5* M,YP"/BB $=:KPJG/6(,[/)J)1^L6HF*5Q:-5GK%0D)YF2.(#$O^I$$J/GJ=0 ML,,0D8M5HX* ><0@>&77)4+\8*;T0W\"8[$<#VE:('X7'J2+..007C@%J"<] M:#+5M._IB66U0Q;(:"5SKE#FH-BHY*P>I(S\]':21,RAKE6U(_*%H=RZ=4 Q MP>#";-F-63FM884E8KEI_4M(>I)NX.(5+&%_(E$I7=HO%"\!G0!U7*I/YJ+B M@QAB.A("?#A<#O_4S8$NGA$*O!AU)T9WHYE6Z6 $;9'&QA-+.9;GW ,A'< / M:^B $O9 38)&H8R*A7K6" ZK*"\45U[OHO%HL02N7= R7*.$9L>MR?<+/D"* MB8 NN#P+R9;R 25ZYU@;=5P7=%VR>_C(+-X)7*JK<+'9 ^2+>%=)H'JL#0L+ M*/@C4BKXJ/^#U*A[BQPU5$X YQ< T:6RL@!?1W0-"A85&0&;#*LOXL/1VQ,7 M9Y-PS0C#N4G:*YGVZ 4&ZA8D:[':#;K89=4E!,/S_0JD[V+0;>2[Q%MP@R?H M_$ZH$H>X5YJ0<6MC1M.7WBC@)!P%5;"X08D>TM+A5.<^NP$5B508]$4$ 8TB MBF%_D"\],4P-_]N#) =OI"!3/BNCI@::.0X:.)DJ_Q"0X0*&#GR.RU7O\E/K MNL <:WP_C6#I*-8Z4R445!1F="!Y/^2#=48HQHI*BC63[J(L\%31)(=LK0 C M4];;MA%=H TP)"P]1O,ER6LO(J?%3-D*]F-I&\^44C/ \#RP@V51/AB/)O:9^2K55QF]94*E899)2\;P\0'Y M24*D/Z%*_,W4[2@4VI#%_JA$511XFKCS.\@N87+>9M)UJ>QMPK'@6Y2P#9+0 M&5?UN2>92R5N73=&V6.J#D,4@V&DMW A4>'2KT]4ST%2]=[C%37<NR1%)&_2'43 LQ\5& -6S8EQ"-YOT->651UGW.RQP2Q3@5 M*D(D6_$[4K?ED1X6G@?DG]ZAQU ?\5RDBE7XV5=1!:#\&"9]BGR^=Z I6.=8 M']@(M!G/^3L<0ZGU 8]]8+Y+3#_*H[G(@\R 9A$G62IHIG03,O0#0:O:4\[C MP2T8T]N^;61^S$3(\[*RRFR>=?D7"$_'V4$1"]%R T7+ T7ASS,D*4LM&WLL MY29K8:$99(/!&9I\R5/ +L@IGJB!#3;AIY6\".Y \?_=2 MM"?HU*&$-OUBCC%Q0#QPAE'<,.N[R:IO9>7C=,.#E/B RAD#Q6>4_7$! LEC M^C>=]$Z01))CN&A5P9 %W5,@MPSI3(1E\FD]T(^0&!4S443&> 2Z.'=/_+3V M!I<7^W!IZ 0@OA8[)B;./8TT]C%W*3^;*1L "P^BLALEF$%54K?6'^$)0,(# MDZ[0LAX*E!ZY$6R6:L6V?>DB-S#/0)5^15X4JK7)+>...\R@\O=/@ M*^>19GXQD;7TTM+SL(O*K/LK3R&U+E*I_E9_DZ2Z_E?VG6#*(^OQ\^X!I6[I MD HKR;!MIP=P>L-M7/VZ@5Q^+1V2UE^U=Y^+(X,=)?HMW.I 6%2DBJ"L9 \WC@*6T(C7L,6\#! C_E\<>>V>V5 M#M)*3;+A[VAY%>0#I9R%H> 5U([S$JZGL037PW5ZMGDBMS)_\='/5C3J!1R86PP=$$.THM MG!Z]BM-08Q+&DTD6DL,^7_3\,3GT@3R1*5!UP@J$WHU\=J&T&M [EBL>7D[> M4A#CN&"?E0%&>8HR3=]T#'T4_0$XP\ M2X4<6 C F,F[U)VK* 3!T4+4ZI$;Y+NE+F]V73/DJX(ZY+P-']R!_))/G+#L MBD:C)R2F=2N>F :"EO(OHX"EQB5"@CPRXUX^;71%B^+CC&/[U$WW^?AG'B]E M=SH\45/$! >/G'$-BQL]8B8^AMB%WO3&LN,F$UY/&L6""-E 0V>?'U)JDVP@ M"0JZ!'P-A7HV:\F9[H#'F %\+BQY@'F]J-*!6FZD9)OS9IP!ID1@*CD-#.24 MU\AK>GNRR05C$3C14+Z,NOXI+Y%*AO#T4#)U_.,D$K7JUQ\'#>52 J4LFV0L M$54:L=1W/!4NR[/$3#TK6D!]CU =6SLPY(3L"4X=(T0-:#@8G1AEH2N5.DCA(K7J^ M>BMH(7PKSD*% ;2'%7D5:)WXVP%R!W, +?0?2+MI-']]8[5I+Z;K5ZG$'RU6 MXE=1T8[?5%OU?X"=GVG]RV76Y>G5-^OB@CQ5[?=?O_WV\KSZ;>+ MKU_6UID[K8KKS';3^@3'3\"JI,!3J(Z8^7.TQDB=P) %_"3S"F,D0W)\1L$M M2U>5]^D&CC^1Z94T_VD^?YEQ@S(TTA>"F<5Z@VYMG<<_FPA?@R,\D#HG :*R M%)."&Q8F&W$")$%'=)1;YJ7G45<,: D*K+"38O<;,A\_]\X/*%PG M*U80YO+ M:BK%KT@;""^5[B2KX%"BJ;*\@/0]?X0RP%#JM L>D7YH#:7"R[,_ M8BE;.*;OE+BQ$7/\IR[I MP6M+7N2"NEV HRJ]F]UA62%B#EM+#-2W)0.K6I8A &"*P&TRBFC_%R6.QQSC,+@7D$%!8Y3-*U3 MF5\@\_E8Y((=R7$OBC)QZHX)R/8$D"*;\OY$KT44TYORRWZ$T5V(UV5LD:HD M>MX^?IVN$S JGJ+%F(;8-4=831.-1Q45CNVE]#V-QXR>8/.%9 MUZKJU,<_,HP^&?!WPD>PSU=D$"+Y J]*+)OM$ZJ]%IS^[W^QVR[]:HZG> M\<::ZNT&5?-!/?RH1VIBK]N$[T4];^7UAB])"5ZZTO62+;BV:(&XEF:8D;$* M$EF>1?IPVBW=PJ4[Q=2Z&R'S>Z>.[Z'-)<\S!#SNUFYMLD,C!I.>J/9G-@15 M$R,16ON9EI4YW"VP29P&S$9"JS#\+(S%)JL3G:CWF.M&1W+4["TQE))H%BJI!YUFB1*)R0'X .Q;LK_7WB\AYG5[5ZS5^/0Q M"G^A_D.';?L0C9N#COKMU_2M^.7K^Z*-91>U93GNM!O'_>-J-U2MQV*^[36/ M=PNYH\IJ+>9;N]MJP"M>M#O[BYT><&:T]>G1?^KIL6*W]C56L8($= 3TTUN3 M%U_E@KWM-D_ZN^7:T=E[N7E^CD.-A9 !LSKQJ=XP[\ MZ[ZDKO72]^\V\U=NQM(MNYXIP#OORBF+\*[ORGFAYH8T9E[[ Q3=[]K]9K># MZ0\8JC:K[JSJ!Z3& M(7Z$6"T72J!K;9Q$(_:"C=X9C $D<_$+!6 A$F4(SN M!%2I]B*_ED;:U:,1HY:4U>XK4)./11X"5T)PS:H6^8W]YM%) M;U/Y^^&72V]:0>:U;5[X3628K'K9^AE[S^FGZ"^5KB%YF"32 M%\H 6L)?\?0,GNHMQ!E!2J9X&)8Y^CT2^;/8_/PUH@I,:^(V\ .S3^YI1J$/+4>__B [3&L1@!'Z7I M-'EW>'AW=]>$<39OHMO#4[#A06M-#H5WX\2'GI,ZA_91JW74;AW">.VC=K_= M;[7A!9W64>M03JEC.[@Y@4@BF(D3W#B3YCB%W3F5'U.=1?Y"%GS!ZQX%@+O M8 C#^QP?M_^W0Z>H*JXGEG:'XBK"I;T3+J]5N!P?=XZT<&E+00&\BH5)@4VE M<.&/%1PK)?[]<'_PR;FSOD1-JZTDC'10GDYC/[#:'*E/2]>!K()34&^ M]!'U3 \H"AGYFN/-29BM2L]>Q.W=7Q(#6")PL7Z>\I\JE&^_$U-KB:G;'Z$S MQ4KU_TX0X(YE!1QL6321,N::.',[YB*F#MRZ11,B.W%K9F.=\E]AJBL'GV)M M,]^Q+JD(-!=_O@C=)ATJ_Q,%/T1L_4,]U?+H>/GLQ%NT*.[88E6]N_$CLHHZ MK]VT_V.G]=;W.'&RZ?@ J?4/6_S\V;%MIN*![B0J:UA=ZIJ;'W4MSJ^R$NPT MBQ-L.(^JJ%$=L;OG[&.]$"J.2'_D^0=&V8R9:J78N/*DTV5KVXNF*!_,QU_+ M])-.JZWKC3KQT E%?'EN@),]1*SOZ!,&NM_/UQ]LBY"S#9VA746N=2;S#J0 MS=WEYY[Z7.?-H_7OQ*J\+%70=[BYPYF3.D"ZV)5)U@G&C"%Z3^K<<.X05ACU M/.F$U\_(!Z3>MPHVK'[$=SWX;4=\UC?G)_8:NP<-(A4A%?.[=L=BXFAJW&XJ M&)Q^J@ 5O!@0\A%2&!C0B4]^^ .C./.$L<4GU-G'\QUY+"2/,^Q(XK]>ZOAT M^J$"U%%!POCD#$7P $UL)35<7GW<44,9-5S&(H$M>^P8V4*B6 9#O87T,*"& M3I=8UK+<-MEC(%/*F40F^5*90X0OU1#9@$&T=S"( MYX%!; =+OU(!?TXY>YB#ARZ#YH9$=MW2[:J4N5:R-B_6RH!E/G_XM]3&\HC;EI#A<'_Q#^[32 ML;C7+5-T8Q,\.QP)UD_OI[*_J4H'2F/AI-2!?1K[MUC" ALG1^&(.^LX0?,9 M3!8XL^N.&J]JDU'KR_^_N7T MV_>KC]<5QZI?&H>PEP&STZGOF1AW*;D2V""N MYH.R?"A UHU4L1V20O("E"$B"['7&#[/R=)Q1(W'ERH!4".L?/>DV>GT-V+; M=9K=3GLC3^IVFB>=ASO<+*EHE2HF1Q6WJ1;T5OA^=?'EXM2Z_.WTZO/IX./W M;Q>#TT_7UL670:F!53B:[&X=(9.5LVP_._>6K7+EE]:/ZS"S#_?OGC:C"KI? M#I-#[HQZ*;!E_=]C,"<#X8S6<4@\8R&#JBWNHBY7%5G3>BW;8.R+T7P"9L,Z M _4'6\R2^KGW0*YFB5][3MR?[*1]U:7]R_EVMEK4_W>4B.G8^NP'0:'&ST[0 MKR>Q*K*B]5HT%O-S2<%%X9Y?0#UQ73<"JQ/]B8ME_<*JUJ^R2N+)8G_3X3#R M[N''.)T$__7_4$L#!!0 ( .LPHEA7*@[F[0\ &"T 1 875P:"TR M,#(T,#,S,2YXF;D)>VB;3] Y)R#8S)'"!='<_ M=81] $V-Q=(>HZ.CHZ.S>?_/,]<] C, M)]2[:#3?'S80>#9UB#>Y:#P,;ZQ/C?]\^>FGS_^RK-\O^QUT3>U@!AY'5PPP M!P<]$3Y%? KH-\I^D$>,>B[F8\IFEO5%5;NB\P4CDRE'1X=')W&Q^"X[;WXZ M/85/3M.R/]F?K)/QR8EU-CX%JWG4'#FG]MF)XQR_FYR//S3''\;VB>7 J&F= M')Z,K3,8VY8-^.C#Z.,I;C:;"O39/_?M*=@2K:B,JZQ/NQ5OIYQ-RX_/&!O#W"/L3%<3"?KA7' M 2,>P?,I9C/\WJ:S ]GGP^/C9EQ% I(-(HCG<^S92Q$.9Q9?S,%O9E<2]P_D M?2GHT#IL6D=-K:JYYI%U>&S)1F+.&1D%'&X$@] 73(FX CU M<$$JP%J!Q&V.V03X/9Z!/\+S\A)*DCLSEE''E:_3'V1ZK=/N.RVG$# MA31WJ(VYTEY9TA=%51>U\@?@7'S(F M /8\RE5]>26Z-I\3;TS#"^*2I/$\YK(/X]BF:F8[8\*H_\XQLQEU#;/K8,[H M'!@GX"=-O@*8,AA?-*3AMV+;]7W.X+UH25Q$$["ND/*VD "^,**JOYU5AV(( MRD.MC!92\@RDG]2C/R52-2]02NA2$A%:V*1 ME/NF#449VK(=J"K8J">G.]&3-RN23]_@:TL,5K=SW>X/VO]]N!W^L5WUR, W M:L&'*EJ0%/0S"D6]$;TBXJHU^'K3Z?ZVY95A!6ND]6,56B4^4@)J1&:73;!' M_E*MP)YS#;[-R%Q^H^/+P"<>^'XI&@L!&@G\)'=(Q+==Z@<,Q)YF&:'HF#%!!*(M6( MBROL3^7?]I\!><2N['T??,Z(S<&1-X3-N?4>Q:7R+)7%-O+73/,G0=ZI?U%" MR#NT$A/>E(8S(:E&_,I>>YPR86$\X*7H2U4ULG.49BX_!'!.G M_3P'SR^Y&*7K&@?^.#WP$0**(6HT\+>BY=Z$C%QH^3Z4-%A:9>/0G^@Z'T.@ M$*-&8]\+#S@6PMI*:SR7MK:LT?E^#R^P, A"#\45%H#3(7A$7,++;E,* 1HY M^ICF*(9%$:Z:,1$R2D#7B+IK& -CPDNE,[F$QKOZ+I\"NZ>>'3 9[:S*8WET M(ZE:X""6@9)"%+-*#!)RK$A033GN$%MZ1V)(KJCKXA%EJD&M"8,*6U(SFI%# M+7H082K6UE#1"K9&A W$D,.4N@XP7R[H?%$NR*-7-U%RI$4,$B _^RB$J1$% M]\ [U/>%8R7,RHQZ:CA*L9"-8"1"V_H+'"2!D$!"(51(3HW84/V563YK*TGY M2:%#&/G0-OL*R%)(:TM.C>BX]<2PPA _EW0'DO6, Z]M]L/:2%6OT6#WP94/ M2/2PV.(-&1;:9I??X.2"&&G0-OX1%%)8* E6(U*D'29AC%4Y0NJ( [S2YS&; M<(S4:)& !%KD2B7P:L2.BHH'-I=C/BDY3Y(UC0QH48"U^C4:\4$P\N'/0'2@ M_5AZ1Z%5-HZ[MK-?0: 0HU9C7^1,=X?'Q46.C<_.3D]./FK.;?%C8_1+_*E. M.5?%"!C*8-8NF(V C;SJ3G()7D,A=6(U\U2_ HF;<(R<:?YU3HY '0DJ>:!? M@;IJ$HRD:MYZQ<2!.I*^G@90@=-, "-EFA>?SB:H(Q>IU( *9&0C&-G0//IT MBD$=V4BG"U2:&YD01CXT3U_+.Z@C(3G) Y6FR28D(SW::=R&9(0Z$I5.+*C M4 Z$D1K]D"V=H5!'0HID%E0@J02LB;A/VE% MM#"]5)910;3P4]7CCKJO5R692GQ\!;W(D&;4#"WZ55TSUH[%:J@;Z\=:5?C. M1C!Q>*8%PO23L1K2D3K8JL)'#H21$"W.I1^.U9"0]-'6RJ%.WZDV=\JB&VG, M>'X]?::V[H1GG+F]\?PRU\@(9F0Q(S]>9['>7DW.X68UD[D1RLB6%C3;>%!: M0Z[2QYPOFEU&,"-?6NQ+/SVM^^Q*#_(RW"0/4Z@G_64ZEH7$AON*^BH\T!=7 MMT%H65E&OLW/\Z]'L59RY;=(,E*BU8R6PM^T0C*U]%?NL#S8D6&9D"I(!&JV MHA.E)!DU0@L^96I$PDM:28U5 M9/Y]^TH1Q'WYNOIP_?FV\:\2H:4213IHHU M*(-K9%J+*Q9/P7FC-'/H7^3.51)@)%D+$18FN>Z>7^G7NE0AO;(0 _&GAUI< ML>(K9&K)O?'U+Y5])Q Y!H M05C@G3K#M\-\L[ 9;[H2,]?R.%&#(CR4@4QZJ+P*5X W:H$6"]VD!5*6%0M# M*VFU)#L[ _IER8/%((VDZLF">>G5=?>>LT?\-Y"_;0Q.ZQ$8GLA3H6"F,FBK MI?Y5E&&D6<_LRZ2@A\(WYY4@-.+5_=-6PM&PQ*U[BB94!-W*MOV4E MGVLE!X6"4"SIC>3E$ F_1?Z8N?P!X]839DYX0!&G'JG1>Q!-\+>O 54E&]5# M"Y)M4(]$(U#8BNB49)E\%2J0:LF;_N@LMEQ7_BRR("SRO]=O1PDXV].:S%(1 M<".#A@=4T]]#CR9\.VJ8"5)'CM-O<1<*R+_CEA >R;[\R&LPO&F%)PF'60%R! MA%=FU!/,L\6MN"/!&P>Y@]$!WP?HBH9@^7"BZLY],!L!ZX[;SUSXGD)B'$B)H2C19^)QF KT.6V(\:'2\=?-)#C.Y -3?8M;%;8M9S"YCXX07CX M5K 3#F>6_.0WSQTZP\0KT)%KUJ>R5<,;88*!;>Y(3N'==:1X/SK4FPR!S:XH MF\LC2['9&O%5_'MSOPI6WH=^IE_4!L_\4FP ?^3.J_P*N]0_'HLIT"7C\VVM M9 @F5;*U]NQ;:T89)W^%GDOND.Q.8'4+[V'7!E-! M3&6#4+3V7G0U:^4,ET_*_P N3PA!Z)BC>1BEUN*"B/OJHZB :1_F ;.GHB,] M1B<,SWK ;.FG3B!W+,P5MZX$$8!PR5_7>CYX#+ KK9D\7H9\7VVG,O?4AHK^ M"$?D3,F?1EO4F1_OCJZ#[-" M<_('^H,'@Y&K@K0?^Y$PASQ2LE8J2SUZ.9DA(%,&8B\Z+688D(FG3@_#^'77 MRPSOYIO$X@A[Z]+%SP2%WJ=LXI62)[?2N1W?7&E'$SJNM VS?@]/URR8M.9S ME]AAPH=8K4C(5@\O9)E5YQ[FU!-%&17[H>HF_B4R]W7]W.*V\C6VKON[515+ MPZ-H&MR)\F;7,[?X7AC6HK&H2.?]GF@=&]+XNKS6#1]C?G&XJXB(?=UJY?91 M6EFQRDAI&ZUT<8"_WV(K9IA-Y/M958)!T6VTN>*^\BM+M=#16NY/'YS ACC:\A6PHSRU M E'SEX'N;#]:8CN:GD% [-^:#')>\7TUPRWQU1'+1F@?I,J'#^;>*A-+'J$GFK'9 M'2L%L1CZ58SJ*Y^M12+W==:LK18J%U2]WWYA MSFXI4'.'(?0R62Y='O@_<$^E;MH@)-C8O:(=;MB<&:OMA06X!.)-@R[O?]*[C#WE]2._L4 ;-#%<$4D)-S/TVUI!;,W>,9SLR8P/GU MMS6VB6W&+^/1,HOL5$)L,U[K4?>C5G>KU?K[?WPZFCWX2,O5=#'_Z:'\03Q\ M0/.\*-/YNY\>_O;V&82'__&/O_WM[_\+X+]^?OWBP=-%/CZB^?K!DR7AFLJ# M/Z;K]P_6[^G![XOEOZ8?\<&K&:[K8GD$\(_-KSU9?/B\G+Y[OWZ@A#)G'SO[ MV^6/,EA+H4C((00M2BDW#YU-Y__ZL?V1<$4/>'CSU>;;GQZ^7Z\__/CHT1]__/'#I[2<_;!8 MOGNDA-"/SC[]\/3CG[[Z_!]Z\VD98WRT^=LO'UU-MWV0'RL?_=>O+][D]W2$ M,)VOUCC/[06KZ8^KS0]?+#*N-U*_$=>#*S_1OH.SCT'[$ -,0+ZM*9Y MH1.YG4&8+?*%#\V:UA;+L]^<8:+9YJ>3XQ6\0_PP>3'%-)U-UU-:34@Y$OQ( M"#X0F" DDS9:L(6C!66 B2AX>$1F?I.0"0G8EP <"^HWFUI \X+0>?/M!\16>C*B1+ M<)Y B,""C0HA.,,3S]9U58@8_)X[J[WR[3>7^;=R/Q\_I'?O5A^ M?DF\ZCKK*Q8!TO'+39(68JP1?$2O>4)E(7K[].??/R;?II^R[RSA;CI^2FG] MAMAF7G"Q0M0I4V84QFIVJWV 6#TCLSYI7Q2QZ]59V5N!C,F;Z:?U_67>;[W* M>7$\7Z\>S\O&RWI-F:8?,QV[#; QN37]Z-%?)]WH\@17[]M_!_]]S(AFC&/UFE;KY32OJ;2_8,P7?W#N MDQ,A8G0A>G!*!C#9$(3"L;OA(50I5"29.M-H+\"WH9?][NAU?SKL&WQ?E F MQ3Q'! RJ)7Y4AA1#@J"C<"JHJ,T@0??)TZFRFZQAHR\3AHA,Z!3_%456?%(140]7-)M*Z:.8YYH*2@% M-NDZ(D\U$@EXO!G()&ME32[8WA2_,HL^FGSR_DRX)L.XD\C[+:J+HZ/INNTN MMM$]6 M*NG&D2WC(T?9%&5!$+7UUSN()1M06F54RZ)0#L'.R9W[S?[MI>>["W>0NHG+:X\) M-IC"'KD7;>V1U4'RN0(%"MIIK7*B_G;^*CCC2^SM:^2["+X;$UXM%^R)K#^_ MFN%\S<%:BZ@^M'"[K3DVH"LF$(^T%.!5)D-,_(=&;8.JWB;3>_/Q.CRWX8+_ M?KC03?1#YC9*)A^8AI!EX.4G!P^HG(8B$#'D8*3I;?O[YW);$FDQWSSW/W%V M3(?'ZU8.W\X83(BR9WM+/.L"V]]<%:2B*O\A;72V6!][5P9= V=, >^>;-B6 MR>NAA'Y.3BG3)@:V"F. %)($'(<0.9 M>'+V]GQN1#6F2+@S1SJKI&=QQO%1DS*=% (PH ]+>D_S%8=KS^=Y<40O%JL6 MIQW6M_AIHI*3)*/GX9-O922%07+$9E3.T9)QU?=>.'>$.*;@N3>)!E16-T:] MIC5.YU0.<#EG"[@Z!_HIU6F>KB=2).^=0/#)LE&,T@$F%H3'2&P0D^;_.I/H M9E1CBKD[\Z:S2H8\Y()52).U!I4%<:C 44)@RP>Y^.A#]%JIWO;EID,N=_'* MYNLEYO7OT_7[)\>K-<_++V<+/I^--$JE$@E6J&/OER5.'!2QX4^L":>%PV1Z M[ZW=!M>8_+0]^?&UG]99+=U+)%_AYU:#QR$3_V1Y3&6+!-@(5%N\ 5NU;X?0 M$B22; A<$2D;BX9ZYRAW@#O7G13Q7#'BX\0^23B=0BT,1CY,$F"2$U_D87);N_\"\\_\^#%X=O^O6SV.&5PS:[N.O8.W7"X!#_SWA_DBHIFZWG M8%!%CO-;$;:@#$$+="$4B;:W2W@!P/Z' ,^>](SGW$DIY#&;S%/;N9BO?J:Z M6)ZF.-[B)UH=?&)7GJ<_3Z'EY^<\:S<[R\W!7\SX->^>S]>TI!4;V)R)G; * MSM4 1K&I1X4E2AJPV/D= 7Y G M,6; :@BDI^ S::.'B6"'&]*8#'DOGFX-B4?"BFZ3^J*M"DX8))5!R-#.P+43 MLEX14&#!>2,+QGQ_GM>W3;<-1:.[2[RC)5]M3NFF^NEQJZL?V?[#0M<=82W.6((^+5 MNGGA'^D,5)(JU6 "")$S3V9I(6D,4##DRKZU5*7W 8H;((W+#'9D1T]5]-UG M^)+7/+'-IX!:@5],6;O _KLRB<8 S*,LPA.YWAN;UR/:<==AV%BG M*STZ:J)C_0>3]#BO6S+MW6:TDX3!58T$Q50%QAO&X94 4L48K621IGH?Z]Y:O MO8ND3YYST;0OYHLSF]_,O*N4BG$9M&BE^I&=1 PA@,;HN4%!:H[EL9+2AMUMP"<*HHH&Q M\F\V8]?G$V]=%_NJ?IO3?&>!=PR--T[[V52_ M7(M\\"G/CMNIL78$D_\M+7,>2L36:!,L1MG.85H&&@W$&%FP7J=*O?WA.\ < MTYK)B<%?8T*>3W]>-+N#Y7W#DV!5O4-QDK'3"@21(HE2!0RJ][=]6Z/ MKFMS:=W%6VVK-15"#<'W0X_;#S=@T^TS%.6PH3E*8-UONUJV'9N M40(F:1A;4%(9957I[0W="&I,*]P]<:>OHOKQYY2]SQ;+U_3A>)G?,[U]P.%F5*,*/.^+0GUUU;.*9]OPVUT9 MJ_7%X5/@0#H&!U2;ZRARA>0]02U.Z8RUI-"[4N_VZ'K-I;>+Q_F_CZ=+^A67 M_Z)-F=6?55D3UDS,GA!2,>T*I=RN4,( Q*&2K6UST?7>O[L5L.]A0=^74E?- MJ'X:ZVZ8OT"[W.UO(DEI\JT15#2MU9\,$+1I-PY%4B$8A]WK.&\$-;9*Z&]" MHKTT-1R!-O4-+(QRW,9]ABT[7B7:156V&@\&K6"'HUW/ZXW$Y HZW7N_ZW;( MOH<5?G J[:^S82(-W!S9_A5;G<3Z\V'=:C>C2Y**-I!=VYBWB>UFE18\"A-L MR<(.T1=N-Y!C*F2Y+Y(-JLB17%V4H],B6 M"(4.6Q(ZPBPZ$U9I*=$&%[O

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�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auph-20240331_htm.xml IDEA: XBRL DOCUMENT 0001600620 2024-01-01 2024-03-31 0001600620 2024-05-01 0001600620 2024-03-31 0001600620 2023-12-31 0001600620 us-gaap:RelatedPartyMember 2024-03-31 0001600620 us-gaap:RelatedPartyMember 2023-12-31 0001600620 us-gaap:ProductMember 2024-01-01 2024-03-31 0001600620 us-gaap:ProductMember 2023-01-01 2023-03-31 0001600620 auph:LicenseRoyaltyAndCollaborationRevenueMember 2024-01-01 2024-03-31 0001600620 auph:LicenseRoyaltyAndCollaborationRevenueMember 2023-01-01 2023-03-31 0001600620 2023-01-01 2023-03-31 0001600620 us-gaap:CommonStockMember 2023-12-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001600620 us-gaap:RetainedEarningsMember 2023-12-31 0001600620 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001600620 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001600620 us-gaap:CommonStockMember 2024-03-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001600620 us-gaap:RetainedEarningsMember 2024-03-31 0001600620 us-gaap:CommonStockMember 2022-12-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001600620 us-gaap:RetainedEarningsMember 2022-12-31 0001600620 2022-12-31 0001600620 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001600620 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001600620 us-gaap:CommonStockMember 2023-03-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001600620 us-gaap:RetainedEarningsMember 2023-03-31 0001600620 2023-03-31 0001600620 auph:TwoSpecialtyPharmacyMember us-gaap:ProductMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001600620 auph:TwoSpecialtyPharmacyMember us-gaap:ProductMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001600620 auph:TwoSpecialtyPharmacyMember auph:LicenseRoyaltyAndCollaborationRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001600620 auph:TwoSpecialtyPharmacyMember auph:LicenseRoyaltyAndCollaborationRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001600620 srt:MinimumMember 2024-01-01 2024-03-31 0001600620 srt:MaximumMember 2024-01-01 2024-03-31 0001600620 us-gaap:FairValueInputsLevel1Member auph:CashCashEquivalentsAndRestrictedCashMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel2Member auph:CashCashEquivalentsAndRestrictedCashMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel3Member auph:CashCashEquivalentsAndRestrictedCashMember 2024-03-31 0001600620 auph:CashCashEquivalentsAndRestrictedCashMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateBondSecuritiesMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateBondSecuritiesMember 2024-03-31 0001600620 us-gaap:CorporateBondSecuritiesMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2024-03-31 0001600620 us-gaap:CommercialPaperMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2024-03-31 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBondSecuritiesMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBondSecuritiesMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBondSecuritiesMember 2024-03-31 0001600620 us-gaap:USTreasuryBondSecuritiesMember 2024-03-31 0001600620 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001600620 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001600620 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001600620 us-gaap:FairValueInputsLevel1Member auph:CashCashEquivalentsAndRestrictedCashMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member auph:CashCashEquivalentsAndRestrictedCashMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member auph:CashCashEquivalentsAndRestrictedCashMember 2023-12-31 0001600620 auph:CashCashEquivalentsAndRestrictedCashMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001600620 us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2023-12-31 0001600620 us-gaap:CommercialPaperMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBondSecuritiesMember 2023-12-31 0001600620 us-gaap:USTreasuryBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member 2024-01-01 2024-03-31 0001600620 us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-12-31 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2024-03-31 0001600620 auph:LongTermCorporateDebtSecuritiesMember 2024-03-31 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2023-12-31 0001600620 auph:LongTermCorporateDebtSecuritiesMember 2023-12-31 0001600620 us-gaap:PatentsMember 2024-03-31 0001600620 us-gaap:IntellectualPropertyMember 2024-03-31 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-03-31 0001600620 us-gaap:PatentsMember 2023-12-31 0001600620 us-gaap:IntellectualPropertyMember 2023-12-31 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0001600620 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001600620 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001600620 us-gaap:OfficeEquipmentMember 2024-03-31 0001600620 us-gaap:OfficeEquipmentMember 2023-12-31 0001600620 us-gaap:FurnitureAndFixturesMember 2024-03-31 0001600620 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001600620 us-gaap:ComputerEquipmentMember 2024-03-31 0001600620 us-gaap:ComputerEquipmentMember 2023-12-31 0001600620 auph:RockvilleMarylandMember 2020-03-31 0001600620 auph:RockvilleMarylandMember 2020-03-01 2020-03-31 0001600620 auph:RockvilleMarylandMember 2024-03-31 0001600620 auph:RockvilleMarylandMember 2023-12-31 0001600620 auph:RockvilleMarylandMember 2023-01-01 2023-12-31 0001600620 auph:RockvilleMarylandMember 2020-03-12 0001600620 auph:EdmontonAlbertaMember 2022-10-31 0001600620 auph:VispSwitzerlandMember 2023-07-31 0001600620 auph:VispSwitzerlandMember 2024-03-31 0001600620 auph:VispSwitzerlandMember 2023-12-31 0001600620 auph:VispSwitzerlandMember 2024-01-01 2024-03-31 0001600620 auph:BeinheimFranceMember 2024-03-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2020-01-01 2020-12-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2021-01-01 2021-03-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember srt:MinimumMember us-gaap:LicenseAgreementTermsMember 2020-12-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember srt:MaximumMember us-gaap:LicenseAgreementTermsMember 2020-12-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2023-11-13 2023-11-13 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:ServiceMember us-gaap:LicenseAgreementTermsMember 2024-01-01 2024-03-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:ServiceMember us-gaap:LicenseAgreementTermsMember 2023-01-01 2023-03-31 0001600620 2024-02-29 0001600620 2024-02-29 2024-02-29 0001600620 srt:MinimumMember 2024-02-29 2024-02-29 0001600620 srt:MaximumMember 2024-02-29 2024-02-29 0001600620 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001600620 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001600620 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0001600620 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001600620 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001600620 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001600620 auph:AmendedAndRestatedEquityIncentivePlanMember 2021-06-01 2021-06-30 0001600620 us-gaap:EmployeeStockMember 2021-06-30 0001600620 us-gaap:EmployeeStockMember 2024-01-01 2024-03-31 0001600620 srt:OfficerMember auph:PerformanceShareSandRestrictedStockUnitsRSUsMember 2023-12-31 0001600620 srt:OfficerMember auph:PerformanceShareSandRestrictedStockUnitsRSUsMember 2024-01-01 2024-03-31 0001600620 srt:OfficerMember auph:PerformanceShareSandRestrictedStockUnitsRSUsMember 2024-03-31 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001600620 us-gaap:InventoriesMember 2024-01-01 2024-03-31 0001600620 us-gaap:InventoriesMember 2023-01-01 2023-03-31 0001600620 auph:EmployeeBenefitObligationsMember auph:DrRobertTFosterMember 2024-03-31 0001600620 auph:EmployeeBenefitObligationsMember auph:DrRobertTFosterMember 2023-12-31 0001600620 auph:DrRobertTFosterMember 2023-01-01 2023-03-31 0001600620 auph:DrRobertTFosterMember 2024-01-01 2024-03-31 0001600620 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-03-31 0001600620 us-gaap:ContractTerminationMember 2024-01-01 2024-03-31 0001600620 us-gaap:OtherRestructuringMember 2024-01-01 2024-03-31 0001600620 us-gaap:SubsequentEventMember 2024-04-01 2024-04-30 shares iso4217:USD iso4217:USD shares pure auph:segment utr:sqft auph:extension_option false 2024 Q1 0001600620 --12-31 10-Q true 2024-03-31 false 001-36421 Aurinia Pharmaceuticals Inc. Z4 #140, 14315 - 118 Avenue Edmonton AB T5L 4S6 98-1231763 (250) 744-2487 Yes Yes Large Accelerated Filer false false false 143019365 Common shares, no par value AUPH NASDAQ 64459000 48875000 255453000 301614000 28909000 24089000 39761000 39705000 7646000 9486000 1995000 1031000 398223000 424800000 199000 201000 1502000 1517000 3198000 3354000 4760000 4977000 104358000 108715000 4394000 4498000 516634000 548062000 50270000 54389000 4909000 4813000 800000 800000 1150000 2388000 13724000 14609000 999000 989000 71052000 77188000 67475000 75479000 6339000 6530000 8800000 7600000 12292000 10911000 157158000 170108000 0 0 143690000 143690000 143833000 143833000 1207982000 1200218000 105419000 120788000 -854000 -730000 -953071000 -942322000 359476000 377954000 516634000 548062000 48073000 34337000 2230000 72000 50303000 34409000 7752000 421000 47695000 50124000 5551000 13158000 6683000 0 4125000 -290000 63556000 63993000 -13253000 -29584000 1283000 0 4526000 3814000 -10010000 -25770000 739000 436000 -10749000 -26206000 0 0 -124000 73000 -10873000 -26133000 -0.07 -0.07 -0.18 -0.18 144013000 144013000 142641000 142641000 143833000 1200218000 120788000 -730000 -942322000 377954000 2231000 21134000 -21106000 28000 2374000 13370000 13370000 5737000 5737000 -124000 -124000 -10749000 -10749000 143690000 1207982000 105419000 -854000 -953071000 359476000 142268000 1185309000 85489000 -1061000 -864302000 405435000 761000 7710000 -6071000 1639000 9467000 9467000 73000 73000 -26206000 -26206000 143029000 1193019000 88885000 -988000 -890508000 390408000 -10749000 -26206000 4847000 717000 3206000 2611000 5737000 9467000 6025000 0 -1559000 -217000 4820000 5559000 56000 6993000 -873000 -3588000 -17000 17000 -6594000 -4117000 -181000 -156000 -18598000 -31670000 121260000 142397000 170505000 167766000 0 347000 12000 162000 49233000 24860000 12301000 0 2778000 0 28000 1639000 -15051000 1639000 15584000 -5171000 48875000 94172000 64459000 89001000 861000 1595000 0 1000 63914000 88327000 545000 674000 64459000 89001000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Organization and Description of Business</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. Aurinia contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for development and commercialization of LUPKYNIS in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the Otsuka Territories).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value, including an exclusive focus on driving the commercial execution of the LUPKYNIS (voclosporin) business. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program and is exploring alternative approaches for AUR200. The corporate restructuring involved the Company reaffirming its commitment to LUPKYNIS growth, while maintaining a sharp focus on operating efficiencies and maximizing cash flows. For further discussion, refer to Note 19, Restructuring.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia's head office and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.</span></div> 0.25 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Summary of Significant Accounting Policies </span><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of March 31, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other (income) expense, net.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and specialty distributors and directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products to patients and healthcare providers. Revenues from product sales are recognized when the customer obtains control of the Company's product, which typically occurs upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed to patients. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of March 31, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration and manufacturing services revenue in the Otsuka Territories. The percentages of total revenues, net from our main customers were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> March 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two main specialty pharmacies</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration partnership</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. specialty pharmacies, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2024. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to customers or receivables.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As of March 31, 2024 and December 31, 2023, accounts receivable, net are $28.9 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the account receivables. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of March 31, 2024 and December 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Expenses: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring expense consists primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Shares: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s shares have no par value or stated value and therefore, upon repurchase or issuance of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of March 31, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other (income) expense, net.</span></div> 1 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and specialty distributors and directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products to patients and healthcare providers. Revenues from product sales are recognized when the customer obtains control of the Company's product, which typically occurs upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed to patients. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of March 31, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span> The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration and manufacturing services revenue in the Otsuka Territories. 2 The percentages of total revenues, net from our main customers were as follows:<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> March 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two main specialty pharmacies</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration partnership</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.91 0.99 0.07 0 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As of March 31, 2024 and December 31, 2023, accounts receivable, net are $28.9 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the account receivables. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of March 31, 2024 and December 31, 2023.</span></div> 28900000 24100000 P30D P45D 0 0 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Expenses: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring expense consists primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Shares: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s shares have no par value or stated value and therefore, upon repurchase or issuance of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.</span></div> Fair Value Measurements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale debt securities are generally based on prices obtained from commercial pricing services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial assets (cash, cash equivalents, restricted cash and investments) measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255,652</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">320,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,815 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Level 1 instruments include cash, cash equivalents and restricted cash that are valued using quoted market prices. Aurinia estimates the fair values of investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of the Company's investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At March 31, 2024 and December 31, 2023, the weighted average remaining contractual maturities of Aurinia's Level 2 investments were approximately 6 months and 7 months, respectively. It is the Company's policy for these investments to have an overall rating of A-1, or higher, by Standard &amp; Poor's, or an equivalent rating by Moody’s or Fitch.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No credit loss allowance was recorded as of March 31, 2024 and December 31, 2023, as the Company does not believe the unrealized loss is a result of a credit loss due to the nature of the investments. Aurinia also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the carrying amount and related unrealized gains (losses) by type of investment.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial assets (cash, cash equivalents, restricted cash and investments) measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255,652</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">320,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,815 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 64459000 0 0 64459000 0 23745000 0 23745000 0 38243000 0 38243000 0 134974000 0 134974000 0 58690000 0 58690000 64459000 255652000 0 320111000 48875000 0 0 48875000 0 33781000 0 33781000 0 39304000 0 39304000 0 122806000 0 122806000 0 105924000 0 105924000 48875000 301815000 0 350690000 P6M P7M Cash, Cash Equivalents, Restricted Cash and Investments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the Company had $320.1 million and $350.7 million, respectively of cash, cash equivalents, restricted cash and investments summarized below. As of March 31, 2024 and December 31, 2023, $255.7 million and $301.8 million were available-for-sale debt securities which are carried at fair market value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,547</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,544</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,975</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,697</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319,960</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investment corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">320,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">320,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,416 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,489 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investment corporate bond</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,616 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,690 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, accrued interest receivable from investments was $1.0 million and $0.7 million, respectively. During the three months ended March 31, 2024 and 2023, the Company had $(124) thousand and $73 thousand of unrealized losses and gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company has determined that the gross unrealized losses on investments at March 31, 2024, were temporary in nature. Realized gains or losses were immaterial during the three months ended March 31, 2024 and 2023.</span></div>The Company's short-term investments as of March 31, 2024 mature at various dates through November 2024 and the longer-term investment matures in August 2025. 320100000 350700000 255700000 301800000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,547</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,544</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,975</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,697</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319,960</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investment corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">320,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">320,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,416 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,489 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investment corporate bond</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,616 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,690 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 64459000 0 0 64459000 23547000 0 3000 23544000 38273000 0 30000 38243000 134984000 0 9000 134975000 58697000 0 7000 58690000 319960000 0 49000 319911000 199000 1000 0 200000 320159000 1000 49000 320111000 48875000 0 0 48875000 33576000 4000 0 33580000 39305000 0 1000 39304000 122757000 49000 0 122806000 105903000 21000 0 105924000 350416000 74000 1000 350489000 200000 1000 0 201000 350616000 75000 1000 350690000 1000000 700000 -124000 73000 Inventories, net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs. Capitalized costs of inventories for LUPKYNIS (voclosporin) mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. Due to the nature of the Company's supply chain process, inventory that is owned by the Company, is physically stored at third-party warehouses, logistics providers, and contract manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses recoverability of inventory each reporting period to determine any write-down to net realizable value resulting from excess or obsolete inventories. As of March 31, 2024 and December 31, 2023, Aurinia recorded reserves of finished goods inventories of approximately $0.5 million and $0.8 million, respectively, which were primarily related to potential inventory obsolescence. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory, net are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,702</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,705 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 500000 800000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory, net are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,702</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,705 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1702000 1746000 35994000 37376000 2065000 583000 39761000 39705000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Prepaid Expenses</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,376</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">563</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,376</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">563</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4707000 6892000 2376000 1345000 563000 1249000 7646000 9486000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Intangible Assets</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,860</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,307)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,859</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,099)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,760</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,297)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,846 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,869)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,977 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended March 31, 2024 and 2023 was approximately $0.2 million and $0.5 million, respectively.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,860</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,307)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,859</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,099)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,760</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,297)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,846 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,869)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,977 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1860000 1307000 553000 15126000 10937000 4189000 2873000 2855000 18000 19859000 15099000 4760000 1847000 1297000 550000 15126000 10737000 4389000 2873000 2835000 38000 19846000 14869000 4977000 200000 500000 Property and Equipment, net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">631</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,155</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,264</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,264</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,066)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">631</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,155</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,264</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,264</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,066)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3243000 3243000 631000 631000 1155000 1155000 235000 235000 5264000 5264000 2066000 1910000 3198000 3354000 Lease Obligations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following lease obligations:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Victoria, British Columbia</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Aurinia entered into a lease for office space in Victoria, British Columbia. During September 2022, the fixed lease term ended on the Victoria lease and the Company exercised its right to enter into a short-term month to month lease, of which expenses are incurred in SG&amp;A. On March 31, 2023, the Company terminated the Victoria lease. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rockville, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately seven years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of March 31, 2024, the Company had a right-of-use (ROU) asset of $4.4 million and lease liability of $7.2 million included in the condensed consolidated balance sheets. As of December 31, 2023, the Company had a right of use asset of $4.5 million and lease liability of $7.4 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Edmonton, Alberta</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During October 2022, the Company entered into a long term lease in Edmonton for a total of 4,375 square feet of office space. The lease is a six year lease and has an option to renew after five years at prevailing market rates. The lease commenced on November 1, 2022 and the Company recorded the lease as an operating lease. The lease is not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all leases, the Company incurs variable lease costs. These costs include operation and maintenance costs included in SG&amp;A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for all leases for the three months ended March 31, 2024 and March 31, 2023 were $0.2 million for both periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Monoplant</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, at lease inception, recorded an ROU asset of approximately $117.6 million and a corresponding lease liability of $94.1 million, which is the present value of the minimum lease payments beginning July 2023 and expiring in 2030. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the ROU asset, net and corresponding lease liability balance were $104.4 million and $81.2 million, respectively. As of December 31, 2023, the ROU asset, net and corresponding lease liability balance were $108.7 million and $90.1 million, respectively. For the three months ended March 31, 2024, ROU amortization was $4.4 million and interest expense was $1.3 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease terms and discount rates as of March 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance lease</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance lease</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash transactions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use asset obtained in exchange for lease obligations (monoplant)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104,359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liability arising from obtaining right-of-use assets (monoplant)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities as of March 31, 2024 are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,227</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96,419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,538)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beinheim</span></div>The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that has not yet commenced operations and is therefore, not included in the above table. As part of the agreement, the Company expects to make payments of approximately $1.0 million prior to lease commencement and the present value of minimum lease payments will total approximately $0.1 million. 30531 P7Y 2 P5Y P11Y P7Y 4400000 7200000 4500000 7400000 -2300000 0.052 4375 P6Y P5Y 200000 200000 117600000 94100000 0.0619 104400000 81200000 108700000 90100000 4400000 1300000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease terms and discount rates as of March 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance lease</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance lease</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash transactions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use asset obtained in exchange for lease obligations (monoplant)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104,359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liability arising from obtaining right-of-use assets (monoplant)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P7Y4M24D 0.0528 P6Y 0.0619 2778000 0 1370000 0 276000 263000 104359000 0 81199000 0 <div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities as of March 31, 2024 are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,227</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96,419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,538)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12052000 838000 16070000 1141000 16070000 1169000 16070000 1198000 16070000 1227000 20087000 3303000 96419000 8876000 15220000 1538000 81199000 7338000 1000000 100000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Accounts Payable and Accrued Liabilities</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,412</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,078</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,665</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring accruals</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,965</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,408</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, liabilities related to restructuring costs of $2.1 million are included within accounts payable and accrued liabilities on the condensed consolidated balance sheets. Restructuring accruals primarily include employee severance and contract termination expenses.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,412</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,078</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,665</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring accruals</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,965</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,408</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11412000 22486000 20078000 16216000 2665000 5503000 5672000 4327000 2070000 0 6965000 5190000 1408000 667000 50270000 54389000 2100000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Deferred Compensation and Other Non-current Liabilities</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded other non-current liabilities of $12.3 million and $10.9 million as of March 31, 2024 and December 31, 2023, respectively. The balance as of March 31, 2024 and December 31, 2023 primarily included deferred compensation arrangements whereby certain former executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. One of the former officers, Dr. Robert T. Foster, is considered a related party following his appointment to the Board of Directors on September 21, 2023. For further discussion, refer to Note 17, Related Party Transactions.</span></div> 12300000 10900000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">License and Collaboration Agreements</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otsuka Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories. For full description of the agreements the Company has entered into with Otsuka, please refer to the Annual Report on Form 10-K for the year ended December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, the Company received an upfront cash payment of $50.0 million in 2020 for the license agreement and has received $40.0 million in regulatory and pricing approval related milestones. The Company provides semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, sharing capacity of the monoplant and receives tiered royalties ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2023, Otsuka filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labour, and Welfare for the manufacture and sale in Japan of voclosporin. The Company is eligible to receive a payment of $10 million upon approval in Japan, which is anticipated in the second half of 2024, along with low double-digit royalties on net sales once launched.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and March 31, 2023, the Company recognized $2.2 million and $0.1 million, respectively of license, collaboration and royalty revenue from services provided under the Otsuka agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Riptide License</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. Effective February 14, 2024 the Company is ceasing future development of AUR300.</span></div> 50000000 40000000 0.10 0.20 10000000 2200000 100000 Shareholder's Equity<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia announced that its Board of Directors had approved a share repurchase program of up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $150 million of common shares of the Company, affirming its confidence in the Company's growth prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program. This program may be implemented through open market or privately negotiated purchases, including under a plan intended to comply with the affirmative defense under Rule 10b5-1, Rule 10b-18 or an automatic securities purchase plan, an accelerated share repurchase program, or other mechanisms. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. The purchase price of any Common Shares will be determined in accordance with applicable U.S. securities laws and subject to receiving the Exemptive Relief, the value of the consideration offered per Common Share will not exceed the market price of the Common Shares calculated pursuant to applicable Canadian securities regulation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2024, the Company had repurchased approximately 2.4 million of Aurinia's common shares for $13.4 million (including transaction costs which consist of commissions and excise tax). The cost of repurchased shares are reported as a reduction in common stock and under Alberta law, the shares were cancelled and not reissued.</span></div> 150000000 0.15 P12M P36M 2400000 13400000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Net Loss per Common Share</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> March 31,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,749)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,206)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,641 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,910</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,582 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> March 31,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,749)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,206)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,641 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -10749000 -26206000 144013000 144013000 142641000 142641000 -0.07 -0.07 -0.18 -0.18 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,910</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,582 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11081000 12678000 1503000 921000 7326000 6983000 19910000 20582000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Share-based Compensation</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards (PAs), and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. As of March 31, 2024, 0.7 million shares were purchased under the ESPP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to stock options, PAs and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the business day immediately prior to the date of grant. The Board of Directors approves the vesting criteria and periods at its discretion. The options issued under the Plan are accounted for as equity-settled share-based payments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The assumptions used for the annual volatility and expected life of the options are reviewed and updated annually. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March 31, 2024 and March 31, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity for the three months ended March 31, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,556</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or cancelled</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted RSUs and PAs under the Plan, as well as inducements for certain new hires as discussed above. The RSUs and PAs are fair valued based on the previous business days' market price of common shares on the date of the grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU and PA activity for the three months ended March 31, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average fair value price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,807</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.94</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance, March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,829</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.07</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three months ended March 31, 2024 and March 31, 2023 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/> March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,166)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,537</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,467 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2024, there was $40.4 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.6 years.</span></div> 23800000 2500000 700000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March 31, 2024 and March 31, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.77 0.71 0.0404 0.0408 P5Y P5Y 0.131 0.127 0.000 0.000 4.62 5.44 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity for the three months ended March 31, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,556</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or cancelled</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 11556000 10.63 63000 7.12 6000 4.85 532000 11.62 11081000 10.57 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU and PA activity for the three months ended March 31, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average fair value price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,807</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.94</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance, March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,829</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.07</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7807000 9.29 4491000 6.94 2225000 9.48 1244000 9.12 8829000 8.07 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three months ended March 31, 2024 and March 31, 2023 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/> March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,166)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,537</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,467 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -2166000 1590000 7537000 7589000 366000 288000 5737000 9467000 40400000 P1Y7M6D <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Income Taxes</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three months ended March 31, 2024 and March 31, 2023 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an income tax expense of approximately $739 thousand and $436 thousand for the three months ended March 31, 2024 and March 31, 2023, respectively. The expense recognized for these periods is a result of income in certain jurisdictions. This tax expense was not offset by a tax benefit as the Company had losses that are fully offset by a valuation allowance in its significant jurisdictions.</span></div> 739000 436000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Related Party Transactions</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2023, the Company appointed Dr. Robert T. Foster to the Board of Directors. Dr. Foster is considered a related party since he is one of the former executive officers of the Company who, as of March 8, 2012 was provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations are contingent on the occurrence of uncertain future events. Dr. Foster was not a related party of the Company between his resignation from the Company in 2014, and his appointment to the Board of Directors on September 21, 2023. As of March 31, 2024, the Company had $0.8 million and $8.8 million of current and non-current liabilities related to Dr. Foster, respectively. As of December 31, 2023, the Company had $0.8 million and $7.6 million of current and non-current liabilities related to Dr. Foster, respectively. As of March 31, 2024 and December 31, 2023 the Company had made payments of $0.1 million to him for each period as a related party for the deferred compensation.</span></div> 800000 8800000 800000 7600000 100000 100000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Commitments and Contingencies</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Restructuring</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value, including an exclusive focus on driving the commercial execution of the LUPKYNIS (voclosporin) business. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program and is exploring alternative approaches for AUR200. The corporate restructuring involved the Company reaffirming its commitment to LUPKYNIS growth ensuring product quality and patient safety, while maintaining a sharp focus on operating efficiencies and maximizing cash flows. The Company also announced it plans to reduce employee headcount by at least 25% by the end of the first quarter of 2024. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the restructuring expenses recorded by the Company were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee severance and one time benefits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract terminations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">919</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">557</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,683</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2024, restructuring expenses of approximately $6.7 million were recorded in connection with this program and are included within operating expenses on the condensed consolidated statements of operations and comprehensive loss.</span></div> 0.25 0.25 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the restructuring expenses recorded by the Company were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee severance and one time benefits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract terminations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">919</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">557</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,683</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div> 5207000 919000 557000 6683000 6700000 6700000 6700000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Subsequent Events</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From April 1, 2024 through April 30, 2024 the Company has repurchased approximately 1.0 million of additional Aurinia common shares for $5.2 million (including transaction costs). The cost of repurchased shares will be reported as a reduction in common stock and subsequently canceled.</span></div> 1000000 5200000